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ABSTRACT 
Disease, injury, and age problems compromise human quality of life and continuously 
motivate the search for new and more efficacious therapeutic approaches. The field of Tissue 
Regeneration and Engineering has greatly evolved over the last years, mainly due to the 
combination of the important advances verified in Biomaterials Science and Engineering with 
those of Cell and Molecular Biology. In particular, a new and promising area arose – 
Nanomedicine – that takes advantage of the extremely small size and especial chemical and 
physical properties of Nanomaterials, offering powerful tools for health improvement. Research 
on Stem Cells, the self-renewing progenitors of body tissues, is also challenging to the medical 
and scientific communities, being expectable the appearance of new and exciting stem cell-based 
therapies in the next years. 
 
The control of cell behavior (namely, of cell proliferation and differentiation) is of key 
importance in devising strategies for Tissue Regeneration and Engineering. Cytokines, growth 
factors, transcription factors and other signaling molecules, most of them proteins, have been 
identified and found to regulate and support tissue development and regeneration. However, the 
application of these molecules in long-term regenerative processes requires their continuous 
presence at high concentrations as they usually present short half-lives at physiological 
conditions and may be rapidly cleared from the body. Alternatively, genes encoding such proteins 
can be introduced inside cells and be expressed using cell’s machinery, allowing an extended 
and more sustained production of the protein of interest (gene therapy). Genetic engineering of 
stem cells is particularly attractive because of their self-renewal capability and differentiation 
potential. For Tissue Regeneration and Engineering purposes, the patient’s own stem cells can 
be genetically engineered in vitro and, after, introduced in the body (with or without a scaffold) 
where they will not only modulate the behavior of native cells (stem cell-mediated gene therapy), 
but also directly participate in tissue repair.  
 
Cells can be genetically engineered using viral and non-viral systems. Viruses, as a result 
of millions of years of evolution, are very effective for the delivery of genes in several types of 
cells, including cells from primary sources. However, the risks associated with their use (like 
infection and immunogenic reactions) are driving the search for non-viral systems that will 
efficiently deliver genetic material into cells. Among them, chemical methods that are promising
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and being investigated use cationic molecules as carriers for DNA. In this case, gene delivery and 
gene expression level remain relatively low when primary cells are used.  
 
The main goal of this thesis was to develop and assess the in vitro potential of 
polyamidoamine (PAMAM) dendrimers based carriers to deliver genes to mesenchymal stem 
cells (MSCs). PAMAM dendrimers are monodispersive, hyperbranched and nanospherical 
molecules presenting unique characteristics that make them very attractive vehicles for both drug 
and gene delivery. Although they have been explored for gene delivery in a wide range of cell 
lines, the interaction and the usefulness of these molecules in the delivery of genes to MSCs 
remains a field to be explored.  Adult MSCs were chosen for the studies due to their potential 
biomedical applications (they are considered multipotent cells) and because they present several 
advantages over embryonic stem cells, such as easy accessibility and the inexistence of ethical 
restrictions to their use. 
 
This thesis is divided in 5 interconnected chapters.  
 
Chapter I provides an overview of the current literature concerning the various non-viral 
systems investigated for gene delivery in MSCs. Attention is devoted to physical methods, as well 
as to chemical methods that make use of polymers (natural and synthetic), liposomes, and 
inorganic nanoparticles as gene delivery vectors. Also, it summarizes the current applications of 
genetically engineered mesenchymal stem cells using non-viral systems in regenerative 
medicine, with special focus on bone tissue regeneration.  
 
In Chapter II, the potential of native PAMAM dendrimers with amine termini to transfect 
MSCs is evaluated. The level of transfection achieved with the dendrimers is, in a first step, 
studied using a plasmid DNA (pDNA) encoding for the β-galactosidase reporter gene. The effect 
of dendrimer’s generation, cell passage number, and N:P ratio (where N= number of primary 
amines in the dendrimer; P= number of phosphate groups in the pDNA backbone) on the level of 
transfection is evaluated, being the values always very low. In a second step, a pDNA encoding 
for bone morphogenetic protein-2, a protein that is known for its role in MSCs proliferation and 
differentiation, is used. The BMP-2 content produced by transfected cells is evaluated by an 
ELISA assay and its effect on the osteogenic markers is analyzed through several classical
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assays including alkaline phosphatase activity (an early marker of osteogenesis), osteocalcin 
production, calcium deposition and mineralized nodules formation (late osteogenesis markers). 
Results show that a low transfection level is enough to induce in vitro osteogenic differentiation in 
MSCs.  
 
Next, from Chapter III to Chapter V, studies are shown where several strategies are 
adopted to change the interaction of PAMAM dendrimers with MSCs cell membrane and, as a 
consequence, to enhance the levels of gene delivery. In Chapter III, generations 5 and 6 of 
PAMAM dendrimers are surface functionalized with arginine-glycine-aspartic acid (RGD) 
containing peptides – experiments with dendrimers conjugated to 4, 8 and 16 RGD units were 
performed. The underlying concept is that by including the RGD integrin-binding motif in the 
design of the vectors and by forming RGD clusters, the level of transfection will increase as 
MSCs highly express integrins at their surface. Results show that cellular uptake of functionalized 
dendrimers and gene expression is enhanced in comparison with the native dendrimers. 
Furthermore, gene expression is dependent on both the electrostatic interaction established 
between the dendrimer moiety and the cell surface and the nanocluster RGD density.  
 
In Chapter IV, a new family of gene delivery vectors is synthesized consisting of a PAMAM 
dendrimer (generation 5) core randomly linked at the periphery to alkyl hydrophobic chains that 
vary in length and number. Herein, the idea is to take advantage of both the cationic nature of the 
dendrimer and the capacity of lipids to interact with biological membranes. These new vectors 
show a remarkable capacity for internalizing pDNA, being this effect positively correlated with the 
–CH2– content present in the hydrophobic corona. Gene expression is also greatly enhanced 
using the new vectors but, in this case, the higher efficiency is shown by the vectors containing 
the smallest hydrophobic chains.  
 
Finally, chapter V reports the synthesis, characterization and evaluation of novel gene 
delivery vectors based on PAMAM dendrimers (generation 5) conjugated to peptides with high 
affinity for MSCs membrane binding - for comparison, experiments are also done with a peptide 
with low affinity binding properties. These systems present low cytotoxicity and transfection 
efficiencies superior to those of native dendrimers and partially degraded dendrimers (Superfect®, 
a commercial product). Furthermore, with this biomimetic approach, the process of gene delivery 
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is shown to be cell surface receptor-mediated. Overall, results show the potential of PAMAM 
dendrimers to be used, as such or modified, in Tissue Regeneration and Engineering. To our 
knowledge, this is the first time that PAMAM dendrimers are studied as gene delivery vehicles in 
this context and using, as target, a cell type with clinical relevancy.  
 
It is shown that the cationic nature of PAMAM dendrimers with amine termini can be 
synergistically combined with surface engineering approaches, which will ultimately result in 
suitable interactions with the cytoplasmic membrane and enhanced pDNA cellular entry and gene 
expression. Nevertheless, the quantity of pDNA detected inside cell nucleus is always very small 
when compared with the bigger amount reaching cytoplasm (accumulation of pDNA is evident in 
the perinuclear region), suggesting that the main barrier to transfection is the nuclear membrane. 
Future work can then be envisaged based on the versatility of these systems as biomedical 
molecular materials, such as the conjugation of PAMAM dendrimers to molecules able to bind 
nuclear membrane receptors and to promote nuclear translocation. 
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RESUMO 
As doenças, acidentes e problemas relacionados com a velhice comprometem a qualidade 
de vida humana, motivando a contínua procura de novas e mais eficientes abordagens 
terapêuticas. Ao longo dos últimos anos, o domínio da Engenharia e Regeneração de Tecidos 
conheceu uma enorme evolução, nomeadamente, devido à combinação dos importantes 
avanços ocorridos na Ciência e Engenharia de Biomateriais com os da Biologia Molecular e 
Celular. Em particular, surgiu uma nova e promissora área científica – a Nanomedicina – que tira 
vantagem do tamanho extremamente pequeno e das propriedades químicas e físicas únicas dos 
nanomateriais, oferecendo ferramentas poderosas para a melhoria da saúde humana. A 
pesquisa em células estaminais (CE), células com capacidade de se auto-renovar e de dar 
origem aos vários tecidos do corpo, constitui também um desafio para as comunidades médicas 
e científicas, sendo expectável que, nos próximos anos, surjam novas e estimulantes terapias 
baseadas em CE.  
 
O controlo do comportamento celular (nomeadamente, da proliferação e da diferenciação 
celular) é de extrema importância aquando da concepção de estratégias no campo da 
Engenharia e Regeneração de Tecidos. Diversas moléculas de sinalização, tais como citocinas, 
factores de crescimento, factores de transcrição, etc., a maioria proteínas, têm sido identificadas, 
sendo conhecido o seu papel na regulação e no suporte do desenvolvimento e regeneração 
tecidulares. Contudo, a aplicação destas moléculas em processos de regeneração prolongados 
exige a sua presença contínua, em elevadas concentrações, pois possuem tempos de vida muito 
curtos em condições fisiológicas e podem ser rapidamente suprimidas do corpo. 
Alternativamente, podem ser introduzidos nas células os genes que codificam essas proteínas, 
sendo estes expressos fazendo uso da maquinaria celular e permitindo uma produção controlada 
e mais prolongada da proteína de interesse (terapia génica). A modificação génica de CE revela-
se particularmente atractiva devido à capacidade de auto-renovação e potencial de diferenciação 
das CE. Para fins de Engenharia e Regeneração de Tecidos, podem ser geneticamente 
modificadas in vitro CE do próprio paciente que, posteriormente, são introduzidas no corpo (por 
injecção directa ou com auxilio de uma matriz) onde irão modular, não só o comportamento da 
células nativas (terapia genética mediada por células estaminais), mas também participar 
directamente na reparação/regeneração dos tecidos.  
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As células podem ser modificadas geneticamente recorrendo a métodos virais ou não-virais. Os 
vírus, como resultado da sua evolução ao longo de milhões de anos, são extremamente 
eficientes na entrega de genes em vários tipos de células, incluindo em células de origem 
primária. Contudo, os riscos associados ao seu uso (tais como infecções e reacções 
imunológicas) estão a direccionar a investigação para sistemas não-virais capazes de transferir 
eficientemente o material genético para dentro das células. Entre eles, estão a ser investigados 
métodos químicos que fazem uso de moléculas cationicas como transportadores de DNA. Neste 
caso, a transferência e expressão de genes continua a ser relativamente baixa aquando do uso 
de células de origem primária. 
 
O principal objectivo desta tese foi desenvolver e avaliar o potencial dos dendrímeros à 
base de poliamidoamina (PAMAM) como veículos para a entrega/transferência de genes, in vitro, 
em células estaminais mesenquimatosas (CEM). Os dendrimeros PAMAM são moléculas com 
um baixo índice de polidispersão, altamente ramificadas e nano-esféricas, apresentando 
características únicas que os tornam veículos atractivos para a libertação de drogas e genes. 
Apesar de terem sido investigados, ao longo dos últimos anos, como veículos para a entrega de 
genes numa grande variedade de linhas celulares, a sua interacção e aplicabilidade na entrega 
de genes em CEM continua a ser um campo por explorar. Neste trabalho, foram utilizadas CEM 
de origem não-embrionária (células adultas) devido ao seu elevado potencial em aplicações 
biomédicas (são consideradas multipotentes) e às variadas vantagens que apresentam em 
relação às células estaminais embrionárias, tais como o seu fácil acesso e a não existência de 
restrições éticas ao seu uso.  
 
Esta tese encontra-se dividida em 5 capítulos interligados:  
 
O capítulo I fornece uma visão global acerca dos diferentes sistemas não-virais 
investigados na transferência de genes em CEM. É dada atenção aos métodos físicos, assim 
como aos métodos químicos que envolvem o uso de materiais poliméricos (naturais e sintéticos), 
liposomas, e nanopartículas à base de materiais inorgânicos para a entrega de genes. 
Adicionalmente, faz-se um sumário das actuais aplicações das CEM geneticamente modificadas, 
usando sistemas não-virais, em medicina regenerativa, com especial ênfase na regeneração de 
tecido ósseo. 
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No capítulo II, é avaliada a capacidade dos dendrimeros PAMAM com grupos amino à 
superfície para transfectar CEM. Em primeiro lugar, foi avaliado o nível de transfecção obtido 
com estas moléculas usando DNA plasmídico (pDNA) que codifica o gene da β-Galactosidase. O 
efeito da geração do dendrímero, do número de passagens celulares, e da razão N:P (onde N 
representa o número de aminas primárias no dendrímero e P o número de grupos fosfato na 
cadeia de DNA) no nível de transfecção é avaliado, tendo-se observado que os níveis de 
transfecção foram sempre relativamente baixos. Seguidamente, utilizou-se um plasmídeo que 
codifica a proteína morfogenética do osso 2 (BMP-2), uma proteína conhecida pelo seu 
importante papel na proliferação e diferenciação das CEM. O teor de BMP-2 produzido pelas 
células transfectadas foi avaliado através de um ensaio ELISA e o seu efeito nos marcadores 
osteogénicos foi avaliado através de métodos clássicos que incluíram a actividade da fosfatase 
alcalina (um marcador precoce da osteogénese), a produção de osteocalcina, a deposição de 
cálcio e a formação de nódulos de mineralização (marcadores tardios da osteogénese). Os 
resultados obtidos demonstram que um baixo nível de transfecção é suficiente para induzir a 
diferenciação osteogénica in vitro de células estaminais mesenquimatosas.  
 
Do capítulo III ao capítulo V, mostram-se os resultados obtidos através da adopção de 
várias estratégias para modificar a interacção dos dendrímeros PAMAM com a membrana celular 
e, por consequência, aumentar o nível de transferência génica. No capítulo III, as gerações 5 e 6 
de dendrímeros PAMAM foram funcionalizadas com o péptido arginina-glicina-ácido aspártico 
(RGD) - foram feitos estudos com 4, 8 e 16 unidades de RGD por dendrímero. O conceito 
subjacente a este estudo baseia-se na afinidade dos péptidos RGD pelas integrinas que são 
receptores celulares expressos em quantidade elevada à superfície das CEM, o que poderá 
levar, conjuntamente com a formação de “aglomerados” de RGD, ao aumento da transfecção 
aquando do uso de dendrímeros modificados com péptidos RGD. Os resultados obtidos 
demonstram que os dendrímeros funcionalizados com péptidos RGD conduzem a níveis de 
expressão génica mais elevados do que os dendrímeros não-modificados. Adicionalmente, a 
expressão génica parece depender da interacção electrostática estabelecida entre a parte 
dendrimérica e a superfície celular, bem como da densidade de RGD nos “nanoaglomerados”. 
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O capítulo IV reporta a síntese de uma nova família de vectores para transferência génica 
baseada num cerne constituído por um dendrímero PAMAM (geração 5), o qual foi 
aleatoriamente funcionalizado à superfície com cadeias alquilo hidrofóbicas que variam em 
comprimento e número. Neste caso, a ideia é tirar partido da natureza catiónica dos dendrímeros 
e da capacidade de interacção dos lípidos com as membranas biológicas. Estes novos vectores 
demonstram uma capacidade notável para internalizar pDNA, sendo este efeito positivamente 
correlacionado com o teor de -CH2- presente na coroa hidrofóbica. A utilização dos novos 
vectores também resulta num aumento da transfecção, mas, neste caso, esta é superior para os 
vectores que apresentam as cadeias hidrofóbicas mais curtas. 
 
Por último, o capítulo V reporta a síntese, caracterização e avaliação de uma nova família 
de vectores para transferência génica baseado em dendrímeros PAMAM (geração 5) 
funcionalizados com péptidos que exibem uma elevada afinidade pela membrana das CEM – 
para efeitos comparativos, todos os estudos foram também efectuados com dendrímeros 
funcionalizados com péptidos de baixa afinidade para as CEM. Os sistemas sintetizados 
apresentam baixa citotoxicidade e eficiências de transfecção superiores às do dendrímeros não 
modificados e, ainda, dos dendrímeros parcialmente degradados (Superfect®, um produto 
comercial). Ademais, comprova-se que, com esta abordagem biomimética, o processo de 
transferência génica é mediado pelos receptores à superfície.  
 
Globalmente, os resultados demonstram o potencial dos dendrímeros PAMAM para serem 
utilizados, com ou sem modificações, em Engenharia e Regeneração de Tecidos. Que seja do 
nosso conhecimento, esta é a primeira vez que os dendrímeros PAMAM são investigados como 
veículos de transferência génica neste contexto e usando, como alvo, um tipo celular com 
relevância clínica. Demonstrou-se que a natureza catiónica dos dendrímeros PAMAM com 
grupos terminais amino pode ser sinergeticamente articulada com estratégias de funcionalização 
de superfície, resultando em interacções mais apropriadas com a membrana citoplasmática e no 
aumento da entrada de pDNA na célula e consequente aumento da expressão génica. Contudo, 
a quantidade de pDNA detectado dentro do núcleo da célula através de microscopia de 
fluorescência é sempre muito baixa comparativamente à quantidade existente no citoplasma (há 
uma evidente acumulação de pDNA na vizinhança do invólucro nuclear), sugerindo que a maior 
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barreira à transfecção será, provavelmente, a membrana nuclear. A versatilidade dos 
dendrímeros como materiais moleculares biomédicos poderá ajudar a ultrapassar este problema, 
nomeadamente através da conjugação, à sua superfície, de moléculas capazes de se ligarem 
aos receptores da membrana nuclear e, dessa forma, promover a translocação nuclear. Este 
será, sem dúvida, um tópico interessante de estudo para o futuro. 
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CHAPTER I. 
Non-Viral Gene Delivery to Mesenchymal Stem Cells: Strategies and Applications* 
 
 
ABSTRACT 
Mesenchymal stem cells (MSCs) can be isolated from several tissues in the body, have the ability 
to self-renewal, show immune suppressive properties and are multipotent, being able to generate 
various cell types. At present, due to their intrinsic characteristics, MSCs are considered very 
promising in the area of tissue engineering and regeneration. In this context, genetic modification 
can be a powerful tool to control the behavior and fate of these cells and be used in the design of 
new cellular therapies. Viral systems are very effective in the introduction of exogenous genes 
inside MSCs. However, the risks associated with their use are leading to an increasing search for 
non-viral approaches to attain the same purpose even if MSCs have been shown to be more 
difficult to transfect by this way. Progress has been made in the last years in the development of 
chemical and physical methods for non-viral gene delivery. Herein, the application of those 
methods specifically to MSCs is reviewed and their success in the delivery of therapeutic genes 
discussed. Key issues in non-viral gene delivery to MSCs are addressed and problems that 
remain to be solved highlighted. 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following publication: 
Santos JL
  
, Pandita D, Rodrigues J, Pêgo AP, Granja PL, Tomás H, Non-Viral Gene Delivery to Mesenchymal Stem 
Cells: Strategies and Applications (2009), submitted. 
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1. GENERAL INTRODUCTION 
 
A huge number of studies have demonstrated the importance of mesenchymal stem cells 
(MSCs) in regenerative medicine and tissue engineering1-9. Indeed, they can be isolated from 
several tissues throughout the body, expanded in culture, and stimulated to differentiate into 
mesenchymal and non-mesenchymal cell lineages, characteristics that make them attractive in 
the biomedical area. Furthermore, MSCs are harvested from adult individuals (autologous cells 
can be used), thus not raising ethical problems in their manipulation and use10. Also MSCs have 
been shown to be able to suppress immune responses in various situations like organ 
transplantation and autoimmune diseases9,11. Indeed, there is now overwhelming evidence that 
the mechanisms of action of MSCs in tissue repair include not only cell engraftment and 
differentiation but also signaling through paracrine secretions and cell-to-cell contacts.  
 
MSCs applications can be potentiated using gene delivery approaches12-18. Processes 
such as proliferation, migration, cell-cell and cell-matrix interactions, differentiation, apoptosis, 
and secretion of soluble signaling molecules can be controlled through the introduction of 
exogenous genes inside cells that will result in the synthesis of a specific protein (therapeutic 
protein). In regenerative medicine and tissue engineering, genetic modification is preferred over 
the exposition of cells to growth factors and cytokines as the short half-life and body clearance of 
these molecules may imply the use of either high (non physiological) concentrations or repeated 
administrations to produce the desired biological effect. Also recombinant proteins may not 
provide the therapeutic benefit of natural proteins13. In fact, the power of cell genetic engineering 
was recently highlighted by experiments that showed the possibility of obtaining pluripotent stem-
like cells (induced pluripotent stem cells, iPS cells) by transferring genes encoding for certain 
transcription factors into non-pluripotent cells19,20.  
 
A simple strategy of gene therapy can be followed where genes are directly delivered into 
the site of injury13,21. In this case, administration to the target tissue/organ can be done by 
injection or controlled release from a scaffold. However, using this method, specific gene transfer 
to MSCs cannot be guaranteed as all cells present in the injury site can be potentially affected, 
unless some specificity factor is added to the system,. Another, more elegant possibility is to use 
a cell-mediated gene therapy strategy where MSCs are first genetically modified in vitro and, only 
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after, implanted in the injury site13,21,22. During the in vitro process, MSCs can be cultured in cell 
culture dishes or already in a three-dimensional (3D) environment (scaffold) that, after cell 
colonization, will be implanted in the patient body.  In fact, a number of studies have 
demonstrated that MSCs can be used for cell-mediated gene therapy and as a tool for 
understanding the molecular mechanisms leading to repair and regeneration of complex tissues 
and organs12-18,21,22. 
 
Both simple gene therapy and cell-mediated gene therapy make use of gene delivery 
systems. An ideal gene delivery system should present various features, like ensure protection of 
DNA, achieve desired level of gene transfer and expression, exhibit specific targeting, prevent 
non-specific interactions with blood components, be nontoxic and non-immunogenic, and be cost 
effective23-25. Broadly, gene delivery systems can be divided in two major categories: viral and 
non-viral systems14,23-25. The traditional method to introduce a therapeutic gene into MSCs 
involves the use of viral vectors, such as lentivirus, retrovirus, adeno-associated virus and 
adenovirus derived vectors26-28. Although viral vectors present high efficiencies in gene transfer (a 
process called “infection”) and may allow stable gene expression, their clinical applications are 
currently narrowed due to potential problems, such as oncogenic transformation, pathogenic risk, 
and induction of immune responses23-25. Furthermore, they present difficulty in large-scale 
production and size limits for exogenous DNA23-25. These complications gave rise to substantial 
efforts in the development of alternative non-viral systems (gene transfer is, in this case, called 
“transfection”) which may be additionally classified in physical and chemical methods (Figure 1). 
Physical methods comprise the simplest, but ineffective, way of delivering genes to cells that is to 
use naked DNA (without any carrier) in contact with cells14,29. They also include physical 
manipulations of the cells that will result in improved gene transfer such as microinjection, particle 
bombardment, electroporation, sonoporation and laser irradiaton14,29,30. Chemical methods imply 
the use of natural or synthetic materials (the so called “non-viral vectors”) that are able to transfer 
the genetic material into the cell31-34. Non-viral systems offer several advantages, like any or low 
immunogenicity (thus, more than one application to the patient may be applied), no risk of 
infectious disease, flexibility towards the molecular size of loaded DNA, and also low cost23-25. 
When non-viral vectors are used, there is also the possibility of engineering them for targeting 
specific tissues35-37. Actually, non-viral vectors offer a great structural and chemical versatility, 
being possible to manipulate them and to tune their physicochemical properties so that the 
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barriers for an improved gene delivery and expression will be overcome31-34. Unfortunately, non-
viral systems present also some drawbacks. On one hand, physical methods are more difficult to 
be applied in an in vivo situation and can cause tissue damage29,30,38. On the other hand, for 
chemical methods: (a) transfection efficiency compared to viral vectors, both in vitro and in vivo, 
is low25,39; (b) gene expression is transient25,39; (c) toxicity may be high40; (d) the level of 
transfection strongly varies with the cell type14,41,42. Indeed, most of non-viral vectors have only 
been tested in cell lines, being difficult to extrapolate the in vitro results to a clinical situation. 
Often, primary cells, as is the case of MSCs, are refractory to transfection using the majority of 
non-viral vectors42. 
 
 
Figure 1. Schematic of DNA delivery to MSCs by chemical (A, B, C and D) and physical methods (F). Non-viral gene 
delivery vectors are based on a number of different materials that support the packing of DNA into nanometer sized 
particles. (A) Conventional non-viral gene delivery (bolus delivery). (B) Ligand-receptor-mediated gene delivery. (C) 
Substrate-mediated gene delivery (reverse transfection). (D) Scaffold-mediated gene delivery (3D environment).  
 
The advantages of exerting genetic control over MSCs behavior and fate associated with 
the need to move towards non-viral gene delivery represent a current challenge. Research is 
being done not only focused on the development of better and safer non-viral gene delivery 
methods but also on the understanding of the mechanisms of the gene delivery process and of its 
effects on the behavior of MSCs. Herein, we start by brief reviewing the current knowledge on the 
nature and properties of MSCs, followed by an overview of the use of non-viral gene delivery 
systems specifically for MSCs transfection. The different strategies used in the delivery of 
therapeutic genes to those cells for tissue engineering and regeneration applications are 
A B
C D
F
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exemplified and discussed. Finally, the main aspects and problems to be solved related with non-
viral gene delivery to MSCs are highlighted. 
 
 
2. MESENCHYMAL STEM CELLS 
 
MSCs were first described in the pioneering studies of Fridenstein, Owen and co-workers 
in the 60s and 70s43-48, followed by intensive work on the study of the properties of these 
cells49,50. They were isolated from rat marrow based on their adherence to plastic tissue culture 
surfaces and were shown to be able to differentiate towards the osteoblastic, adipogenic and 
chondrogenic lineages. Early studies demonstrated that these cells proliferated rapidly in vitro 
and gave rise to distinct colonies from single precursors, being thus called “fibroblast colony 
forming units” (CFU-F). The term “mesenchymal stem cells” came after, being first applied by 
Caplan in 1991, reflecting their “stem cell” nature51 – that is, capacity for self-renewal (when 
dividing, they give rise to at least one daughter cell identical to the initial cell) and retention of 
differentiation potential (MSCs are considered multipotent and can differentiate into specific 
mesenchymal cell types under the control of environmental cues). Meanwhile, several other 
names have been attributed to these cells, such as “marrow stromal cells”, “mesenchymal 
stromal cells”, “skeletal stem cells”, “multipotent mesenchymal stromal cells”, and “multipotent 
adult progenitor cells” This controversy in cell’s nomenclature is certainly related with the reduced 
knowledge that still exists concerning the nature, functions and differentiation potential of 
MSCs1,7,52. 
 
For many years MSCs have been isolated from low-density mononuclear cell population of 
bone marrow based on their selective adherence to plastic surfaces, compared to hematopoietic 
cells which are non-adherent and can therefore be removed through medium changes53-56. MSCs 
reactivity to monoclonal antibodies was also applied to sort a homogeneous population of cells 
with defined phenotype by flow cytometry (FACS)57-59. Indeed, along the years, several 
approaches have been investigated for the preparation of a more homogeneous cell population, 
as is the case of the recently published work of Masoud et al. for isolation and culture of MSCs 
from mouse bone marrow based on the frequent medium change in primary culture and 
diminishing the trypsinization time60. MSCs isolated using this protocol were not contaminated 
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with hematopoietic cell lineages and readily differentiated into osteoblasts, adipocytes and 
chondroblasts. However, up to now, all the isolation methods used suffer from lack of absolute 
specificity due to the lack of specific “markers” that can be employed to select MSCs.  
 
Besides bone marrow, MSCs were also isolated from other adult and foetal tissues – e.g., 
cord blood, placenta, amniotic fluid, heart, skeletal muscle, adipose tissue, synovial tissue, brain, 
spleen, liver, kidney, lung, thymus, pancreas, etc.1-9,61-70. The wide distribution of these cells in 
the body raised the hypothesis that MSCs exist in perivascular niches5. Furthermore, there are 
reports about MSCs differentiation not only into mesenchymal tissue lineages but also into non-
mesenchymal tissue lineages (such as epithelial, endothelial, and neural cells)1-9,52,71. Some 
discussion exists however around these discoveries and the characterization of these cells and 
so, in order to distinguish them from MSCs derived from bone marrow (the most studied source of 
MSCs), it was suggested that they should be called “MSCs-like cells”9. In an interesting review, it 
was even suggested that MSCs under certain conditions (i.e. depending on the cell environment), 
can de-differentiate returning to a stem state and becoming pluripotent52.  
 
As explained before, the potential of delivering genes to MSCs (or MSCs-like cells) has 
been recognized and a broad range of gene delivery systems are now available for the effect. 
Non-viral systems, being more versatile and safer, are increasingly attractive for the researchers 
and clinicians that are working in this field. 
 
 
3. NON-VIRAL GENE DELIVERY TO MESENCHYMAL STEM CELLS 
 
Non-viral gene transfer is normally accomplished using a plasmid DNA (circular molecules 
of double stranded DNA, pDNA) which contains the gene encoding the protein of interest under 
the transcriptional control of several eukaryotic regulatory elements and is amplified in bacteria72. 
A number of barriers must be overcome so that the pDNA can efficiently reach the cell nucleus 
and be transcripted: (a) it must be protected from degradation (and body clearance, in an in vivo 
situation); (b) it must cross the cell membranes (both the cytoplasmic and the nuclear 
membranes); (c) when chemical methods are used, the complexes formed by pDNA and by the 
non-viral vectors, and which enter cells through an endocytic pathway, must be released from the 
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formed endosomes and decomplexation must occur 33,73,74. The all process of gene transfer will 
then depend on the preparation, purification and composition of the pDNA, but also on the type of 
cell used as target, on the non-viral system chosen for the transfection and on the experimental 
conditions used in the process. Due to all these variables, a strict comparison among the 
research works published on this subject is difficult to make. However, it is possible to extract 
general conclusions from a literature survey and to get an idea of the best directions to be 
followed.  
 
 
3.1. Chemical Methods  
 
3.1.1. Liposome-based vectors 
 
Cationic lipids have polar heads and non-polar tails, and as such, can self-assemble 
forming liposomes33,75. The positive charge associated with these structures allows their 
interaction with the anionic molecules of pDNA, being possible to use them as gene delivery 
vehicles.  The DNA molecules are either entrapped in the internal aqueous space of liposomes or 
bounded on their surface, in both cases forming “lipoplexes”. It is believed that, after endocytosis, 
lipoplexes destabilize the endosomal membrane causing the release of DNA into the cytoplasm. 
“Lipofection” is a term currently used to mean transfection mediated by liposomes. 
 
Several lipid transfection reagents commercially available, like Lipofectin® and 
Lipofectamine™, Effectene®, Fugene® 6, and Metafectene®, etc., are now being used for genetic 
engineering of cells76-79. Even if liposome-based DNA delivery systems were one of the earliest 
strategies used to introduce exogenous genetic material into animal cells, lipofection studies 
specifically dealing with MSCs are scarce. Hoelters et al. transfected human MSCs (hMSCs) with 
three different liposome-based transfection reagents and a plasmid containing the sequence for 
enhanced green fluorescent protein (EGFP)76. The highest fraction of fluorescent cells was 
obtained using Lipofectamine™2000 (50%), followed by Metafectene® (22%), and Lipofectamine 
Plus™ (13%). Often, these commercially available liposome-based vectors are used as reference 
materials in gene delivery studies for the evaluation of the performance of new gene carriers, as 
can be noticed throughout this review. In one of these studies, Hamm et al. were unable to 
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transfect hMSCs using 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), Effectene™ and 
Lipofectamine Plus™ 42. Indeed, this is not the unique case for which liposome-based vectors 
were shown to be inefficient for MSCs transfection.  
 
Vanderbyl et al. demonstrated the potential utility of mammalian artificial chromosomes 
(ACEs) for the ex vivo gene therapy of MSCs80. ACEs are autonomous, being stably maintained 
in cell nucleus without integrating in cell genome. ACEs delivery was shown to be possible into a 
variety of mammalian cell lines and primary cells using cationic lipids81. Vanderbyl et al. work 
presented the transfer of ACEs into bone marrow derived hMSCs using Lipofectamine Plus™ (4-
5 days post-transfection, 11% of the cells were positive for the protein coded in the reporter 
gene). 
In general, the literature reveals that transfection levels attained with liposome-based 
vectors in MSCs are low and MSCs source-dependent. Also, due to their capacity to interact with 
biological membranes, the cytotoxicity of these carriers is often considerable and has been 
pointed out as a limiting factor for liposomes application in gene delivery. 
 
 
3.1.2. Synthetic polymer-based vectors 
 
Polymers are very versatile molecules that can be tuned to act as gene carriers. Variations 
in polymer molecular weight, 3-D architecture, size, chemical composition, number of repeating 
units, degree of branching, side chain length, density, etc., may be used in vector’s design. 
Cationic polymers have been used since last three decades as a material for gene delivery31-33. 
They possess high density of positively charged primary amines which can interact with the 
negatively charged phosphate groups of DNA to form condensed structures (polyplexes) which 
enter cells by endocytosis. “Polyfection” is a term currently used to mean transfection mediated 
by polymers. 
 
Poly-L-lysine (PLL) was the first cationic polymer based gene delivery vehicle82. Earlier 
studies served to elucidate its unnecessary cytotoxicity associated with an intrinsic limited activity 
and a tendency to aggregate and precipitate depending on the ionic strength of the solution83,84. 
Recently, Farrell et al. investigated the potential of PLL as a gene carrier for modification of bone 
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marrow derived MSCs85. In vitro studies by flow cytometry showed a poor delivery and 
transfection efficiency of pDNA to MSCs85. In an effort to improve its properties as a gene vehicle, 
PLL was conjugated with palmitic acid (PA) via amide linkages. PA, a naturally occurring lipid, 
was shown to improve the interaction of polyplexes with the lipid bilayer of plasma membrane. 
PLL-PA conjugate resulted in a ~10 fold increase in the cellular uptake which was attributed to 
better cellular binding and internalization of the conjugate as quantified by flow cytometry. This 
improved delivery of pDNA was clearly evident in EGFP expression by MSCs86. PLL-PA 
conjugate was further compared with the lipid-based transfection agent Lipofectamine™2000 for 
plasmid delivery to MSCs. The conjugates achieved a maximum transfection efficiency of ~22%, 
which was significantly higher than Lipofectamine™2000 mediated transfection (11%). Also 
increased transfection efficiency with additive effect was observed for PLL-PA and 
Lipofectamine™2000 combination87. 
 
Polyethylenimine (PEI) based gene carriers are popular due to their superior gene 
transfection when compared to other systems, being often used as a reference in gene delivery 
experiments. PEI exists in both linear and branched forms but the linear molecule is considered 
more efficient as gene carrier than the branched material, with several linear derivatives of PEI 
being available commercially as transfection agents, such as ExGen500 and jetPEI™88-90. PEI is 
believed to have a “proton-sponge” effect, that is, it acts as a buffer system inside endosomes 
leading to pumping of protons and concomitant influx of chloride anions into these organelles, 
increasing their internal ionic strength and causing their osmotic rupture; lysosomal trafficking of 
pDNA is then avoided, polyplexes are delivered into the cytoplasm, and pDNA degradation is 
circumvented. PEI has been studied as a gene carrier over a wide range of molecular weights 
(0.42-800 kDa) with highest transfection efficiency at molecular weights between 12-70 kDa91,92. 
Recently, several groups have evaluated the transfection potential of PEI into MSCs from 
different sources. Ahn et al. reported transfection up to 10% when pDNA/PEI polyplexes were 
delivered into rat bone marrow derived MSCs93. A good transfection efficiency was achieved at 
an N:P ratio (N= number of primary amines in the polymer; P= number of phosphate groups in 
the pDNA backbone) of 16 which was comparable with that obtained with Lipofectamine™. 
However, at this N:P ratio, only 15% cells were viable as the cationic charge of polyplexes 
resulted in cytotoxicity. In another study, human adipose tissue-derived MSCs were employed to 
study the gene transfer properties of pDNA/PEI polyplexes94. The highest transfection efficiency 
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was observed at an N:P ratio of 8, decreasing with further increase in N:P ratio, which was 
attributed to the increased toxicity. Functionalization of PEI has been used to improve the 
physicochemical and biological properties of PEI as a gene carrier. A gene delivery system (PEI-
RGD) designed for cell targeting was developed by incorporating integrin-binding RGD (arginine-
glycine-aspartic acid) peptides in PEI structure95. PEI-RGD complexes did not lead to a better 
transfection and displayed a negative effect on PEI binding to bone marrow derived MSCs. In an 
effort to improve the transfection efficiency of branched PEI into hMSCs while maintaining cell 
viability, Saraf et al. covalently combined hyaluronic acid (HA) with PEI96. They hypothesized that 
HA could improve the cell targeting as it binds CD44 receptors expressed by hMSCs at their 
surface and also reduce the toxicity by balancing the cationic amine groups of PEI with the 
carboxylic groups present in HA. PEI-HA was found to be more cytocompatible and feasible for 
tissue engineering applications showing cell viability levels of about 86.0 ± 6.7% and a maximum 
transfection efficiency of 33.6 ± 13.9%. In an interesting study, pDNA/PEI polyplexes were 
encapsulated in poly(ethylene glycol) (PEG) hydrogels cross-linked with matrix metalloproteinase 
peptides in an attempt to develop methods for the assessment of gene transfer of infiltrating 
cells97. The infiltrating mouse bone marrow cloned MSCs being transfected multiple times as they 
encountered new polyplexes during their migration into the scaffold showed gene expression that 
rose several times through the incubation. 
 
Synthetic polymers can show significant cytotoxicity which limits their clinical application. 
So, several research works focused on the development of biodegradable non-toxic polymers for 
gene delivery32-34. Such vectors have the advantage to be eliminated after pDNA release, being 
their degradation products non-toxic. Several biodegradable polymers are being investigated for 
nucleic acid delivery, such as polyesters, polyurethanes, PLL and PEI based degradable cationic 
polymers, phosphorus containing polymers, polymers with degradable side chains, polylactic acid 
(PLA) and poly (lactic-co-glycolic acid) (PLGA)32-34. To date, only few studies report the use of 
biodegradable polymers for transfection of MSCs. Gwak et al. developed PLGA nanospheres as 
vehicles for gene delivery to human cord blood-derived MSCs98. The authors were the first to 
report the low cytotoxicity and long-term transgene expression of PLGA nanospheres compared 
to PEI. In addition, a library of poly(β-amino esters) end-modified derivatives was recently tested 
for gene delivery to hMSCs, human adipose-derived stem cells (hADSCs) and human embryonic 
stem cell-derived cells (hESCds)99. The best polymeric vector exhibited transfection efficiencies 
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of about 27 ± 2% in hMSCs, 24 ± 3% in hADSCs, and 56 ± 11% in hESCds, with high cell 
viability (87–97%) achieved in all cell types.  
 
 
3.1.3. Natural polymer-based vectors 
 
Naturally derived non-viral vectors including chitosan, pullulan, gelatin, alginate, dextran 
and their modified derivatives are being employed for a range of gene delivery applications31,33. 
The use of natural polymers as non-viral vectors is being extensively studied due to their reduced 
toxicity and because they can provide greater stability in physiological fluids. The 
biodegradability, biocompatibity and potential of functionalization of these natural polymers can 
be explored when designing a gene delivery vector. Chitosan, a cationic polysaccharide obtained 
by deacetylation of chitin, has a strong affinity for DNA and has been investigated as a gene 
delivery vehicle in several types of cells100-103. Variables such as degree of deacetylation, serum 
concentration and pH of the transfection medium, and stoichiometry of complex were shown to be 
important in enhancing the transfection efficiency. Although it is the most studied naturally derived 
non-viral vector, only recently chitosan-DNA complexes have been applied for the transfection of 
MSCs by Corsi et al.104. In this study, the transfection efficacy and the cell viability of the 
complexes on hMSCs, human osteosarcoma and human embryonic kidney cells were compared 
to Lipofectamine™ 2000. Results showed a transfection efficacy that was cell type dependent 
and always lower than that obtained using the lipidic vector. However, chitosan-DNA 
nanoparticles were significantly non-cytotoxic when compared to the complexes formed by 
Lipofectamine™ 2000 and DNA (for which toxicity was around 50%). When MSCs were 
employed, transfection efficiency was very low, independently of the chitosan molecular weight 
tested (150, 400, 600 kDa) showing transfection levels similar to those obtained using naked 
DNA. A recent study with hMSCs reported higher cell attachment, higher cell viability and 
desirable gene expression when complexes formed by a plasmid encoding for Bone 
Morphogenetic Protein-2 (BMP-2) and chitosan nanoparticles were delivered from 
PLGA/hydroxylapatite (HA) composite scaffolds105. Also Hu et al. prepared multilayered and 
gene-functionalized titanium films composed of chitosan and pDNA to investigate the surface-
mediated in situ differentiation of MSCs106. They demonstrated that the films over titanium were 
beneficial for sustained in situ inducing osteoprogenitor cells to differentiate into mature 
osteoblasts over long time. 
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Recently, pullulan, a polysaccharide polymer consisting of maltotriose units, was 
chemically cationized using spermine to prepare a naturally derived non-viral carrier for gene 
transfection107. In this study, a new reverse transfection method was evaluated wherein the 
spermine-pullulan/pDNA complex was coated onto a culture substrate together with pronectin 
(cell-adhesion molecule), and then rat MSCs were cultured on the coated substrate. The reverse 
transfection method significantly enhanced and prolonged gene expression in MSCs when 
compared with the conventional method. The level and duration of gene expression in MSCs was 
significantly enhanced when the reverse transfection method was further carried out in a 3-
dimensional culture substrate of polyethylene terephthalate (PET) coated with the complex and 
pronectin and using stirring culture methods. This was attributed to the medium circulation that 
improved the culture condition of cells in terms of oxygen, nutrition supply and waste excretion. 
Hosseinkhani et al. used dextran, a polysaccharide, cationized with spermine to complex 
pDNA108. The study was done to enhance the gene transfection of MSCs by combination of a 3-
dimensional tissue engineered scaffold and a non-viral gene carrier. A collagen sponge 
reinforced by incorporation of poly(glycolic acid) (PGA) was selected as scaffold and the 
polysaccharide derivative-plasmid DNA complexes were there impregnated. The expression 
levels of MSCs significantly increased when seeded into the scaffolds and cultured in a 3-
dimensional environment. In an effort to enhance gene transfection to MSCs and in vivo bone 
formation, the same group also used gelatine, a denatured form of collagen, cationized with 
spermine to deliver a pDNA encoding for BMP-2109. Static and perfusion culture methods were 
used for these studies to evaluate the effect of the culture system on the transfection efficiency, 
being the perfusion method superior to the static one – perfusion facilitates the supply of nutrients 
and oxygen to the cells and the excretion of harmful metabolic products, thus resulting in better 
cell proliferation and higher gene transfection. 
 
 
3.1.4. Dendrimer-based vectors 
 
A disadvantage of classical polymers is that they are polydisperse materials (they have 
undefined molecular weights), being more difficult to assure the reproducibility of their 
formulations. Dendrimers, which have been classified as polymers although possess well-defined 
3D architectures and specific molecular weights, are attractive molecules to be used in gene 
delivery. They are tree-like molecules, composed of different layers (called “generations”), and a 
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high multivalent surface. Poly(amidoamine) (PAMAM) dendrimers with amine termini are the most 
studied dendrimers for gene transfer and have been shown to present an intrinsic ability to 
associate, condense and efficiently deliver pDNA into a wide variety of cell types33,74,110,111. They 
possess primary amines at the surface and tertiary amines in their interior that, like previously 
described for PEI, lead to a “proton-sponge” effect. PAMAM dendrimers are also described as 
possessing low cytotoxicity and immunogenicity110-112. Partially degraded PAMAM dendrimers, 
also called “activated dendrimers”, are also available in the market (under the names SuperFect® 
and PolyFect®) and, like some liposome-based carriers, are also frequently used as reference in 
gene delivery assays113,114. 
 
Very recently, our group reported the first study on the use of native PAMAM dendrimers 
(without any treatment or functionalization) as gene delivery vehicles towards bone marrow 
derived rat MSCs115. The results revealed that the level of transfection was low and dependent on 
the dendrimer’s generation, the N:P ratio and the cell passage number. However, using a plasmid 
encoding for BMP-2, the low level of transfection was sufficient to induce the in vitro osteogenic 
differentiation of MSCs as shown by several osteogenic markers. Other authors, have found that 
PolyFect® and SuperFect® were able to deliver pDNA to rat MSCs with transfection efficiencies of 
16.29 ± 7.44% and 9.59 ± 3.12%, respectively, both values being lower than that obtained with 
LipofectamineTM2000 (19.60±3.12)116. Studies conducted by Holladay et al. presented collagen 
scaffolds as a reservoir for non-viral gene delivery to rat MSCs117. They used complexes 
composed of SuperFect® and pDNA entrapped in the 3D collagen matrix and results showed a 
slow and sustained rate of transfection with a longer time of transgene expression. The authors 
postulated that primary cells, being more sensitive to matrix interactions, would beneficiate from 
the 3D environment which would act as a powerful adjuvant for gene delivery in these cells.   
 
The great potential of dendrimers in the biomedical area is related with their versatility in 
terms of chemistry. Dendrimers can be obtained from different building blocks, can have different 
functional groups, can grow from low until high generations, can retain small molecules in their 
interior, and can be used as templates for nanoparticle synthesis, etc.111. In terms of gene 
delivery, the functionalization of dendrimers with chemical moieties that have targeting 
capabilities is being explored as a powerful tool35,118. Dendrimeric systems can be tailored to the 
desired application by linking functional groups at their surface which are recognized by receptors 
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existent in the cytoplasmic membrane, in the nuclear membrane and/or in the extracellular matrix 
of the target tissue or cell population. Our most recent work devoted to PAMAM dendrimers 
consisted in their functionalization with peptides that are recognized by receptors at MSCs 
membrane119. In a first approach, PAMAM dendrimers (generation 5 and 6) were conjugated with 
up to 16 RGD containing peptides (that bind integrins at cell surface) leading to an improvement 
of transfection efficiency when compared with native dendrimers. In a second study, PAMAM 
dendrimers (generation 5) were engineered with osteotropic peptides with high binding affinity for 
MSCs120. This novel system presented low cytotoxicity and transfection efficiencies superior to 
those of native dendrimers and SuperFect®. By saturating cell receptors with the osteotropic 
peptide prior to transfection experiments, the transfection efficiency was similar to that of the 
native dendrimer showing the receptor-mediated nature of the process. In another study, we have 
functionalized PAMAM dendrimers with alkyl chains of different length at their periphery121. These 
systems showed a remarkable capacity for mediating the internalization of pDNA with minimum 
cytotoxicity, being this effect positively correlated with the –CH2– content of the alkyl chains. 
Gene expression in MSCs was found to be greatly enhanced using these lipidic dendrimers but, 
in this case, the higher efficiency was shown by the vectors containing the smallest –CH2– 
content. 
 
 
3.1.5. Inorganic nanoparticles 
 
Inorganic nanoparticles have emerged as attractive novel non-viral gene carriers in the last 
decade122,123. Inorganic nanoparticles, such as calcium phosphate, carbon nanotubes, gold, 
silica, iron oxide, quantum dots and double hydroxide possess several properties suitable for 
cellular delivery124. Although they have been shown to exhibit moderate transfection efficiencies, 
some of the advantages make them score over other non-viral vectors like availability, low 
polydispersity, shape control, good storage stability, capability of targeted (by surface 
functionalization) and controlled delivery, as well as the possibility of having low toxicity. 
 
Until the present, very few studies of DNA delivery to MSCs using inorganic nanoparticles 
have been reported. Uchimura et al. conjugated colloidal gold nanoparticles to DNA/Jet-PEITM 
complexes in an attempt to enhance their uptake by hMSCs having in mind their application in 
cell array-based analyses and in regenerative medicine125. Negatively charged gold colloids of 
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different diameters were used as nano-scaffolds which formed complexes via electrostatic 
interactions with the positively charged Jet-PEITM reagent. A 2.5-fold increase in gene 
transfection was obtained as compared to the control without gold nanoparticles. In an elegant 
approach, MSCs were coated with acid-functionalized calcium phosphate nanoparticles to 
prepare an osteoinductive hybrid “living” material126. The functionalized HA nanoparticles 
provided a 3D structural support that stimulated cell differentiation in the absence of osteogenic 
media. A plasmid encoding for the green fluorescent protein (GFP) was incorporated in the 
construct and it was shown that gene expression was enhanced when compared to 2D methods 
involving adherent cells.  
 
 
3.2. Physical Methods 
 
The non-viral chemical methods discussed till now here are being extensively investigated 
for improvement of the transfection efficiency, but for their success they need to circumvent 
numerous barriers to get desired rate and extent of gene delivery. It is postulated that physical 
approaches may prove to be an efficient tool for transfecting hard-to-transfect cell lines and 
specially primary cells29,30. As for chemical methods, successful in vitro and in vivo gene 
expression by physical methods requires efficient DNA delivery while displaying low cell death. 
To fulfill these requirements, parameters inherent to each method should be properly optimized 
according to the cell characteristics. Several classical physical methods including electroporation, 
nucleofection and sonoporation have been used to introduce DNA into MSCs, as well as cutting 
edge methods that make use of molecular vibrations or nanomaterials as tools for injection of 
genes into cells. 
 
 
3.2.1. Electroporation and Nucleofection 
 
In the electroporation technique, a high-intensity electric pulse is applied which makes the 
cell membrane highly permeable to DNA such that it directly enters into the cytoplasm and is 
trapped within the cell when the pores close again29. In a study, human and rat MSCs (rMSCs) 
were stably and successfully transfected with pDNA by electroporation at 600V and 100µs127. 
After electroporation, the transient expression of EGFP increased from 12 to 50% with the 
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exposure to chloroquine that was used to transiently inhibit lysosomes and limit plasmid 
degradation. However, the presence of chloroquine decreased stable integration. Recently, 
Ferreira et al. optimized the conditions for electrotransfer of the reporter gene lacZ into rat derived 
MSCs128. The pulse electric field intensity, electric pulse type, electropulsation buffer conductivity 
and electroporation temperature were the parameters studied for optimization of the process. 
This study confirmed the feasibility of electroporation to introduce genes in MSCs, simultaneously 
preserving their viability and multipotency. Also, a micro-electroporation concept has been tested 
with MSCs that employs alternating currents electrical pulses instead of a conventional direct 
current so as to avoid electrolytic gas bubble formation which could be responsible for the failure 
of the system129. 
 
NucleofectionTM is a relative new approach that combines electroporation and cell-type 
solutions to direct delivery of the DNA into the cell nucleus. This technique has been successfully 
applied for the transfection of hard-to-transfect cell lines and primary cells, including human bone 
marrow derived MSCs. NucleofectionTM of hMSCs induced high transient transfection efficiency 
(73.7 ± 2.9% and 42.5% ± 3.4 of GFP positive cells for U-23 and C-17 pulsing programs, 
respectively) compared with the non-viral systems FuGENE6 (4.4 ± 2.2%) and DOTAP (6.8 
±4.1%)130. U-23 and C-17 pulsing programs were designed for obtaining high transfection 
efficiency and a high cell survival, respectively. Cell viability was 44.5±3.9% for program U-23 
and 94.3±0.9% for program C-17. In a previous study of Hamm et al., the same technology was 
used for various primary cells, including hMSCs, using ten different pulsing programs42. They 
were able to transfect all primary cells with high efficiencies (45.3±5.6% of GFP fluorescent cells 
in the case of hMSCs), whereas for the same cells unsatisfactory transfection was obtained with 
various liposome systems. Cell viability was however low, being 16.5±9.3% for hMSCs. 
Lakshmipathy et al. compared nucleofection and electroporation methods to introduce pDNA into 
embryonic and MSCs131. Nucleofection was found to be superior to the conventional method and 
transfected both transiently and stably at a rate nearly 10-fold higher. In another study, 
nucleofection also provided a much better rate of transfer than electroporation particularly in 
hMSCs132. Importantly, the authors showed that transfection efficiency varied with the origin of 
the cells. Transfection efficiency in rMSCs was about three fold higher than in hMSCs. 
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3.2.2. Sonoporation 
 
“Sonoporation” is a term employed when mechanical energy in the form of ultrasound is 
used to transiently enhance the permeability of the cell membrane and increase the efficiency of 
gene delivery29. Although effective, some disadvantages have been pointed out concerning this 
method as it is limited to a specific tissue type or anatomical region, requires complex equipment 
and causes damage to the cell membrane133.  
 
Otani et al. used, for the first time, ultrasound in combination with microbubbles (US-MB) to 
deliver nucleic acids (siRNA) into rMSCs134. The transfection efficiency was significantly 
enhanced but cell viability was significantly affected by US-MB treatment. However, cell viability 
was dependent on the acoustic intensity and not on the dose of microbubbles.  
 
 
3.2.3. Molecular vibration 
 
A non-invasive method for high-efficiency DNA transfection based on the principle of 
electric field-induced molecular vibration was introduced135. Genes penetrated into the cytoplasm 
by eliciting vigorous vibration between molecules and cells. Vibration was induced by two 
electrodes, which do not have direct contact with the cells nor create a current through the cell 
suspension during transfection. High efficiency of gene delivery and relatively low cell viability 
were observed for both human and chick MSCs. The results suggested that the principal cause of 
low cell viability was the incorporation of exogenous DNA, and not the molecular vibration force. 
 
 
3.2.4. Nanoinjection 
 
In an effort to develop a low-invasive and direct gene delivery method Han et al. injected 
DNA into single hMSCs using a nanoneedle guided by an atomic force microscopy (AFM) 
system136. Cell viability was maintained without apoptosis signs. Despite of some limitations like 
availability of AFM apparatus, and time consumption in nanoneedle fabrication and operation, this 
strategy is unique for accurate single-cell analysis. 
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Park et al. developed a new platform for intracellular delivery of genetic material based on 
vertically aligned hollow carbon nanotubes arrays of controllable height and showed that that 
technology efficiently delivered pDNA to hMSCs137. They showed that the tubes acted like 
nanosyringes injecting genes inside cells. 
 
 
4. THERAPEUTIC APPLICATIONS 
 
There has been a growing body of literature suggesting the inherent potential of MSCs for 
experimental and clinical applications. MSCs are being explored as cellular vehicles for 
therapeutic genes, for a wide range of acquired or inherited disorders of bone, cartilage, muscle, 
tendon and ligaments, and also haemophilia, Parkinson’s disease, Alzheimer’s disease, and 
spinal cord injury1-9,138-146. In this section, we present an overview of the studies comprising the 
delivery of therapeutic genes by non viral approaches specifically to MSCs having in mind tissue 
engineering and regeneration applications.   
 
4.1. Bone tissue  
 
One of the most widely examined applications of non-viral genetically engineered MSCs to 
date has been in the context of bone tissue engineering and regeneration2,6. The use of non-viral 
systems has been shown to be promising since short-term gene expression is sufficient for bone 
formation147. Several strategies have been proposed for gene therapy applications in bone 
regenerative medicine (Figure 2). The first one involves the immobilization of gene carriers into 
nano- or micro-scaffolds designed to control the DNA release and support the cells proliferation at 
the target site. In this case, the cells are recruited from the body and MSCs are not the only cells 
to be transfected. Due to the relevance and success of these studies, we decided to include them 
also in this discussion. The scaffolds can be, or not, associated with non-viral gene delivery 
vectors that are able to condense and protect pDNA. 
 
In 1990’s, one of the pioneer works was devoted to the indirect delivery of bone growth 
factors in situ using gene-activated collagen matrices148. A plasmid DNA encoding for bone 
morphogenetic protein-4 (BMP-4) and a plasmid DNA encoding for a fragment of parathyroid 
hormone (amino acids 1-34, PHT1-34) were physically entrapped in the collagen sponge to form 
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a gene-activated matrix (GAM), which was shown to promote wound healing. After migration of 
surrounding host cells to GAM, cells were able to transiently express BMP-4 and PHT1-34 and to 
induce new bone formation. GAM with both plasmids worked synergistically in faster bridging of 
the gap than the delivery of either plasmid alone. In a later study, localized pDNA delivery for 
approximately 6 weeks was achieved using GAM strategy and a plasmid encoding for PHT1-
34149. The GAM with highest dose of pDNA (100mg per sponge) showed stable, reproducible, 
and dose- and time-dependent new bone formation over at least a six month period. 
 
 
Figure 2. Gene delivery strategies. Therapeutic transgenes may be delivered to bone defects by (A) direct 
application of gene carrier to the defect or loading the gene carriers onto a biomaterial support (the biomaterial 
support can deliver the DNA to cells inside the surrounding tissue or can target those cells infiltrating the scaffols or 
gels), (B) carriers incorporated into the biomaterial support together with cells (hybrid system), or (C) genetic 
engineering of cells in culture and subsequent implantation into the defect. 
 
In another study, Kasper et al. examined and reported lack of enhancement in bone 
formation using the same strategy with novel hydrogel composites of oligo(poly(ethylene 
glycol)fumarate) and cationized gelatine microspheres loaded with DNA150. It was likely due to the 
low release of plasmid DNA from the composites attributed to the lack of complete degradation of 
cationized gelatine microspheres. Kuroda et al. modified collagen scaffolds with calcium 
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phosphate precipitates (CaP)  and successfully enhanced the efficiency of plasmid gene transfer 
in vivo151. Later, the authors evaluated the performance of the modified GAM using a pDNA 
encoding for BMP-2 on critical size bone defects152. The systems completely bridged the bone 
defects in less than half the time needed in the previous studies and using a lower DNA 
dose148,149. Thus, the use of pDNA condensing agents in association with GAM may avoid the 
use of high doses of plasmid which are not practical and might induce some side-effects. 
 
Studies in rat cranial critical-sized defects demonstrated that PLGA scaffolds were able to 
deliver pDNA encoding for BMP-4 condensed with PEI in a sustained manner and thus to 
enhance bone formation153. Nie et al. investigated the bone regeneration capability of BMP-2 
plasmid loaded PLGA/HA composite scaffolds in the nude mice154. When naked pDNA was used 
as a coating in fibers surface the release of plasmid was faster and scaffolds performance was 
better in the first two weeks. At four weeks of treatment, the fibers coated with pDNA/chitosan 
nanoparticles performed better. The in vitro release profiles of pDNA were influenced not only by 
the DNA presentation, but also by the HA content in the scaffolds. Previously, Ono et al. reported 
the combination of porous HA and cationic liposomes as a carrier for the BMP-2 gene155. 
Conversely, this study reported that osteogenesis was apparently faster in the rats treated with 
BMP-2 plasmids without scaffolds than in the ones treated with scaffolds. In another study, 
liposomal vectors carrying pDNA encoding the BMP-2 gene were directly introduced into peri-
implant bone defects in pig calvariae with autologous bone grafts resulting in significantly 
enhanced new bone matrix formation after 4 weeks78.  
 
The use of physical methods for the in vivo gene delivery of therapeutic genes has also 
been attempted in bone regeneration approaches. In this situation, naked pDNA containing the 
gene of interest is previously injected into the injured site and, only after, transfection is achieved 
using physical means. In a study of Kishimoto et al., in vivo electroporation was adopted as a 
gene transfer system for pDNA encoding the BMP-4 gene156. More recently, sonoporation based 
non-viral gene delivery was developed which induced bone formation in vivo for skeletal 
disorders157. This direct gene delivery system was simple, cost effective and delivered BMP-9 
gene sufficient enough to elicit bone formation in an ectopic site. Though it was not clear which 
cells were responsible for the formation of bone tissue, the authors speculated that myocytes, 
muscle progenitors and satellite cells received the gene and expressed it. They refer that the 
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expressed protein might recruit both bone marrow-derived osteoprogenitor cells in the blood 
stream and skeletal muscle-derived osteoprogenitor cells within the muscle. 
 
A different and more controllable strategy was used by co-localization of MSCs and genes 
within a scaffold and by performing transfection in a 3D environment. Also here, non viral vectors 
can be introduced in the system to protect DNA and facilitate transfection of MSCs. Hosseinkhani 
et al. have published several studies concerned with the in vitro transfection of MSCs inside PGA 
fiber reinforced collagen based scaffolds and using cationized gelatin, cationized dextran or PEI 
as non viral vectors108,109,158,159. Gene expression in vitro was positively influenced by the 3D 
environment, by the use of non-viral condensation agents, and by the perfusion method used in 
cell culture. Indeed, scaffolds can guide cell organization and spatial arrangement, providing a 
higher available surface area for cell attachment and proliferation and interfering in the 
transmission of biochemical and mechanical signals among cells. Furthermore, in a perfusion 
culture method, medium is recycled and continuously renewed guaranteeing nutrients and 
oxygen for cells growing in the 3D matrices while wastes and harmful metabolic products from 
cells can be avoided. The implantation of such kind of systems into the back subcutis of rats 
resulted in ectopic bone formation109. 
 
An elegant demonstration comprising a scaffold, a dual factor delivery and MSCs 
dramatically enhanced bone regeneration160. Cells were seeded within PLGA scaffolds containing 
vascular endothelial growth factor (VEGF) and condensed plasmid DNA (using PEI) encoding for 
bone morphogenetic protein-4 (BMP-4) and were then implanted into the subcutaneous tissue of 
mice. All these factors acted synergistically to provide new bone formation of greater quantity and 
quality in comparison with the single factors alone. Such multi-factor scaffold delivery systems 
mimic the natural microenvironment more closely and can have broader implications in tissue 
regeneration and engineering. 
 
MSCs can simply be transfected in vitro adherent to the surface of cell culture dishes, in a 
2D environment, with or without the aid of non-viral vectors, and then be implanted with or without 
the support of a scaffold to help bone tissue regeneration. Park et al. reported a study where 
rMSCs were genetically engineered ex vivo making use of either adenoviruses or liposomes 
carrying a pDNA encoding for human BMP-2 and, after, transplanted into rat mandible critical size 
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defects79. Both vectors were shown to be suitable for cell transfection and for bone defect healing 
achievement. As liposomes have proven sufficient for the purpose and do not present the 
disadvantages of viral vectors, the authors suggested that they should represent the best vector 
for future clinical trials of bone regeneration by BMP-2 gene therapy. In contrast, Blum et al. 
showed that among ex vivo genetically modified rMSCs by adenoviral, retroviral and cationic lipid 
vectors, after implantation within titanium fiber mesh scaffolds, the performance of MSCs 
modified by adenoviral vectors was better in the percent of bone formation in orthotopic critical-
size defects created in the rat cranium161. Physical methods of gene delivery can also be used for 
the ex vivo genetic engineering of MSCs for posterior implantation. NucleofectionTM based 
genetic modification of human MSCs was found to be efficient to deliver hBMP-2 and hBMP-9 
genes to form bone tissue in vivo162. Nucleofected MSCs were injected directly in ectopic sites in 
a mouse model and the harvested transplants showed bone formation 4 weeks post-injection. 
Using this method, the authors were able to induce moderate levels of BMP-2 expression in an 
attempt to mimic physiological conditions.   
 
 
4.2. Cartilage tissue 
 
Cartilage engineering and regeneration may be needed due to trauma or as a result of 
degenerative diseases. For this, chondrocyte-based therapy may represent a good choice even if 
it is difficult to obtain sufficient amounts of autologous chondrocytes for clinical application. MSCs 
are potential candidates as source of cells for chondrocytes as it has been reported that they 
have the ability to differentiate into chondrocytes by exposure to appropriate chondrogenic 
differentiation factors17. Reviews on gene therapy for cartilage repair have been published but the 
number of mentioned studies involving MSCs and non viral delivery systems are scarce17,21.  
 
The design of gene delivery strategies for cartilage regeneration is similar to the one 
described for bone tissue repair. Scaffolds, non-viral vectors, genes and cells can be combined to 
attain the desired effect. In addition to genes with anabolic chondrogenic effects, the delivery of 
genes encoding for anti-inflammatory agents has also been performed as inflammation is often a 
problem impairing cartilage regeneration17. 
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Katayama et al. transfected autologous rabbit bone marrow derived MSCs by lipofection 
(FuGENE®) in a monolayer culture and using the gene coding for cartilage-derived 
morphogenetic protein 1 (CDMP1)163. CDMP1 is a morphogen believed to be involved in skeletal 
development and joint morphogenesis. It has been shown to modulate MSCs in vitro and to 
maintain cell viability and chondrogenic differentiation in vivo. The genetically modified cells were 
then implanted into full-thickness articular cartilage defects in the rabbit knee joints resulting in an 
enhancement in cartilage regeneration in comparison with untreated cells. The regeneration 
occurred with hyaline cartilage filling the defects and reconstruction of subchondral bone over 
time. Similar articular cartilage repair in rabbits was demonstrated by Guo et al.164. In this study 
MSCs were transfected using LipofectamineTM and a gene coding for transforming growth factor 
beta 1 (TGF-β1). TGF-β1 is a multifunctional molecule important in the promotion of cartilage 
repair, and inhibition of inflammatory and immune responses. Modified MSCs were then seeded 
in biodegradable poly-L-lysine coated polylactide biomimetic scaffolds in vitro and allografted into 
full-thickness articular cartilage defects of rabbits. Joint repair was improved and occurred with 
synthesis of hyaline cartilage at the upper portion of the defect, reconstitution of the subchondral 
bone at the lower portion of the defect and inhibition of inflammatory and immune responses. 
 
In an innovative experiment of Babister et al., hMSCs were modified in vitro with the gene 
coding for Sox-9 by NucleofectionTM 165. Sox-9 is a high-mobility group domain transcription factor 
believed to have an essential role in chondrogenesis. It is required for the conversion of 
condensed mesenchymal cells into chondrocytes and prevents conversion of proliferating 
chondrocytes into hypertrophic chondrocytes17,166. The authors developed a “bead-in-bead” 
system encapsulating transfected (in an alginate “guest” bead) and non-transfected cells (in a 
chitosan “host” bead) in different localizations of the constructs. In vivo studies were performed 
for a period of 28 days by subcutaneously implantation in mice. The regions with transfected cells 
showed the presence of chondrocitic cells and a cartilaginous matrix positive for proteoglycans, 
type II collagen and Sox-9. In vitro assays were also done and were in agreement with the in vivo 
data. A previous study of Tsuchiya et al. used lipofection to demonstrate the potential of Sox-9 
delivery into MSCs for chondrogenesis promotion167.  
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4.3. Other tissues 
 
MSCs can differentiate into a myriad of cell types and examples can be found in the 
literature of genetically modified MSC-based experiments using non-viral systems for the 
regeneration of tissues other than bone or cartilage. It is the case of cardiac and neural tissues 
for which this approach seems to be very promising. 
 
It is known that transplantation of MSCs into cardiac tissue induces angiogenesis and 
improves cardiac functions, thus acting as a tool for tissue repair168. MSCs can differentiate into 
cardiomyocytes and vascular endothelial cells and further act through paracrine pathways to 
trigger angiogenesis as shown by Miyahara et al.169. The authors transplanted monolayered 
MSCs onto scarred myocardium and the engrafted sheet gradually grew to form a thick stratum 
that included newly formed vessels, undifferentiated cells and few cardiomyocytes. Jo et al. 
further reported that genetically engineered MSCs significantly improved cardiac functions 
compared to MSCs alone170. The authors used a spermine-dextran complex with pDNA encoding 
for adrenomedullin, a potent vasodilator peptide with anti-apoptotic and angiogenic properties, for 
genetic engineering of rMSCs. The transfected cells reduced apoptosis in vitro and in vivo and 
enhanced the therapeutic efficacy in a rat myocardial infarction model. The proposed strategy 
represents a promising therapeutic tool to increase the survival of engrafted MSCs and overcome 
the limitation of a low viability microenvironment like happens in ischemia.  
 
In another study, Potapova et al. tested the ability of hMSCs to deliver a biological 
pacemaker to the heart171. hMSCs were transfected with a cardiac pacemaker gene by 
electroporation and were shown to influence the beating rate in vitro when plated onto a localized 
region of a coverslip and overlaid with neonatal rat ventricular myocytes. 
 
Dezawa et al. showed that it was possible to induce cells with neuronal characteristics, 
without glial differentiation, from MSCs using gene transfection with Notch intracellular domain 
(NICD, using LipofectamineTM 2000) and subsequent treatment with molecular factors that induce 
neuronal differentiation172. MSCs expressed markers related to neural stem cells after 
transfection with NICD, and subsequent trophic factor administration induced neuronal cells. This 
study showed that MSCs can play a pivotal role as an alternative source of cells for neural 
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regeneration and highlight the importance of MSCs genetically engineering in the process. The 
authors further tested the applicability of the induced neuronal cells in the treatment of 
Parkinson’s disease, a neurogenerative disorder, obtaining promising results. Later, Nagane et al. 
used a spermine-pullulan-mediated reverse transfection method to overcome the cytotoxicity 
issues associated with lipofection in MSCs173. Dopaminergic neurons, which are expected to 
apply to cell-based therapy in Parkinson's disease, were successfully induced from MSCs 
(derived from monkey, human and mouse) with high efficiency and low cytotoxicity.  
 
 
5. KEY ISSUES AND PROBLEMS TO BE SOLVED IN NON-VIRAL GENE DELIVERY TO 
MSCs 
 
From the current knowledge and experience in non-viral gene delivery to MSCs, there are 
already important general conclusions that can be drawn and that will certainly point out 
directions for future work. Key issues that must be addressed include: 
 
 
5.1. Type of non-viral gene delivery system 
 
Chemical and physical non-viral systems have been successfully applied in in vitro and in 
vivo situations for MSCs transfection. On one hand, physical methods give rise to higher 
transfection efficiencies but are less practical and can cause severe damage in cells and 
surrounding tissues. On the other hand, chemical methods, showing low or moderate levels of 
transfection, can be less cytotoxic and more versatile. In fact, most of the works show positive 
effects or therapeutic benefits even with low levels of transfection, revealing that transfection 
efficiency by itself may not be decisive for the all process. From the literature, it is clear that 
autocrine and paracrine signalling, as well as cell-to-cell contacts, can result in an amplification of 
the effects of gene delivery. As an advantage, non-viral delivery vectors can be chemically 
modified to interact with cell structures, namely with nuclear and cell surface receptors, likely 
improving gene transfer and toxicity parameters. Indeed, the nuclear membrane has been 
pointed out as the rate limiting step of the transfection process and the development of a high 
efficient non-viral vector able to overcome that barrier is still an outstanding challenge. Also, the 
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search for natural and biodegradable non-viral vectors is evident due to concerns related with 
cytotoxicity.  
 
 
5.2. MSCs vs the recruitment of body cells 
 
In vivo gene delivery can be done by simply gene injection or through the controlled 
release from implanted scaffolds. The use of non-viral vectors to assist the transfection process is 
advantageous. As exemplified by several works, these strategies are based on the recruitment of 
neighboring cells or body cells to the injured site and several cellular types can simultaneously 
suffer transfection. Although good results have been obtained with these approaches, the 
implantation (either by injection or seeded in a scaffold) of MSCs genetically engineered ex vivo – 
MSCs mediated gene delivery - should constitute a better option as a higher concentration of 
potential tissue building cells will be present at the injured site, and because such a system will 
depend on a less number of variables. Moreover the use of MSCs as vehicles for gene delivery 
may potentiate the expression of therapeutic genes for longer periods whereas the direct 
administration of genes will present an effect limited in time.  
 
 
5.3. Source of MSCs 
 
MSCs from different animals and origins within the animal body have been used for non-
viral gene delivery. The few reports that made comparisons among the behavior of MSCs of 
different sources revealed that the extension of cell response may diverge. Further work still 
needs to be done to understand these differences and to allow a confident extrapolation of the 
results for the clinical scenario. Moreover, further research on MSCs nature and properties, as 
well as on the methodologies for MSCs isolation and characterization, is required to optimize 
genetically modified MSCs-mediated therapies. 
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5.4. 2D (static culture) vs 3D environment (perfusion culture) 
 
Ex vivo MSCs transfection, with and without the contribution of non-viral vectors, has been 
performed in 2D monolayer cultures, usually using static cell culture methods, and in 3D 
environments for which perfusion culture methods are frequently used. The second case implies 
the previous seeding of MSCs inside a scaffold and has special interest in the tissue engineering 
area as scaffolds, after implantation, can be important to fill tissue gaps and to guide tissue 
regeneration. Works done also show that transfection by itself is more efficient in a 3D 
environment using perfusion culture methods as this approach allows the establishment of cell-
cell and cell-substratum interactions that better mimic the in vivo situation, as well as the 
continuous addition of fresh culture media and removal of waste products which will contribute to 
improve the metabolic state of the cells. 
 
 
5.5. Genes to be delivered 
 
Non-viral gene delivery does not pose restrictions to pDNA size and type. Literature shows 
that the choice of genes delivered into MSCs is only dependent on the body tissue to be 
regenerated, and that genes encoding for a wide range of functional proteins, anti-inflammatory 
agents, and transcription factors are being used. Although some works studied the effect of the 
combined delivery of different genes into MSCs, much work needs to be done to understand 
which genes, in which doses and when should they be delivered to MSCs to obtain the right 
therapeutic effect. 
 
 
6. CONCLUSION 
 
From the data accumulated over the last few years, it can be concluded that non-viral 
systems are actually able to deliver genes into MSCs thus controlling their behavior and fate. The 
interesting biological characteristics of MSCs together with non-viral gene delivery systems, can 
offer innovative therapies for disease treatment and tissue regeneration, as shown by the growing 
number of publications on the subject. In addition, by allowing the control of stem cell signals, 
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non-viral gene transfer is being used as a tool for understanding the biology and potentialities of 
MSCs.  
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CHAPTER II. 
Osteogenic Differentiation of Mesenchymal Stem Cells using PAMAM Dendrimers as Gene 
Delivery Vectors* 
 
 
ABSTRACT 
This paper reports the use of different generations of polyamidoamine (PAMAM) dendrimers for 
the in vitro transfection of mesenchymal stem cells (MSCs). A systematic study was carried out 
on the transfection efficiency achieved by the PAMAM dendrimers using a β-Galactosidase 
reporter gene system. Transfection results were shown to be dependent upon the generation of 
dendrimers, the amine to phosphate group ratio and the cell passage number. In all cases, the 
transfection efficiency was very low. Nevertheless, it was hypothesized that a low transfection 
level could be sufficient to promote the in vitro differentiation of MSCs towards the osteoblastic 
lineage. To address this possibility, dendrimers carrying the human bone morphogenetic protein-
2 (hBMP-2) gene-containing plasmid were used. All quantitative (alkaline phosphatase activity, 
osteocalcin secretion and calcium deposition) and qualitative (von Kossa staining) osteogenic 
markers were significantly stronger in transfected cells when compared to non-transfected ones. 
This study not only clearly demonstrates that a low transfection level can be sufficient for inducing 
in vitro differentiation of MSCs to the osteoblast phenotype but also highlights the importance of 
focusing research on the development of gene delivery vectors in the concrete application. 
 
 
 
 
 
 
 
*This chapter is based on the following publication : 
Santos JL
  
, Oramas E, Pego AP, Granja PL, Tomás H. Osteogenic differentiation of mesenchymal stem cells using 
PAMAM dendrimers as gene delivery vectors. J. Controlled Release 2009; 134: 141-148. 
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1. INTRODUCTION 
 
Stem cell-mediated gene therapy is currently one of the most attractive strategies under 
investigation for bone regeneration. In this approach, an osteoinductive factor is secreted by the 
cells that have been genetically modified to express the desired gene1-7. Reports on bone 
regeneration by genetically modified Mesenchymal Stem Cells (MSCs) mainly employ adenovirus 
or retrovirus vectors carrying bone morphogenetic proteins (BMPs) as therapeutic genes8-12. This 
can be attributed to the high efficiency in gene transfer by the viral vectors, especially in slowly 
dividing or non-dividing cells. However, the risk of mutagenesis and/or oncogenesis associated 
with viral systems, as well as their potential immunogenicity, provides a strong motivation for the 
search of alternative methods. In this scope, several investigations are currently focused on 
developing high efficiency nonviral vectors, covering a wide range of systems, such as the ones 
based on cationic polymers, liposomes and calcium phosphates13-15. In general, these systems 
have been shown to be effective in well-established cell lines but have limitations when using 
primary cell cultures, namely bone marrow-derived MSCs16,17. Also, authors often base their 
conclusions on reporter gene assays and disregard the concrete applications, not exploring the 
delivery of genes encoding for bioactive agents18,19.  
 
Dendrimers are spherical macromolecules that consist of a core moiety from which 
branches radiate. A typical dendrimer consists of a multifunctional central core, branched units 
(organised in layers called “generations”, G) and surface groups. Polycationic dendrimers entail a 
particularly interesting system for nuclei acid delivery. These molecules display a well-defined 
architecture as well as a high multivalent surface moiety (amino termini) to molecular volume 
ratio20-22. Polyamidoamine (PAMAM) dendrimers are amongst the earliest synthesized and 
commercialized dendritic systems. Since the pioneer work of Haensler and Szoka in 199323, 
these molecules have been tested and used as gene transfer agents in unmodified and modified 
forms24,25. Systems based on the PAMAM dendrimers have been shown to transfect a series of 
cell types, most of which include cell lines26. Gebhart et al. compared the performance of several 
dendrimeric systems and found that the transfection efficiency strongly varied not only with the 
kind of vector molecule but also with the cell-type27. 
 
 
CHAPTER II. Osteogenic Differentiation of MSCs using PAMAM Dendrimers as Gene Carriers  
 
49 
 
In the present work, the transfection efficiency achieved by different generations of 
PAMAM dendrimers was evaluated. MSCs were employed here due to their relevance in bone 
regeneration applications. To our knowledge, this is the first report on the use of polyamidoamine 
(PAMAM) dendrimers for in vitro transfection of MSCs. A β-Galactosidase reporter gene system 
was used and several experimental conditions were assayed. The transfection efficiency obtained 
for this system was always very low but it was however hypothesized that such low transfection 
levels could still be sufficient for the envisaged application, i.e., to improve the in vitro 
differentiation of MSCs towards the osteoblastic lineage. To confirm this possibility, MSCs were 
genetically engineered to express human BMP-2 (hBMP-2) using PAMAM dendrimers. The 
differentiation of the MSCs was studied in the absence of other osteoinductive factors (e.g. 
dexamethasone). This was achieved through the analysis of established markers of the 
osteoblastic phenotype, including alkaline phosphatase (ALP) activity, osteocalcin, and deposition 
of a calcified matrix. The results clearly indicate that the PAMAM/hBMP-2 system strongly 
induces in vitro differentiation of MSCs to the osteoblast phenotype. 
 
 
2. MATERIALS AND METHODS  
 
2.1. Materials and reagents  
 
Generations 5, 6 and 7 of the PAMAM dendrimers, possessing ethylenediamine cores and 
amine termini, were purchased in water solution from Dendritech Inc.. The chemical structures, 
molecular weights and number of amine surface groups presented by the dendrimers are shown 
in Table 1. Tissue culture plates were from NUNC. All other materials and reagents were 
obtained from SIGMA-ALDRICH unless otherwise stated.  
 
 
2.2. Isolation and culture of bone marrow-derived mesenchymal stem cells 
 
Rat bone marrow-derived MSCs were harvested from the marrow of young adult male (6 
weeks) Wistar rats (Charles River Laboratories, Spain) according to a previously described 
method28,29. Briefly, rats were euthanized using 1 ml of 20% pentobarbital. The femurs and tibias 
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were aseptically excised from the hind limbs. External soft tissue was discarded and the bones 
were then washed in α-Minimum Essential Medium (α-MEM) containing 5% antibiotic-antimycotic 
(AbAm) solution. Epiphyses were removed and the bone marrow was flushed out with α-MEM 
supplemented with 10% Foetal Bovine Serum (FBS, GIBCO), 1% AbAm and 50 µg.ml-1 ascorbic 
acid. This was done using a 21-gauge needle syringe. The cell suspension was seeded into six 
T-75 flasks and cultured at 37ºC and 5% carbon dioxide atmosphere. In order to remove 
nonadherent hematopoietic cells, the medium was changed on day 4 of culture, and every 3 days 
thereafter. Between days 7 and 10 the cells were trypsinized using trypsin-EDTA (GIBCO) and 
subcultured at a density of 2×104 cells.cm-2 for expansion. When they reached 90% confluency 
the cells were detached and subsequently used.  
 
Table 1. Molecular weight and number of amine surface groups for the three generations of PAMAM dendrimers 
used. 
Generation Molecular Weight Number of Amine Surface Groups 
G5 28,826 128 
G6 58,048 256 
G7 116,493 512 
 
 
2.3. Culture of human embryonic kidney cells 
 
Human embryonic kidney cells (HEK 293T) were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, GIBCO) with high glucose content and GlutaMAX-I containing 10% FBS and 
1% AbAm. For transfection experiments, HEK 293T cells were subcultured at a density of 2×104 
cells.cm-2. 
 
 
2.4. Plasmid propagation and isolation 
 
Plasmid DNA (pCMV SPORT-β-Gal, 7.8 kb, Invitrogen) encoding β-galactosidase under 
the control of the cytomegalovirus (CMV) promoter was used as a reporter gene to evaluate the 
transfection of MSCs by conventional measurement of β-galactosidase activity. For BMP-2 gene 
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delivery, a pcDNA3.1/Hist©/hBMP2 vector/plasmid (8.5 kb) (kindly donated by Prof. Yasuhiko 
Tabata, University of Kyoto, Japan) encoding a human BMP-2 sequence inserted downstream 
the CMV promoter was used. The plasmids were amplified in Escherichia Coli host strain, DH5α, 
grown overnight in Luria-Broth Base medium containing ampicillin. Afterwards, the plasmids were 
isolated and purified using a Qiagen Plasmid Maxi Kit (Qiagen). The isolated plasmids were 
dissolved in a small amount of ultra-pure water and the concentration of plasmid DNA in solution 
was determined from the UV absorbance at 260 nm. For evaluation of plasmid purity the 
absorbance ratio at 260 and 280 nm was measured and was always found to be in the range of 
1.7 and 1.9. The plasmid integrity was assessed through agarose gel electrophoresis. 
 
 
2.5. Cytotoxicity studies 
 
The cytotoxicity of the dendrimers and polyplexes was evaluated by the MTT assay. MSCs 
were seeded on 96-well plates at a density of 1.5×104 cells.cm-2 and cultivated in 100 µl of 
media. After 24 h the medium was removed, the cells were washed once with Phosphate 
Buffered Saline solution (PBS) and 85 µl of fresh medium containing 5% FBS was added. Then, 
15 µl of the dendrimers and polyplexes solutions were added to each well and incubated further 
for 4 h. The β-galactosidase reporter gene carrying plasmid was used in these cytotoxicity 
experiments and was kept constant at a concentration of 1 µg.cm-2 of plate surface. The 
polyplexes solutions were prepared by mixing 50 µl of α-MEM containing the adequate 
concentration of dendrimer with an equal volume of α-MEM containing the adequate 
concentration of plasmid DNA. The mixture was gently vortexed and incubated for 20 min at room 
temperature prior addition to the wells. The final concentration of dendrimers in polyplexes 
solutions, in the wells, ranged from 0 to 1000 nM. As the number of amine groups in the periphery 
of the dendrimers double in each generation, these conditions correspond to a range of N:P ratios 
tested of 0-13.3, 0-26.6 and 0-53.2 for the G5, G6 and G7 dendrimers, respectively. 
 
The polyplexes solutions were removed from the wells after 4h and replaced with fresh 
medium. The cells were incubated for 44 hrs, followed by the addition of 10 µl of MTT stock 
solution (5 mg.ml-1) per well. After further incubation for 3 h at 37ºC the medium was removed 
and 100 µl of DMSO was added to dissolve the formazan crystals formed by metabolically active 
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cells. Absorbance was measured at 550 nm and the cellular metabolic activity was expressed as 
a percentage of the value obtained for the control (untreated cells). 
 
 
2.6. Transfection assays using a β-galactosidase reporter gene 
 
For transfection assays using a β-galactosidase reporter gene carrying plasmid, MSCs 
were seeded (1.5×104 cells.cm-2) into 24-well plates and grown in 1 ml of culture medium for 24 h 
prior to transfection. At the time of transfection, the medium was replaced by 500 µl α-MEM 
containing 5% FBS. Polyplexes solutions were prepared as described in the last section for three 
N:P charge ratios (see Table 2). 50 µl of α-MEM containing the adequate concentration of 
dendrimer were added to an equal volume of α-MEM containing the adequate concentration of 
plasmid DNA. The mixtures were gently vortexed and incubated for 20 min at room temperature 
and then added to the wells. The polyplexes were incubated with the cells for 4 h and then 
removed and replaced with α-MEM containing 10% FBS and ascorbic acid. After 48 h, 
transfected and non-transfected cells (control) were washed with PBS, lysed in lysis buffer (0.25 
M Tris, pH = 8) and either analyzed immediately or stored at –20ºC for later analysis. The β-
galactosidase activity was detected spectrophotometrically (405 nm) using o-nitrophenol 
galactoside as the substrate and purified β-galactosidase enzyme as the primary reference 
standard. The β-galactosidase activity was normalized to the protein concentration in the lysed 
cell samples, which was measured by the BCA protein assay method. Each experiment was 
carried out two times independently.  
 
Cytochemical X-Gal staining was performed to visualize the β-galactosidase expression in 
transfected cells. The cells were incubated with a glutaraldehyde-formaldehyde fixing solution 
and then with a solution containing 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal, 
BDH-PROLABO). In transfected cells, β-galactosidase cleaves 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-Gal) to produce a blue stain. 
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2.7. Transfection assays using a plasmid carrying the hBMP-2 gene 
 
For dendrimer-mediated hBMP-2 gene delivery, MSCs (1.5×104 cells.cm-2) were plated in 
12- or 24-well plates at 37ºC in culture medium for qualitative and quantitative tests, respectively. 
After 24 h, the cells were transfected as described before, but now using the hBMP-2 plasmid 
(final dose of 1 µg.cm-2). After 4 h the medium was removed and the cells were washed with 
PBS. The cells (transfected and non-transfected) were cultured in complete  medium containing 
10% FBS, 50 µg.ml-1 ascorbic acid and 5 mM of β-Glycerophosphate. The medium was replaced 
every 2 days. At different time points, the cultures were characterized for osteogenesis 
evaluation.  
 
Table 2. Concentration of dendrimers in solution for the N:P charge ratios used in the transfection experiments (the 
concentration of DNA was always kept constant at a value of 1µg.cm-2 of plate surface). 
N:P ratio 
Concentration of dendrimers (nM) 
G5 G6 G7 
5:1 376 188 94 
8:1 602 301 150 
10:1 752 376 188 
 
 
2.8. Expression of the BMP-2 protein 
 
Three days after transfection, the expression level of BMP-2 gene was measured. 100 µl 
of the supernatant was collected and the amount of BMP-2 protein was determined by a human 
BMP-2 ELISA Kit (Human BMP-2 Super X-ELISA, Antigenix America INC., USA) according to the 
manufacturer’s instructions. 
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2.9. Alkaline phosphatase activity assay 
 
The intracellular alkaline phosphatase activity was quantified by using a colorimetric 
endpoint assay that involves the hydrolysis of p-nitrophenyl phosphate to p-nitrophenol. A 
standard curve was generated by using serial dilutions of p-nitrophenol, and the ALP values were 
normalized to the total protein in cell lysates. Cells were harvested after 7, 14 and 21 days in 
culture. Each experiment was carried out two times independently. 
 
 
2.10. Osteocalcin (OC) secretion assay 
 
The amount of OC secreted to the culture medium was measured by using a commercially 
available sandwich ELISA assay (BT-490), specific for rat osteocalcin (BTI, Stoughton, MA). The 
ELISA assay is based on two goat OC antibodies, recognizing both the carboxylated (C-terminal 
protein) and the decarboxylated (N-terminal protein) rat osteocalcin. Media samples were 
collected at 14, 21 and 28 days of the culture period and stored at -20 ºC for later analysis. These 
samples were thawed on an ice bath, vortexed for 10 s and analysed according to the 
manufacture’s recommendations. The lowest detectable level of OC with this assay kit is 0.5 
ng.ml-1. Samples were run in triplicates and compared against rat osteocalcin standards. 
 
 
2.11. Calcium deposition assay 
 
Deposited calcium on the cell layers was measured by using ortho-cresolphthalein 
complexon method (Wako, Calcium C test). Briefly, non-transfected and transfected MSCs were 
cultured during 21 days in complete medium. At this time point, the cells were washed twice with 
PBS and the calcium content was quantified by dissolving the cell matrix in 0.25 ml of 0.6 N HCl 
at room temperature for 24 h, with gentle shaking. The calcium content was quantified according 
to the manufacture’s recommendations and the values normalized to the total protein 
concentration. 
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2.12. Von Kossa staining 
 
Mineralization was assessed qualitatively by the von Kossa staining. For that purpose, 
cells were first fixed using the same procedure used for ALP staining. Cells were then incubated 
with 2.5 wt-% silver nitrate solution under ultra-violet light for 45 min. Then, the plates were rinsed 
with deionised water followed by treatment with 5% sodium thiosulfate for 3-5 min. 
 
 
2.13. Statistical analysis 
 
Data were analyzed by two-way analysis of variance, and then differences between means 
were analyzed using the Fisher’s protected least significant difference multiple comparison test. 
Calculations were performed using SPSS® version 15.0. 
 
 
3. RESULTS  
 
3.1. Cytotoxicity studies 
 
The toxicity of the PAMAM dendrimers towards MSCs was evaluated using the MTT 
assay. This was done for the dendrimers and for the polyplexes based on dendrimers and the β-
galactosidase reporter gene carrying plasmid. The cytotoxicity profiles shown in Figure. 1 indicate 
the percentage of metabolic activity of the transfected cells in relation to the unexposed, control 
cells. The studies involved generations 5, 6 and 7 of the PAMAM dendrimers, at concentrations 
ranging from 0 to 1000 nM. This interval includes dendrimer concentrations used in later 
transfection assays (table 2). For polyplexes cytotoxicity evaluation, the plasmid DNA 
concentration was kept constant at 1 μg.cm-2 of plate surface. This value was selected during 
preliminary gene transfection experiments as it provided the highest levels of gene expression 
allowing for cell viability. Larger amounts of plasmid DNA implied the use of higher dendrimer 
concentrations, and consequently decreased cellular viability. PAMAM dendrimers (G=5-7) 
displayed concentration- and generation-dependent toxicity. Toxicity was observed to increase 
with increasing dendrimer concentration, and followed the order of G5 < G6 < G7 (Figure 1A), 
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confirming that a high density of cationic amines can be damaging to cell membranes. Polyplexes 
cytotoxicity followed the same trend (Figure. 1B). 
 
Due to the differences in the number of amine surface groups among G5, G6 and G7 
dendrimers, the dendrimer concentration used during the transfection experiments varied with the 
dendrimer generation number for the fixed N:P ratios used (table 2). The highest dendrimer 
concentrations used corresponded to the N:P ratio of 10 and were 752 nM for G5 dendrimers, 
376 nM for G6 dendrimers and 188 nM for G7 dendrimers. In these conditions, the G5 
dendrimers, at N:P ratios of 8 and 10, were the more cytotoxic, even if around 70% of metabolic 
activity percentage values were achieved.  
 
 
Figure 1. Effect of dendrimer concentration on the percentage of metabolic activity of MSCs in relation to the control 
(0 nM): (A) for dendrimers and (B) for polyplexes - this range includes dendrimer concentrations used in later 
transfection assays (table 2). Values represent means from six replicates ± s.e.m.. 
 
 
3.2. Transfection assays using a β-galactosidase reporter gene  
 
The ability of the PAMAM dendrimers to transfect MSCs in vitro was assayed using 
generation 5, 6 and 7 dendrimers and a plasmid encoding the β-galactosidase reporter gene. 
Assays were carried out at different N:P ratios (Figure 2A). Two factor ANOVA revealed that the 
level of gene expression was always significantly higher at the highest N:P ratio used (10:1) for all 
the dendrimer generations tested (p<0.05, power = 1). At this N:P ratio, results obtained for G5 
and G6 dendrimers were significantly higher than those obtained for G7 (p<0.001, power = 1). 
Higher transfection efficiencies were then obtained in conditions of higher cytotoxicity. 
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Transfection with lower generation PAMAM dendrimers (data not shown) or with naked DNA did 
not result in any significant increase in β-galactosidase activity when compared to control 
cultures. Moreover, the extent of transfection was affected by the passage number of the cells 
(Figure. 2B). Increasing the cell passage number from 2 to 4 resulted in a marked decrease in 
gene expression levels in MSCs transfected with either G5 or G6 dendrimers (p<0.05, power = 
1). Based on these results, MSCs from passage 2 were always used in the transfection 
experiments involving the hBMP-2 encoding plasmid. 
 
 
Figure 2. In vitro β-Galactosidase activity in MSCs 2 days after transfection using G5-7 PAMAM dendrimers at (A) 
different N:P ratios, using cells from the second passage, and (B) at a fixed N:P ratio of 10, using cells from different 
passages. For comparison, the β-Galactosidase activity in MSCs and HEK 293T cells, 2 days after transfection and 
using G6 PAMAM dendrimers, is also presented (C). Results for non-transfected cells (control) and naked DNA 
(DNA) are also shown. Values represent means from 6 replicates ± s.e.m.  
 
Similar transfection experiments were performed using human embryonic kidney 293T 
cells. The results obtained here clearly indicate that the transfection levels attained using MSCs 
are very low (p<0.001, power = 1). This is exemplified by the quantitative comparison of β-
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galactosidase activity in both cell types after transfection using generation 6 PAMAM dendrimers 
at a N:P ratio of 10 and under the same experimental conditions (Figure 2C). A qualitative 
comparison based on X-Gal staining (Figure. 3), a substrate that turns blue when hydrolyzed by 
β-galactosidase, revealed a high number of blue cells in HEK 293T transfected cultures, and a 
scarce number of blue cells in MSCs transfected cultures.  
 
Figure 3. X-Gal Staining for (A) non-transfected MSCs, (B) transfected MSCs and (C) transfected HEK 293T cells, 
using G6 dendrimers at a N:P ratio of 10. 
 
 
Figure 4. In vitro BMP-2 expression by MSCs 3 days after transfection. Values represent means from three 
replicates ± s.e.m.. 
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3.3. Transfection assays using a plasmid carrying the hBMP-2 gene  
 
The first set of experiments involving the use of the β-galactosidase reporter gene revealed 
very low levels of transfection efficiency. The results of BMP-2 expression 3 days after 
transfection (Figure 4) showed a pattern similar to the results obtained with the β-galactosidase 
reporter gene. BMP-2 expression was higher for the N:P ratio of 10. At this ratio, results obtained 
for G5 and G6 dendrimers were significantly higher than those obtained for G7 (p<0.5, power =1). 
 
Anyway we decided to determine whether the low levels of gene expression obtained using 
the hBMP-2 containing plasmid would still be sufficient for the in vitro differentiation of MSCs 
towards the osteoblastic lineage. In order to assess this, established markers of the osteogenic 
phenotype were evaluated: alkaline phosphatase (ALP) activity, an early marker of osteogenesis; 
osteocalcin (OC) secretion, a non-collagenous matrix protein that is only synthesized by mature 
osteoblasts, and is not present in the early stages of calcification, being expressed only after 
calcified deposits start to form; and extracellular matrix mineralization, the ultimate step in 
osteogenic differentiation.  
 
Figure 5 shows the time course of the ALP activity (normalized to the total protein content) 
presented by the transfected MSCs. Significantly higher levels of ALP activity were always 
observed for cells harvested at day 7 compared to those harvested on days 14 and 21 (p<0.05, 
power = 0.99). From this it is clear that the expression of ALP by cells is a transient event with a 
peak at the beginning of the osteogenesis process. At days 7 and 14, the ALP activity values for 
the transfected MSCs were always significantly higher (p<0.05, power = 1) than those obtained 
for the non-transfected cells. However, the effects of the different dendrimer generations and N:P 
ratios tested were not distinguishable. 
 
The OC content secreted into the culture media was determined at days 14, 21 and 28, 
and is presented in Figure 6. A peak in the levels of secreted OC was always observed on day 
21, revealing the late nature of this marker of osteogenesis. The results at this time-point clearly 
highlight that the transfected MSCs secreted significant higher amounts of OC than the non-
transfected cells (p<0.001, power = 1). In fact, the OC content in culture was observed to 
increase with an increasing N:P ratio (significant differences were detected for the G6 and G7 
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dendrimers). As for ALP activity, the effects of the different generations of dendrimers were not 
distinguishable. 
 
 
Figure 5. Time course of ALP activity presented by MSCs transfected with a plasmid DNA containing the hBMP-2 
gene using generations 5, 6 and 7 of PAMAM dendrimers at various N:P charge ratios. The values represent means 
from six replicates ± s.e.m..   
 
 
To further examine cell differentiation in the osteoblastic lineage, the calcium content on 
the extracellular matrix was assessed at day 21. The calcium deposition assay data (Figure 7) 
indicated that the transfected cells had accumulated significantly higher levels of calcium when 
compared with the control group (non-transfected cells-p<0.001, power = 1).  The highest levels 
of deposited calcium were observed for the cells transfected with the G5 and G6 dendrimers, 
using a N:P ratio of 10. For G5, it was clear that an increase in the N:P ratio resulted in a 
progressive increase in mineralized matrix deposition (p<0.001, power = 0.998). 
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Figure 6. Time course of osteocalcin content secreted by MSCs transfected with a plasmid containing the hBMP-2 
gene using generations 5, 6 and 7 of PAMAM dendrimers at various N:P charge ratios.The values represent means 
from three replicates ± s.e.m..  
 
 
The presence of a mineralized matrix on day 21 was also confirmed by von Kossa staining. 
The expression of BMP-2 by the transfected cells dramatically enhanced matrix mineralization 
(Figure 8). This was detectable by the typical black colour of the cultures and was particularly 
noticeable when using the G5 and G6 dendrimers.  
 
To confirm if this enhanced osteogenic activity was specific to the hBMP-2 gene, as earlier 
suggested, the response of the osteogenesis markers in the MSC cultures after transfection with 
polyplexes formed by dendrimers and the β-Galactosidase reporter gene containing plasmid was 
also evaluated. The results obtained here did not differ from the control. 
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Figure 7. Calcium deposition on extracellular matrix. The cells were transfected with a plasmid DNA containing the 
hBMP-2 gene using generations 5, 6 and 7 of PAMAM dendrimers, and cultured for 21 days. The values represent 
means from three replicates ± s.e.m..  
 
 
Figure 8. Von Kossa staining showing matrix mineralization. (A) Non transfected MSCs were compared with MSCs 
transfected with a plasmid DNA containing the hBMP-2 gene using PAMAM dendrimers of generations (B) 5, (C) 6 
and (D) 7 at a N:P charge ratio of 10. Cells were cultured for 21 days.  
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4. DISCUSSION 
 
The reported successful works23-25 on the use of cationic dendrimers as vectors for gene 
delivery encouraged the present authors to assess their efficacy on MSCs with a view on 
applications related to bone regeneration and tissue engineering. To our knowledge, the present 
study is the first of its kind in this field. The efficacy of dendrimers in gene delivery can be 
explained by the charge-based interactions between these molecules and DNA. The PAMAM 
dendrimers bear positively charged primary amine groups on their surface, while having tertiary 
amine groups inside. The primary amine groups participate in DNA binding, compact DNA into 
nanoscale particles and promote the cellular uptake of DNA, while the buried tertiary amino 
groups act as a proton sponge in endosomes and enhance the release of DNA into the 
cytoplasm21,30. 
 
From the beginning, investigators have searched for a correlation between transfection and the 
molecular size and shape of the PAMAM dendrimers. Haensler and Szoka (1993) found that the 
generation 6 PAMAM dendrimers, with a diameter of 6.8 nm and resembling the histone core in 
chromatin around which DNA is wrapped, were optimal in mediating transfection23. Another study 
using a variety of cell lines showed that the best performing generation (from G5 to G10) for cell 
transfection was strongly dependent on the cell type, and that the DNA binding ability increased 
with the generation number26,31. However, while some authors describe PAMAM dendrimers as 
conducting to high levels of transfection, others still search for ways of modifying them to improve 
their efficiency24. In this respect, it is worth mentioning that partially degraded PAMAM 
dendrimers were shown to be 100-fold more active as gene delivery vectors21. 
 
In order to determine their behaviour as gene transfer agents towards MSCs, three 
different generations of PAMAM dendrimers (G5, G6 and G7), at different N:P charge ratios, were 
analysed in the first set of the present results. Plasmid DNA encoding the β-galactosidase 
reporter gene was employed here. From the data it was found that the MSCs could be 
transfected with the PAMAM dendrimers. However, the observed transfection levels were very 
low. Several investigators have faced the same problem when using other non-viral gene vehicles 
and MSCs, thereby indicating that this cell type, like other primary cells, is typically refractory to 
transfection32. Nevertheless, even with low levels of transfection, it was possible to distinguish 
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different levels of transfection efficacy amongst the different dendrimer generations and the 
different N:P charge ratios tested. The best results were obtained with the G5 and G6 
dendrimers, using a N:P ratio of 10. These results however, corresponded to higher cytotoxicity 
conditions. This was to be expected, since the cytotoxicity of cationic polymers has been reported 
to be a function of the interaction between the polymer and the cell membrane and/or of cellular 
uptake efficiency, two factors that are also important for the efficacy of gene delivery agents33,34. 
In practice, the increase in transfection efficiency was accompanied by an increase in the polymer 
concentration. Interestingly, the cytotoxicity shown by the polyplexes was not very different from 
that presented by the dendrimers. This is in contrast to studies which have shown that 
complexation with DNA tends to reduce toxicity20. The present study also reinforces the 
conclusions reached by other authors that transfection may strongly vary with the type of cells 
used. Here, the PAMAM dendrimers were shown to be efficient towards the HEK 293T cell line, 
which was used as a positive control in the experiments. Additionally, transfection varied 
drastically with the cell passage number, showing that not only the cell type but also the cell 
proliferation state, are important parameters to take into account. Indeed, the transfection 
efficiency has been shown to be related with the cell cycle activity and cell growth35,36. 
 
It has been reported that while MSCs possess intrinsic osteogenic activity, their level of 
BMP production is extremely low37. Combined therapy with recombinant BMP has been shown to 
promote osteogenic differentiation in vitro38-41 and to induce bone formation in vivo42,43. The high 
concentrations of BMP-2 protein required to achieve a biological effect, as well as its rapid 
degradation after introduction into the body, has however rendered its use cost ineffective. 
Recently, several studies on bone regeneration have reported successful results using 
adenoviruses, retroviruses and baculoviruses vectors to carry BMP-2 cDNA8,10-12,43,44. Although 
work in this field is expanding, the data available on nonviral gene delivery for bone regeneration 
and tissue engineering applications is still scarce6,45. 
 
In the second set of the present results, using a DNA plasmid encoding the hBMP-2 gene, 
it was aimed to evaluate whether or not a low transfection level would be sufficient for the 
envisaged application, i.e., to improve the in vitro differentiation of MSCs towards the osteoblastic 
lineage. All quantitative assays involving the osteogenic markers (ALP activity, osteocalcin and 
mineralization) responded positively to this hypothesis. Taken together, the results confirmed 
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optimal transfection efficacies for the G5 and G6 PAMAM dendrimers at a N:P charge ratio of 10 
(as for the assays employing the β-galactosidase reporter gene). The von Kossa staining 
performed here was in agreement with the quantitative data.  
 
In conclusion, a coherent set of results was obtained indicating a clear correlation between 
the data obtained with the hBMP-2 and the β-galactosidase reporter gene containing plasmids. 
Furthermore, the low levels of transfection achieved were shown to be sufficient to promote the 
osteogenic differentiation of MSCs. A recent in vivo study, using C3H10T1/2-derived C9 MSCs 
expressing BMP-2 under control of the doxycycline(Dox)-repressible promoter, revealed that the 
short-term expression of this proteinaceous growth factor was sufficient to irreversibly induce 
bone formation. From this it is clear that a stable genetic modification of MSCs is not required for 
stem cell-based bone engineering46. The fact that nonviral gene delivery vectors, such as 
polycations, only mediate the transient expression of the transferred genes, opens the door to the 
use of such vectors in this kind of application. In addition, the present in vitro results suggest that 
a low level of gene expression may also be enough for the successful treatment of bone defects 
or bone-related diseases. This finding may be relevant in the clinical scenario, where the delivery 
of high or uncontrollable doses of BMP-2 is a cause of concern and thus should be avoided. The 
present results also point out the relevance of focusing research on the development of nonviral 
gene delivery vectors on concrete applications, instead of focusing on the improvement of the 
transfection efficiency.  
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CHAPTER III. 
Delivery of the BMP-2 Gene into MSCs: a Biomimetic approach using RGD Nanoclusters based 
on Poly(amidoamine) Dendrimers* 
 
 
ABSTRACT 
Poly(amidoamine) (PAMAM) dendrimers (generation 5 and 6) with amine termini were conjugated 
with peptides containing the amino-acid sequence arginine-glycine-aspartic acid (RGD) having in 
view their application as gene delivery vectors. The idea behind the work was to take advantage 
of the cationic nature of dendrimers and of the integrin targeting capabilities of the RGD motif. 
Dendrimers were used as scaffolds for RGD clustering and, by controlling the number of peptides 
(4, 8, and 16) linked to each dendrimer, it was possible to evaluate the effect of nanoclusters 
RGD density on the gene delivery process. The new vectors were characterized in respect to 
their ability to neutralize, compact and dissociate from plasmid DNA (pDNA). The complexes 
formed by the vectors and pDNA were studied concerning their capacity of being internalized by 
cells and of transferring genes. Transfection efficiency was analysed, first, by using a pDNA 
encoding for Enhanced Green Fluorescent Protein and Firefly Luciferase and, second, by using a 
pDNA encoding for Bone Morphogenetic Protein-2 (BMP-2). Gene expression in mesenchymal 
stem cells (MSCs), a cell type with relevance in the regenerative medicine clinical context, was 
enhanced using the new vectors in comparison to native dendrimers and was shown to be 
dependent on both the electrostatic interaction established between the dendrimer moiety and the 
cell surface and the nanoclusters RGD density. The use of dendrimer scaffolds for RGD cluster 
formation is a new approach that can be extended beyond gene delivery applications. These 
nanoclusters can be connected with other materials and systems where RGD clustering is 
important for modulating cellular responses. 
 
 
*This chapter is based on the following publication: 
Pandita D#, Santos JL#, Rodrigues J, Pêgo AP, Granja PL, Tomás H. Delivery of the BMP-2 gene into MSCs: a 
biomimetic approach using RGD nanoclusters based on poly(amidoamine) dendrimers (submitted). 
# Equally contributing authors  
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1. INTRODUCTION 
 
The aminoacid sequence arginine-glycine-aspartic acid (Arg-Gly-Asp, RGD), together with 
integrin receptors in cell surfaces, provide a major recognition system that can be used as a tool 
in numerous biomedical applications. Since the discovery of RGD in fibronectin, in 19841, and its 
central role in cell adhesion2,3, the RGD sequence has been applied in the design of new drugs 
and materials with the aim of controlling their behaviour and improve their efficacy. In the last  few 
years, the RGD motif has been explored as a cell-targeting agent in anti-tumour therapies, cell 
imaging, and nucleic acids and drug delivery, as well as a mean to modulate the process of 
integrin regulation and increase the adhesion of cells to substrates in the Biomaterials and Tissue 
Engineering fields4-17. 
 
Integrins constitute a family of cell-adhesion receptors which simultaneously interact with 
the proteins in the extracellular matrix and the internal constituents of the cell18,19. Integrins 
transfer signals bidirectionaly so that the cell can sense and respond to its environment. They 
consist of two distinct subunits (noncovalent heterodimers α and β), each containing a 
transmembrane domain, a large extracellular domain and a small cytoplasmic domain. Many 
integrins  respond to RGD-binding and changes in cell morphology, differentiation, proliferation 
and gene expression consequently occurs. Interestingly, RGD peptide clustering has been shown 
to interfere with cell responses and with the gene transfer properties of non-viral vectors10,11,13,16. 
Additionally, clustered RGD ligands present in the penton base capsomers at the capsid 
icosahedral vertices of several adenovirus types were shown to have a role in promoting virus 
entry into host cells20,21. Integrin-mediated gene delivery together with RGD ligands clustering 
can, thus, be a suitable biomimetic approach to be used in non-viral gene delivery. 
 
Dendrimers were shown to be very attractive as non-viral gene delivery vectors22-25. They 
are tree-like molecules that growth from a central core, are composed of several layers (called 
generations) and present a multivalent surface. In particular, poly(amidoamine) (PAMAM) 
dendrimers with amine termini (they are cationic molecules at physiological pH) are the most 
studied dendrimers for gene delivery and were shown to present an intrinsic ability to bind, 
compact and deliver pDNA into a high variety of cells22-25. Partially degraded PAMAM dendrimers 
are even available in the market (under the names Superfect® and Polyfect®) and are frequently 
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used as reference materials for non-viral gene delivery26,27. The success of PAMAM dendrimers 
in gene delivery has been attributed to a “proton-sponge” effect24 as, in addition to the primary 
amines at the surface, they possess secondary and tertiary amines in their interior. That is, 
dendrimers act like a buffer system inside endosomes or endo-lysosomes (containing digestive 
enzymes) leading to the pumping of protons and concomitant influx of chloride ions. The ionic 
strength inside these organelles will then increase causing their osmotic rupture and the release 
into the cytoplasm of the pDNA or the complexes formed between dendrimers and pDNA. 
 
The efficacy of PAMAM dendrimers as gene transfer agents, however, greatly varies with 
the cell type28. Recently, we showed that PAMAM dendrimers (without any treatment or 
functionalization) were able to deliver the BMP-2 gene to mesenchymal stem cells (MSCs) but 
with a low efficiency29. In spite of in vitro osteogenic differentiation of MSCs achieved as shown 
by several osteogenic markers, there is an unquestionable interest in raising the transfection 
efficiency when using these cells due to their promising properties and clinical relevance in 
several fields. Indeed, MSCs isolated from several adult tissues, show immune suppressive 
properties, and are considered multipotent, being of key importance in tissue engineering and 
regeneration30,31. 
 
Herein we designed a new family of gene delivery vectors based on PAMAM dendrimers 
conjugated with RGD containing peptides (GRGDSPC). In fact, MSCs were shown to express the 
integrin receptors α1β1, α2β1, α5β1, α6β1, αvβ3 and αvβ5 at their surfaces32,33 which are known for 
recognizing the RGD sequence3. The idea subjacent to the work was to take advantage of the 
cationic nature and the “proton-sponge” effect of these dendrimers and of the RGD moiety 
targeting capabilities. The multivalent surface of dendrimers makes them ideal scaffolds for RGD 
containing peptides attachment and, by varying the degree of functionalization, the effect of RGD 
peptide targeting and clustering can be evaluated in the process of gene delivery. Gene delivery 
vectors were prepared by conjugating generation 5 (G5) and generation 6 (G6) of PAMAM 
dendrimers with 4, 8 and 16 peptide units. The complexes formed between RGD modified 
dendrimers and pDNA were characterized and their cytotoxicity evaluated. Transfection was, in a 
first step, evaluated using a plasmid encoding for Enhanced Green Fluorescent Protein (EGFP) 
and Firefly Luciferase (Luc) and, further, using a plasmid encoding for BMP-2.  
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2. MATERIALS AND METHODS 
 
2.1. Materials and reagents 
 
Generation 5 and 6 PAMAM dendrimers, possessing ethylenediamine cores and amine 
termini, were purchased in water solution from Dendritech Inc. (USA). The molecular weights and 
number of amine surface groups presented by the dendrimers were 28,826 u.m.a. and 128, and 
58,048 u.m.a. and 256, respectively, for G5 and G6. The peptide GRGDSPC was purchased from 
American Peptide Company, Inc. (USA) with a purity of 95 %. Tissue culture plates were from 
NUNC. Agarose was purchased from Cambrex Bio Science Rockland (USA) and N-(2-
Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) i.e. HEPES from USB (USA). The pDNA 
encoding for enhanced Green Fluorescent Protein and Firefly Luciferase (pEGFPLuc, 6.4 kb) with 
a cytomegalovirus promoter (CMV) was generously provided by Prof. Tatiana Segura (Dep. of 
Chemical and Biomolecular Engineering, UCLA, USA). The pDNA encoding a human BMP-2 
sequence inserted downstream the CMV promoter (pcDNA3.1/Hist©/hBMP2, 8.5 kb) was kindly 
donated by Professor Yasuhiko Tabata, University of Kyoto, Japan). All other materials and 
reagents were obtained from SIGMA-ALDRICH unless otherwise stated. 
 
 
2.2.  Experimental determination of primary amine group content of dendrimers 
 
The primary amine group content of G5 PAMAM dendrimers was determined by 
spectrophotometry after reaction of the free amine groups with 2,4,6-trinitrobenzenesulphonic 
acid (TNBS), as described in the literature34, and using glycine as standard. A total of 115  and 
220 amine groups were attributed to G5 and G6 dendrimers, respectively, being these values in 
agreement with the Mass Spectrometry data furnished by Dendritech Inc. Based on this result, 
the TNBS method was further used to calculate the concentration of dendrimers (also of 
functionalized dendrimers) when needed. In both cases the standard solutions and the sample 
solutions were serially diluted in 0.1 M sodium tetraborate to a final volume of 1 ml. To each 
standard and sample 25 µl of TNBS (0.03 M) diluted in water was added. After 15 min at room 
temperature (RT), absorption was measured at 420 nm in a GBC-Cintra 40, UV-Visible 
spectrophotometer.  
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2.3. Synthesis and characterization of dendrimer/RGD conjugates  
 
Same experimental procedure was followed for the synthesis of G5 as well as G6 
dendrimer/RGD conjugates. In a first step, G5/G6 PAMAM dendrimers (Figure 1, compound 1, 
C1) were substituted with various amounts of the bifunctional 3-(2-pyridyldithio)propionic acid N-
hydroxysuccinimide  ester (SPDP), as described earlier by Szoka et al.35. G5/G6 PAMAM 
dendrimers (0.50 µmol) in 2 ml buffer (0.25 M NaCl, 0.1 M phosphate, pH 8) were mixed with 
SPDP (2-16 µmol) dissolved in 250 µl ethanol. The mixtures were allowed to react for 3 h, at RT, 
under nitrogen and with continuous stirring. Several derivatives were obtained (compound 2, C2) 
by varying the molar ratio dendrimer/pyridyldithiol (PDP) (1/4, 1/8 and 1/16). Afterwards, low 
molecular weight products were removed by gel permeation chromatography on a PD-10 column 
(GE Healthcare) equilibrated in 0.15 M NaCl, 0.1 M phosphate buffer, pH 7.4. The fractions 
containing dendrimers linked to PDP were pooled, concentrated, and snap frozen in liquid 
nitrogen and stored at -80 ºC. The dendrimer content in C2 was estimated by the 2,4,6-
trinitrobenzenesulphonic acid (TNBS assay as described previously. The degree of modification 
with the SPDP linker was evaluated spectrophotometrically at 343 nm by the release of pyridine-
2-thion (compound 4, C4) after reduction of an aliquot with excess dithiothreitol (DTT, 0.1 M). As 
calibration standards, known concentrations of SPDP solutions were treated with 0.1 M DTT 
under the same conditions, and the changes in absorbance were used as a measure of pyridine-
2-thion (C4) in solution. In a second step, the GRGDSPC peptides with a terminal cysteine were 
dissolved in 100 mM phosphate buffer, pH 7.2 and mixed, under nitrogen, with C2 compounds 
diluted in 100 mM phosphate buffer, pH 7.2. An excess of peptide (2-fold) to PDP present in C2 
was used to increase reaction yields since a competitive peptide dimerization reaction may occur. 
After 3 h at RT, the amount of released pyridine-2-thion (C4) was measured at 343 nm to 
determine the extent of reaction. Peptide-functionalized dendrimers (C5) were purified by gel 
filtration using PD-10 columns equilibrated in 0.5 M NaCl, 20 mM sodium acetate, pH 5. 
Conjugates were applied to the column and the void fractions containing the conjugates were 
dialyzed against phosphate buffered saline (PBS) solution, pH 7.2, using dialysis tubes with a 
molecular weight cut-off of 10 kDa (Spectrum Laboratories) for 3 days. After dialysis, conjugates 
were sterile filtered and aliquots were snap frozen in liquid nitrogen and stored at -80ºC. 
Conjugates were characterized by 1H NMR using D2O as solvent in a Bruker 400 MHz Avance II+ 
NMR spectrometer. 
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Figure 1. Schematic illustration of the synthesis of PAMAM dendrimers/RGD conjugates (pathway A+B), and of the 
indirect estimation of the number of peptide units by spectrophotometry (pathway A+B+C). Note: The amine content 
of G5 PAMAM dendrimers (115 amines/dendrimer) was previously determined experimentally. 
 
 
2.4. Plasmid DNA amplification  
 
The plasmids were amplified in Escherichia Coli host strain, DH5α, grown overnight in 
Luria-Broth Base medium containing antibiotic. Afterwards, the plasmids were isolated and 
purified using a GenElute™ HP Endotoxin-Free Plasmid Megaprep Kit. The isolated plasmids 
were dissolved in a small amount of ultra-pure water and the quantity and quality of the purified 
plasmid DNA was assessed by spectrophotometric analysis at 260 and 280 nm. The plasmid 
integrity was assessed through agarose gel electrophoresis. pDNA was stored in ultrapure water 
at -20ºC. 
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2.5. Complex assembly 
 
The complexes formed by pDNA and dendrimers/RGD conjugates were prepared at 
several N:P ratios by mixing equal volumes of the conjugate solution and the pDNA solution. 
Conjugate and pDNA concentrations varied according the experiments. Hepes-buffered glucose 
(HBG, Hepes 10 mM, Glucose 5% w/w, pH = 7.1) was always used to prepare these solutions. 
Polyplex solutions were vortexed gently and allowed to incubate for 20 min at room temperature 
prior to experiments. Native PAMAM dendrimers were always used as a control. Superfect® 
(Qiagen, Germany) was also used as a reference. Superfect polyplexes were prepared according 
to the manufacturer’s instructions for transfection of primary cells.  
 
 
2.6. Agarose gel electrophoresis retardation assay 
 
Gel electrophoresis in agarose gels was carried out at 75 V. Agarose gel (0.7 % w/v) 
containing ethidium bromide (0.05 μl.ml-1) was prepared in Tris-acetate-EDTA buffer. Complex 
solutions were prepared at different N:P ratios, as described above, using 1 μg of pDNA diluted in 
50 μl of buffer and 2.5 μl of Blue Loading Buffer (Fermentas, Germany) were added before the 
samples were subjected to gel electrophoresis. Vectors-pDNA interaction is shown by a lack of 
migration of the pDNA in the electrophoretic field. DNA was visualized by a UV lamp using a 
BioRad Imaging System. 
 
 
2.7. Pico green assay for evaluation of pDNA condensation 
 
The complexes formed by pDNA and dendrimer/RGD conjugates were prepared at 
different N:P ratios, as described above, with 0.1 µg of pDNA in 100 μl of HBG, and the mixtures 
were incubated for 20 min at room temperature. Then, the complexes (100 µl) were transferred 
into white flat-bottom 96-well plates followed by addition of 100 µl Picogreen (PG) reagent diluted 
200× in Tris-EDTA buffer (TE, 10 mM Tris, 1 mM EDTA, pH 7.5) and incubated further for 5 min. 
Each measurement was performed in triplicate and the fluorescence of PG (λex= 485 nm, λem= 
535 nm) for each sample was measured using a microplate reader (model Victor3 1420, 
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PerkinElmer). The relative fluorescence percentage (%F) was determined using the equation 
below: 
 
% 100 sample blank
DNAonly blank
F F
F
F F
−
= ×
−  
 
2.8. Pico green assay for evaluation of salt-induced complex dissociation 
 
The complexes formed by pDNA and dendrimer/RGD conjugates were prepared as 
described above with N:P ratio of 5 and diluted with water to a concentration of 0.3 µg pDNA/100 
µl solution. PG solutions were prepared by a 200× dilution of PG reagent with 10mM Hepes 
buffer containing adequate concentrations of NaCl. After the complex solutions were arrayed into 
white flat-bottom 96-well plates, 100 µl of the PG solutions were added to each well to achieve 
the desired concentration of NaCl (0.1 M, 0.3 M, 0.5 M, 0.7 M and 1.5 M). The fluorescence of 
Picogreen for each sample was then measured.  
 
 
2.9. Isolation and culture of rat bone marrow-derived mesenchymal stem cells 
 
Rat bone marrow-derived mesenchymal stem cells (MSCs) were isolated from long bones 
of 8-week-old male Wistar rats (Charles River Laboratories, Spain). Following euthanasia by 
pentobarbital 20% (v/v), femora were aseptically excised, cleaned of soft tissue, and washed in 
PBS. The metaphyseal ends were cut off and the marrow was flushed out from the midshaft with 
5 ml of α-Minimum Essential Medium (α-MEM) using a 23-Gauge needle and syringe. The cells 
were centrifuged (600 g, 10 min), suspended in fresh medium containing 10% heat-inactivated 
foetal bovine serum (FBS, Gibco), 50 µg.ml-1 ascorbic acid, 100 U.ml-1 penicillin and 100 µg.ml-1 
of streptomycin - the basic medium - and seeded in 75 cm2 flasks. Cells were cultured at 37oC in 
a 5% CO2 atmosphere. After removal of non-adherent cells and medium exchange at day 3, cells 
were harvested at day 7 by trypsinization, and used in subsequent experiments. 
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2.10. Cellular uptake studies by fluorescence-activated cell sorting (FACS) 
 
Cells were seeded in 12-well plates at a density of 1.5×104 cell.cm-2 and incubated in basic 
medium at 37ºC, 5% CO2, for 24 h, to yield a cell confluency of around 60-80%. Prior to complex 
formation, pDNA was labelled with PicoGreen dye (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s directions. Complex solutions (100 μl) were prepared at a N:P ratio of 5 as 
previously described. Cells in 1 ml of basic medium were then transfected using 100 µl of the 
complex solution (2 μg.cm-2 of pDNA was used). The cells were incubated with each solution for 
1 h and then rinsed twice with PBS. The extracellular fluorescence associated with cell surface-
bound nanoparticles was quenched with 0.4% (w/v) Trypan-Blue (TB) for 5 min. The cells were 
washed multiple times with PBS, trypsinized, pelleted, and resuspended in 400 µl of PBS 
containing 2% FBS for FACS analysis (Cytomics FC500, Beckman Coulter). The untreated cells 
were used as a control to set up the gating and to adjust the forward and side scatter and the 
cellular debris were gated out of the sample. A total of 10000 events within the gated region were 
collected in triplicate for each sample. The positive fluorescence level was established by visual 
inspection of the histogram of negative control cells such that less than 1% appeared in the 
positive region using PG-labelled naked pDNA transfected cells as the primary negative control. 
Data was analysed using CXP software analysis program. 
 
 
2.11. Gene delivery studies 
 
Gene delivery was studied based on reporter gene expression (using pDNA encoding 
EGFP and Luc) and also on BMP-2 expression (using pDNA encoding BMP-2).  
Expression of the Luc gene: Cells were seeded at 1.5×104 cell.cm-2, in 24-well plates, 24 h prior 
to transfection. At the time of transfection, cells reached 60-80% confluency. Before contact with 
polyplexes, medium was exchanged for 0.5 ml of fresh basic medium. Complex solutions (100 µl) 
were then added to the cells and, after 4 h, the culture medium was again replaced with fresh 
medium. Transfection was carried out at a N:P ratio of 4 and using 2 μg.cm-2 pDNA. Non-
transfected cells were used as negative controls. At different time points (48, 72 and 96 h) after 
transfection, the media was removed and the cells were washed with PBS solution and treated 
with 100 µl reporter lysis buffer (Promega). Cell lysates were analysed for luciferase activity with 
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Promega’s luciferase assay reagent in triplicate (following the supplier’s instructions). For each 
sample, the microplate reader (model Victor3 1420, PerkinElmer) was set for 3 s delay with signal 
integration for 10 s. The amount of protein in cell lysates was determined using the bicinchoninic 
acid assay (BCA assay) with bovine serum albumin as a standard. The gene delivery efficiency of 
each sample was characterized by Firefly Luciferase expression and denoted as relative light 
units per mg of protein (RLU.mg-1 protein).  
Expression of the EGFP gene: Enhanced Green Fluorescent protein expression studies were 
carried out as mentioned above for the Luc gene expression. Twenty-four hours after 
transfection, cells were observed with an inverted fluorescence microscope (Nikon Eclipse TE 
2000E) equipped with a cold Nikon camera. Digital image recording and image analysis were 
performed with the NIS Elements Advanced Research (version 2.31) software. 
 
 
2.12. Cytotoxicity studies 
 
The cytotoxicity of the gene delivery vectors (alone) and the respective complexes they 
form with pDNA were studied. Cytotoxicity was evaluated by determining the percentage of cell 
viability (in respect to unexposed cells) using the resazurin reduction assay that establishes a 
correlation between the cellular metabolic activity and the number of viable cells in culture36. 
 
Gene delivery vector cytotoxicity: Cell viability was studied as a function of the gene delivery 
vector type and concentration. Cells were seeded in 96 well-FluoroNunc plates at a density of 
3x104 cell.cm-2. After 24 h, medium was replaced with fresh basic medium and 10 µl of each 
polymer (diluted in HBG) was added to achieve the final desired concentration. After 4 h, the 
medium was exchanged for fresh medium containing 0.1 mg.ml-1 resazurin and incubated for 
another 4 h. Resorufin fluorescence (λex = 530 nm, λem = 590 nm) was measured in a microplate 
reader (model Victor3 1420, PerkinElmer). 
 
Complex cytotoxicity: The information about complex cytotoxicity was obtained during the 
experiments performed to study the expression of the Luc gene (described above), being cell 
viability evaluated 24 h post-transfection. 
 
 
CHAPTER III. RGD Nanoclusters based on PAMAM Dendrimers as Gene Carriers 
 
81 
 
2.13. Fluorescence microscopy studies 
 
Fluorescence microscopy was used to visualize pDNA cellular uptake. Prior to complex 
assembly, pDNA was labelled with rhodamine isothiocyanate (RITC) by a slight modification of a 
reported method37. Briefly, 0.1 mg of pDNA diluted in 297 µl of sodium carbonate-buffered 
solution (0.1 M, pH 9.0) was mixed with 3 µl of RITC solution (100 mM solution prepared in 
dimethyl sulfoxide) at RT, for 5 h. The RITC-labelled pDNA was separated from residual RITC by 
gel filtration using a PD 10 column (GE Healthcare), followed by ethanol precipitation to obtain 
the RITC-labelled pDNA. Experiments were performed in the same conditions as above 
described for transfection experiments although using RITC-labelled pDNA at a lower 
concentration (1 μg.cm-2) to avoid blur. Live cells were analyzed under the inverted fluorescence 
microscope (Nikon Eclipse TE 2000E) four hours post transfection after quenching of extracellular 
fluorescence with 0.4 % (w/v) TB for 5 min and washing with PBS. The RITC-labelled pDNA was 
detected by a red signal.  
 
For observation at higher magnifications, 24 h prior to transfection, cells were seeded at a 
density of 1.5×104 cell.cm-2 in 24-well plates containing collagen-treated cover slips. Before 
contact with complexes, medium was exchanged for fresh basic medium. Transfection was 
carried out with complexes prepared at N:P ratio of 5 using 1 μg.cm-2 RITC-labeled pDNA. The 
distribution of pDNA inside cells was analyzed 2, 4, and 24 h post-transfection. Thirty minutes 
prior, the acidic late endosome and lysosome compartments were stained with the addition of 
LysoSensor DND-189 dye (Molecular Probes) to the medium at a final concentration of 1 µM. 
After quenching with 0.4% (w/v) TB, cells were washed twice with PBS and fixed with 3.7% (v/v) 
formaldehyde prepared in PBS at room temperature for 10 min. Cell nuclei were then stained 
using a 300 nM 4',6-diamidino-2-phenylindole (DAPI) solution for another 10 min. Cells were 
washed several times with PBS and stored at 4ºC (protected from light).  Fluorescence images 
were acquired using the Nikon Eclipse TE 2000E inverted microscope equipped with a 100x NA 
0.5-1.3 Plan Fluor objective.           
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2.14. Statistics  
 
Statistical analyses were performed using GraphPad Prism 5.0 for Windows. Results are 
reported as mean± standard error of mean (s.e.m). Unpaired, Student’s t-test and 2-way ANOVA 
with Bonferroni Post Hoc test were used to assess the statistical differences between the group 
means. 
 
 
3. RESULTS AND DISCUSSION 
 
3.1. Synthesis and characterization of PAMAM dendrimers/RGD conjugates 
 
Generation 5 (G5) and generation 6 (G6) PAMAM dendrimers with amine termini (C1) 
were conjugated to GRGDSPC peptides via a two-step method using the 3-(2-pyridyldithio) 
propionic acid N-hydroxy-succinimide ester (SPDP), a heterobifunctional crosslinker which 
contains both amine- and sulfhydryl-reactive groups (Figure 1). For linkage, a cysteine residue 
was present at the end of the amino-acid sequence. During the synthesis, the concentration of 
dendrimers (also of functionalized dendrimers) was determined by spectrophotometry, based on 
primary amine content. The degree of functionalization was under stoichiometric control and was 
indirectly estimated by spectrophotometric quantification of pyridine-2-thion (C4) that is released 
after reduction of the dendrimer-PDP intermediate (C2) with excess of dithiothreitol (DTT) and 
after reaction of C2 with the peptides. Conjugates with approximately four (RGD4-G5 and RGD4-
G6), eight (RGD8-G5 and RGD8-G6) and sixteen (RGD16-G5 and RGD16-G6) peptide arms 
were prepared. Table 1 shows the average number of PDP moieties per dendrimer determined 
after reaction A and the average number of peptides per dendrimer after reaction B. 
 
The conjugates were further characterized by 1H NMR spectroscopy (400MHz) using D2O 
as solvent (as exemplified in Figure 2). 1H NMR spectra revealed the solvent peak of D2O at 4.7 
ppm and multiple peaks attributed to PAMAM dendrimers between 2.2 and 3.4 ppm. The 
successful conjugation of RGD peptides to PAMAM dendrimers is showed by the appearance of 
new proton signals such as the methylene protons around δ = 3.9 (CH2, s) from glycine 
aminoacid and methine protons (CH, s) at δ = 3.65 from arginine aminoacid. 
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Table 1. Average number of PDP and of peptides per dendrimer, respectively, after reactions A and B. *Theoretical 
value based on the molecular weight of dendrimers provided by the supplier. 
Conjugate 
Average number of PDP 
per dendrimer 
(after reaction A) 
Average number of 
peptides per dendrimer 
(after reaction B) 
Mol. weight* 
(u.m.a) 
RGD4-G5 4.4 4.2 30412.9 
RGD8-G5 8.2 8.2 33520.6 
RGD16-G5 18.8 17.5 40745.8 
RGD4-G6 4.6 3.9 53902.9 
RGD8-G6 8.3 7.2 56466.6 
RGD16-G6 16.9 14.4 62060.4 
 
 
 
Figure 2. 1H NMR spectra (400MHz, in D2O) of (A) G5 PAMAM/RGD conjugate (sixteen peptides per dendrimer) and 
native G5 PAMAM dendrimer, inset is a magnified image of part of the spectrum from 3.4-4.0 ppm; (B) G6 
PAMAM/RGD conjugate (sixteen peptides per dendrimer) and native G6 PAMAM dendrimer, inset is a magnified 
image of part of the spectrum from 3.4-4.0 ppm. 
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3.2. Characterization of the complexes formed by PAMAM dendrimers/RGD conjugates 
and pDNA 
 
PAMAM dendrimers/RGD conjugates were first investigated for their ability to bind, 
neutralize and compact pDNA. Plasmid DNA encoding for enhanced Green Fluorescent Protein 
and Firefly Luciferase (pEGFPLuc, 6.4 kb) was used in these studies. Prior to all studies, 
conjugates were mixed with pDNA at several N:P ratios in HBG buffer for complex formation. 
Agarose gel retardation assays revealed that binding to and charge neutralization of pDNA 
occurred at N:P ratios of 1 for all the vectors. These results are exemplified in Figure 3 for G5 
PAMAM dendrimer and for its conjugates. By using the PicoGreen (PG) dye (Figure 4), we 
concluded that complete pDNA packaging was achieved at an N:P ratio of 2 for all vectors. 
Indeed, PicoGreen gives a fluorescent signal when bounded to dsDNA. In these experiments, 
complexes are first prepared and then allowed to be in contact with PicoGreen; only free pDNA 
will bind with PicoGreen and give rise to a fluorescent signal. No fluorescence signal is indicative 
of all pDNA compacted. 
 
 
Figure 3. Electrophoretic pattern of pDNA complexes with G5 (A), RGD4-G5 (B), RGD8-G5 (C) and RGD16-G5 (D) 
vectors. Lane 1, pDNA only; Lane 2-8, for an N:P ratio of 0.25, 0.5, 1, 2, 5, 8 and 10, respectively. 
 
pDNA packaging is essential for its entry inside cells but, after, its dissociation from the 
vector is a crucial step for an efficient gene delivery process. The evaluation of the strength of the 
interaction between pDNA and the gene carrier is, thus, an important parameter that may provide 
clues concerning the mechanism of gene transfer. Complexes formed by pDNA and the vectors 
were then submitted to an increasing ionic strength by increasing the concentration of sodium 
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chloride (NaCl) in solution. PicoGreen assay was used to measure the amount of pDNA released 
at each NaCl concentration. Results are presented in Figure 5 and do not show significant 
differences either between G5 and G6 dendrimer based vectors or between native dendrimers 
and dendrimers/RGD conjugates. Release of pDNA occurred by increasing the ionic strength in 
solution but the percentage of unpacked pDNA did not surpassed 25%. Results indicate the 
existence of a strong electrostatic interaction between pDNA and the gene delivery vectors that is 
likely related with the high cationic character of the dendrimer moiety. 
 
 
Figure 4. PicoGreen (PG) assay results at various N:P ratios for (A) G5 and G5 PAMAM dendrimers/RGD 
conjugates and (B) G6 and G6 PAMAM dendrimers/RGD conjugates. The results are reported as the relative 
percentage of PG fluorescence, where 100% intensity was observed for a N:P of 0 (pDNA only). Data represents the 
mean ± s.e.m., n=3. 
 
 
Figure 5. Salt induced dissociation of the complexes formed by pDNA and (A) G5 and G5 PAMAM dendrimer/RGD 
conjugates and (B) G6 and G6 PAMAM dendrimers/RGD conjugates. The PicoGreen assay was used to estimate 
the amount of pDNA released. Results are expressed as the mean ± s.e.m., n=3. 
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3.3. Cellular uptake of the complexes formed by pDNA and PAMAM dendrimers/RGD 
conjugates 
 
PicoGreen-labeled pDNA was used to compare complexes uptake by MSCs through the 
FACS technique. Cellular uptake was studied in the presence of serum, at a N:P ratio of 5 and 
using a seeding density of 1.5x104  cell.cm-2 and 1 µg.cm-2 pDNA (Figure 6). After 1h of contact 
between complexes and cells, the percentage of cells positive for PG-labeled pDNA significantly 
increased for dendrimers/RGD conjugates in comparison with native dendrimers (p< 0.05), being 
higher for G6 dendrimer based vectors (p<0.05). Maximum values were attained with dendrimers 
functionalized with eight peptide arms (an increase of about 20% and 10% of positive cells in 
respect to native dendrimers was observed when using RGD8-G5 and RGD8-G6 conjugates, 
respectively). The number of positive cells for PG-labeled pDNA obtained with conjugates 
containing 4 and 16 peptide units was similar and lower than that observed for conjugates with 8 
peptide units. A slight increase in the amount of pDNA delivered per cell was also observed for 
functionalized dendrimers in comparison with native dendrimers. These results followed the same 
trend displayed by the number of cells.positive for PG-labeled pDNA. 
 
Figure 6. MSCs uptake of the complexes formed by pDNA and (A) G5 and G5 PAMAM dendrimer/RGD conjugates 
and (B) G6 and G6 PAMAM dendrimers/RGD conjugates, after 1 h of contact . The bars shows the number of cells 
positive for PG-labeled pDNA, whereas the lines reveal the amount of pDNA delivered per cell (displayed as the 
mean average fluorescence intensity). Results are expressed as the mean ± s.e.m., n=3.   
 
A possible explanation for our results is that there are two possible different mechanisms 
by which complexes are internalized by MSCs. In one hand, complexes may enter cells through 
the RGD-integrin recognition system. By increasing the number of peptide arms in the dendrimer, 
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a higher density of RGD ligands will be displayed in the nanoclusters and this will facilitate the 
cellular internalization of the complex. In the other hand, cell entry will also depend on the cationic 
charge associated with the complex that, in this case, will be internalized following the classical 
endocytic pathway. By increasing or decreasing the charge of the complex, its internalization will 
increase or decrease, respectively. This is evident in two situations. (A) In the first one, a 
decrease in the number of cells positive for PG-labeled pDNA is observed when using 
dendrimers functionalized with 16 peptide arms. Likely, peptides can present a shield effect over 
the dendrimer moiety. This is in agreement with other studies made in our laboratory where the 
functionalization of PAMAM dendrimers with osteotropic peptides38 and alkyl groups39 with the 
aim of improving the gene delivery performance of dendrimers was performed. Other authors also 
report the same shielding effect40. In addition, by increasing the number of peptides connected to 
the dendrimer, the number of anionic aspartic acid residues in the periphery of the dendrimer will 
also increase thus reducing the net positive charge of the complexes, diminishing the complex 
attraction by the anionic cell surface. (B) In the second one, a higher number of cells positive for 
PG-labeled pDNA are observed for G6 dendrimer based vectors in comparison to G5 dendrimer 
based ones. This occurs because G5 dendrimer is smaller than G6 dendrimer and, so, the 
shielding effect caused by the peptides will be more pronounced in the first case. Cell entry will 
then be favored for complexes formed by pDNA and G6 dendrimer based vectors as for them the 
electrostatic interaction with the cell membrane will be stronger. The higher shielding effect over 
G5 dendrimers will result in weaker electrostatic interactions with cells, being the effect of RGD 
presence in cell uptake more prominent. Complex cellular uptake is, thus, a result of the 
combination of these two mechanisms of cell entry (one specific and the other non-specific). 
Cellular uptake studies were also performed using fluorescence microscopy. Figure 7 shows the 
merged bright field and fluorescent microscopy images of MSCs four hours after transfection with 
RITC-labeled pDNA (red). Although these experiments provide only qualitative data, it can be 
seen that there is a correlation between them and the previous quantitative data.  
 
Figure 8 correspond to images taken at a higher magnification and shows the distribution 
of RITC-labeled pDNA (red) inside cells after transfection using native dendrimers and 
dendrimers conjugated with 8 RGD peptides. The acidic late endosome and lysosome 
compartments were stained with LysoSensor Green DND-189 (green), and the nucleus with DAPI 
(blue).  
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Figure 7. Microscopy RITC-labeled pDNA visualization in culture, 4 h post-transfection. Live cell images were 
captured. (A), (B), (C) and (D) are, respectively, the merged images of bright field mode (gray) and fluorescence 
mode using G5, RGD4-G5, RGD8-G5 and RGD16-G5 vectors. (E), (F), (G) and (H) are, respectively, the merged 
images of bright field mode (gray) and fluorescence mode using G6, RGD4-G6, RGD8-G6 and RGD16-G6 vectors. 
The micrographs were obtained at an original magnification of 200×. 
 
Two hours post-transfection, a higher accumulation of pDNA could be observed inside cells when 
using dendrimer/RGD conjugates, being these data in agreement with FACS results which 
showed that they were able to deliver a high amount of pDNA per cell. As time progressed, it was 
possible to observe the appearance of orange spots representing the co-localization of pDNA and 
endosome/lysosome compartments. pDNA co-localization with the nucleus (pink dots, white 
arrows) could already be observed after 4 h when dendrimer/RGD conjugates were used. The 
number of pink dots inside the nucleus is, however, very small in all cases, whereas a high 
accumulation of RITC-labeled pDNA is clearly seen in nucleus periphery, in great part associated 
with the endosome/lysosome compartments. These microscopy results evidence a noticeable 
difficulty of pDNA to reach the cell nucleus where the expression of the carried genes occurs. 
This happens for different reasons24,41, such as the entrapment of the complexes and degradation 
of pDNA inside endo-lysosomes, difficulties in the release of pDNA from the complex (our results 
showed strong electrostatic interactions between the vectors and pDNA), low pDNA diffusion 
inside cytoplasm, pDNA degradation in the cytoplasm, and inifficient nuclear translocation of 
pDNA. 
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Figure 8. Cellular distribution of (RITC)-labeled pDNA in MSCs at 2 h, 4 h and 24 h post transfection. (A), (B), (C), 
and (D) represents cells transfected using G5, RGD8-G5, G6 and RGD8G6 vectors, respectively. The cell nuclei 
were stained with DAPI (blue), and the acidic late endosome and lysosome compartments were stained with 
LysoSensor Green DND-189 (green). The bar represents 10 µm. 
 
 
3.4. Gene delivery using the PAMAM dendrimers/RGD conjugates 
 
The ability of PAMAM dendrimers/RGD conjugates to efficiently deliver exogenous genes 
was evaluated using a plasmid encoding Enhanced Green Fluorescent Protein (EGFP) and 
Luciferase (Luc) and, after, for selected conditions, using a plasmid encoding BMP-2. Indeed, 
whereas EGFP and Luc are used due to their fluorescence and luminescence properties and 
easy detection, BMP-2 is a protein known for inducing the proliferation and differentiation of 
MSCs towards the osteoblastic lineage42. The idea was to confirm if the dendrimers/RGD 
conjugates were indeed able to deliver the gene encoding a protein with pharmacological 
relevance with an effective expression of that protein in culture. 
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Figure 9. (A) Luc gene expression achieved with G5 dendrimer based vectors. (B) Luc gene expression achieved 
with G6 dendrimer based vectors. (C) Cytotoxicity evaluation of the complexes formed by pDNA and G5 dendrimer 
based vectors, 48 h post-transfection. (D) Cytotoxicity evaluation of the complexes formed by pDNA and G6 
dendrimer based vectors, 48 h post-transfection. Results are expressed as the mean ± s.e.m., n=6.  
 
For the first set of gene delivery studies, MSCs were incubated with the complexes in 
optimized conditions in the presence of 10% FBS, and for 4 h. Cells were then assayed for 
expression of the luciferase (Luc) reporter gene after 48, 72 and 96 h post-transfection (Figure 9). 
Results were normalized to protein content and are shown as relative light units (RLU). A 
transient expression of the Luc gene was obtained in all cases as RLU values decrease with time. 
After a 48 h period, dendrimer/RGD conjugates lead to higher gene delivery efficiencies than the 
correspondent native dendrimers (p<0.05). After 72 and 96 h, only G6 dendrimer based vectors 
presented gene expression values superior to those shown by native dendrimers. In fact, the 
improvement of gene expression was higher for G6 dendrimer based vectors and, in particular, 
for the RGD8-G6 vector. After 48 h, the RGD8-G6 vector presented a transfection level that 
almost reached the level obtained with SF (used as reference) and was approximately 5-fold 
higher than that obtained with the native G6 dendrimer. Interesting, the gene expression pattern 
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after 48 h was similar to that observed in the cellular uptake studies suggesting that gene 
expression is dependent on the amount of complexes internalized by cells that, in turn, will 
depend on the balance between the nanoclusters RGD density and the electrostatic interactions 
established between the complexes and the cell membrane. 
 
Gene delivery achieved by dendrimer/RGD conjugates was also qualitatively studied, 24 h 
post-transfection, by visualization of Enhanced Green Fluorescent Protein expression using 
fluorescence microscopy (Figure 10). These results were in accordance with the quantitative 
analysis using the Luc reporter gene.  
 
 
Figure 10. Fluorescence microscopy images showing Enhanced Green Fluorescent Protein expression 24 h post-
transfection. The micrographs (A), (B), (C) and (D) are respectively the transfected MSCs with G5, RGD4-G5, RGD8-
G5 and RGD16-G5. The micrographs (E), (F), (G) and (H) are respectively the transfected MSCs with G6, RGD4-G6, 
RGD8-G6 and RGD16-G6. The micrographs were obtained at an original magnification of 100× 
 
Cell viability was evaluated simultaneously to transfection experiments using the resazurin 
reduction assay (Figure 9). Results are presented as the percentage of cell viability in relation to 
non-transfected cells. For most of the cases, cell viability was close to 100% (only the complexes 
formed by pDNA and the RGD16-G6 vector showed some cytotoxicity but, even so, the 
percentage of cell viability was above 80%). SF was more toxic than native dendrimers and 
dendrimer/RGD conjugates43. 
 
Studies on the cytotoxicity of vectors alone (not complexed with pDNA) were also 
performed (Figure 11). As expected, cytotoxicity was dependent on concentration but, till 25 
μg.mL-1 (the concentrations used in the present study were included in this interval), all the 
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systems displayed a high level of cell viability (>60%). It is well known that at high concentrations, 
the cationic charge of the dendrimers may lead to a strong cytotoxic effect22,24. 
 
 
Figure 11 Cytotoxicity evaluation of dendrimers/RGD conjugates without being complexed with pDNA . Data 
represents the mean ± s.e.m., n=6. 
 
The second set of gene delivery studies was carried out using a plasmid encoding BMP-2. 
Similar experimental conditions to those used with the EGFPLuc pDNA were applied but 
expression of the protein was measured after 48h post-transfection (Figure 12). The 
dendrimer/RGD conjugates were able to deliver the BMP-2 gene to MSCs, being in general more 
efficient than native dendrimers. The trend in gene delivery was identical to that observed in the 
first set of gene delivery assays and the RGD8-G6 vector was shown to be the more efficient, 
doubling the amount of protein expressed in comparison to G6 native dendrimer. Also here, 
together with the electrostatic interactions, RGD clustering modulated the gene delivery process 
and resulted in an improved gene expression of a therapeutic gene.  
 
Several authors introduced the RGD motif in the design of gene delivery vectors with the 
aim of increasing gene expression8,13-15. In the present work, by conjugating dendrimers with a 
varying number of RGD containing peptides, it is shown that the electrostatic interaction 
established between the dendrimer moieties and the cell membrane is important and must be 
taken into account in the gene delivery process but, also, that gene transfer increases with 
nanoclusters RGD density. Results are in agreement with other authors that pointed out the 
importance of RGD clustering in the gene transfer process11,13. 
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Figure 12. BMP-2 gene expression achieved with (A) G5 dendrimer based vectors and (B) G6 dendrimer based 
vectors. Results are expressed as the mean ± s.e.m., n=3.   
 
In one of those works, in an attempt to mimic adenovirus entry in host cells, 5 nm gold 
nanoparticles were surface modified with RGD containing peptides via thiol/gold chemisorption13. 
They were then used to modify the surface of complexes formed by DNA and poly(ethyleneimine) 
used in gene delivery into cells with αvβ3 integrin receptors (HeLa cells). The authors observed an 
increase in gene delivery that was dependent on the integrin surface density of cells. Instead of 
gold nanoparticles, we use dendrimers that have similar dimensions (5.4 nm and 6.7 nm, 
respectively, for the G5 and G6 PAMAM dendrimer). In our approach, the dendrimer/RGD 
conjugates present the advantage of being simultaneously used as gene carriers (without the 
need of an additional molecule for that effect) and as scaffolds for RGD clustering. 
 
 
4. CONCLUSIONS 
 
RGD nanoclusters were formed by conjugation of PAMAM dendrimers with a varying 
number of peptides containing the RGD motif having in view their use as gene delivery vectors. 
The complexes formed by these nanoclusters and pDNA were able to enter inside MSCs through 
a mechanism that results from a balance between the non-specific electrostatic interactions of the 
complexes with the cell surface and the specific interactions established through the RGD/integrin 
recognition system. The density of RGD motifs in the dendrimeric scaffold was shown to play a 
role in complex cellular uptake mechanism and also in gene expression. The system with best 
performance was based on the G6 PAMAM dendrimer conjugated to eight peptide arms (RGD8-
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G6). This vector presented a 2-fold higher BMP-2 expression in comparison to the G6 native 
dendrimer.  
 
Due to the role of integrins in the modulation of cell processes, these dendrimeric RGD 
nanoclusters may have important biomedical applications, not only in gene delivery, but also in 
other fields such as in tissue engineering and regeneration. 
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CHAPTER IV. 
Functionalization of Poly(amidoamine) Dendrimers with Hydrophobic Chains for Improved Gene 
Delivery in Mesenchymal Stem Cells* 
 
 
ABSTRACT 
A new family of gene delivery vectors is synthesized consisting of a medium-size generation 
PAMAM dendrimer (generation 5, with amine termini) core randomly linked at the periphery to 
hydrophobic chains that vary in length (12 to 16 carbon alkyl chains) and number (from 4.2 to 9.7 
in average). The idea subjacent to the present work is to join the advantages of the cationic 
nature of the dendrimer with the capacity of lipids to interact with biological membranes. Unlike 
other amphiphilic systems designed for the same purpose, where the hydrophobic and 
hydrophilic moieties coexist in opposite sides, the present vectors have a hydrophilic interior and 
a hydrophobic corona. The vectors are characterized in respect to their ability to neutralize, bind 
and compact plasmid DNA (pDNA). The complexes formed between the vectors and pDNA are 
analyzed concerning their size, ζ-potential, resistance to serum nucleases, capacity of being 
internalized by cells and transfection efficiency. These new vectors show a remarkable capacity 
for mediating the internalization of pDNA with minimum cytotoxicity, being this effect positively 
correlated with the -CH2- content present in the hydrophobic corona. Gene expression in MSCs, a 
cell type with relevancy in the regenerative medicine clinical context, is also enhanced using the 
new vectors but, in this case, the higher efficiency is shown by the vectors containing the smallest 
hydrophobic chains. 
 
 
 
 
 
 
*This chapter is based on the following publication: 
Santos JL, Oliveira, H, Pandita D, Rodrigues J, Pêgo AP, Granja PL, Tomás H. Functionalization of 
Poly(amidoamine) Dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells 
(submitted). 
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1. INTRODUCTION 
 
Gene therapy is a branch of medicine that aims to replace deficient genes, modulate gene 
expression or integrate new genes (new functions) in cells1,2. In fact, nowadays, gene therapy is 
not only concerned with genetically inherited diseases, but also with the treatment of acquired 
diseases (by interfering with gene expression)3,4 and with tissue engineering and regeneration5,6. 
Bone marrow derived mesenchymal stem cells, being multipotent cells with the ability to 
differentiate into multiple lineages, including the osteogenic, chondrogenic, myogenic and 
adipogenic lineages, hold tremendous promise for the construction and regeneration of tissues7,8. 
Furthermore, they are relatively easy to isolate, manipulate and culture, and, at least in vitro, 
show significant expansion capability7,8. These characteristics make them very interesting 
candidates for the delivery of exogenous genes. 
 
A wide variety of viral systems (e.g. retroviruses, lentiviruses, adenoviruses or 
baculoviruses) have been extensively investigated as gene delivery vectors, including in MSCs9. 
These carriers have proved to be very efficient leading to high levels of expression of the 
delivered genes. However, their application in the clinical scenario as a successful approach has 
not yet met expectations as viruses pose serious problems in terms of safety (e.g. immune 
responses)10. Because of such inherent risks, non-viral gene delivery has been pursued as an 
alternative strategy. Moreover, very often, a long-term expression of the delivered gene (that can 
be obtained using viruses) is normally not required. That is the case of tissue engineering and 
regeneration approaches for which transient signaling is ideally needed11. Therefore, a wide 
range of non-viral synthetic vectors has emerged based on lipids, classical polymers, dendrimers, 
polypeptides and inorganic nanoparticles12. Despite the advantages of these systems over their 
viral counterparts, some of them show significant citotoxicity and all exhibit low gene delivery 
efficiency when dealing with primary cells. MSCs, in particular, have been shown to be very 
difficult to transfect by non-viral methods13,14. 
 
Among the numerous non-viral vectors investigated, dendrimers have great potential over 
the traditional polymeric systems as a result of their unique characteristics15,16. Dendrimers are 
hyperbranched polymers that present well-defined three-dimensional architectures (they are 
organized in layers called generations), molecular weights, and size, as well as a multivalent-
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functionalized terminal surface. Poly(amidoamine) (PAMAM) dendrimers, with primary amine 
termini and tertiary internal amines, are protonated at physiological pH and can form complexes 
with the anionic deoxyribonucleic acid (DNA) molecule. PAMAM dendrimers have the intrinsic 
ability to bind, condense and efficiently deliver DNA into a wide variety of cell types without 
inducing significant cytotoxicity and immunogenicity17-22. It is accepted that the primary amine 
groups at the periphery bind and compact DNA, thus promoting its cellular uptake, while the 
buried tertiary amino groups act as a proton sponge in endosomes, thus enhancing the release of 
DNA into the cytoplasm17-22. Early studies conducted by Baker et al. showed that high 
transfection efficiency was achieved using generations 5 – 10 of PAMAM dendrimers, even if 
results varied significantly among the cell lines tested23. In a previous study, believing that these 
results could be extended to MSCs, we have used generations 5 – 7 of PAMAM dendrimers for 
MSCs transfection using a plasmid encoding hBMP-2 protein24. Although the process resulted in 
osteogenesis promotion, the level of gene expression attained in those in vitro assays was low. 
Parallel experiments using HEK 293T cells (a human embryonic kidney derived cell line) and the 
β-galactosidase reporter gene revealed higher levels of gene delivery. Indeed, these results 
confirmed that PAMAM dendrimers were able to deliver genes into cells but that the process was 
strongly cell type dependent. 
 
PAMAM dendrimers have been modified in different ways having in view an improvement 
in their performance as nucleic acid carriers. Several reviews have been specifically devoted to 
this topic17-21. Physical modifications like those conducting to partially degraded PAMAM 
dendrimers have been reported – actually, these dendrimers are being sold in the market under 
the name of SuperFect® (SF) and PolyFect®25 and have been shown to transfect a series of cell 
types. Chemical modifications are also described in the literature, the majority involving 
functionalization at the dendrimers periphery, such as conjugation with poly(ethyleneglycol), 
cyclodextrins, amino-acids, peptides, proteins, and glucocorticoids17-21. In particular, dendrimers 
having hydrophobic amino-acid residues as terminal groups were shown to have improved 
transfection properties26. Additionally, PAMAM dendrons (asymmetric partial dendrimers) 
differently functionalized at their focal points have been synthesized and tested for gene delivery. 
Despite all these studies, progress has been moderate and new strategies are needed for 
enhancing the gene delivery activity of PAMAM dendrimers. 
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Herein, we focused on the possibility of associating the advantages of the cationic nature 
of amine terminated PAMAM dendrimers with the capacity of lipids to interact with biological 
membranes. Takahashi et al.27-29 synthesized low generation PAMAM dendrons (generations 1 – 
4) bearing two dodecyl tails and concluded that transfection activity increased with the generation 
of the dendron in CV1 cells (the fusogenic lipid dioleoylphosphatidylethanolamine was added 
during the process). An increment in the length of the alkyl chain (octadecyl chains) positively 
influenced cell transfection only when serum was present showing that the hydrophobic moieties 
played a role in the stability of the complexes formed between the cationic lipids and DNA. Other 
asymmetric dendrimers with potential for gene delivery have been reported. Jones et al.30 
combined cholesterol units with spermine-functionalized dendrons. Using solid phase methods, 
Shah et al.31 linked branched polypeptides to a hydrophobic tail containing 14 carbons. Ewert et 
al. and Ahmad et al.32,33 synthesized cationic lipids with dendritic head groups based on the 
aminoacid ornithine. Joester et al.34,35 prepared a series of low generation amphiphilic dendrimers 
through connection of a lipophilic dendron with a hydrophilic dendron by a rigid diphenylethyne 
core. All these systems, shared a common feature – the dendritic hydrophilic moiety is presented 
at one side of the vector and the hydrophobic moiety in the opposite side. 
 
In this study, we followed a different strategy and synthesized a new family of gene 
delivery vectors consisting of a medium-size generation PAMAM dendrimer core randomly linked 
at the periphery to hydrophobic chains that varied in length and number. Generation 5 PAMAM 
dendrimers (G5) were chosen due to their high amine content both at the periphery and in the 
interior. We hypothesized that the strong positive character of the dendrimer would favor 
complexation with DNA, the electrostatic attraction between the complex and the negatively 
charged cell membrane, and the release of DNA into the cytosol due to the proton sponge effect. 
The hydrophobic tails would act synergistically with the cationic core, facilitating the transport of 
the complexes across the cell membrane and helping the escape of the complexes to the cytosol 
by fusing or destabilizing endosomes. Lauric (dodecanoic acid, 12 carbons, La), myristic 
(tetradecanoic acid, 14 carbons, My) and palmitic (hexadecanoic acid, 16 carbons, Pa) fatty acids 
were chosen to be conjugated to dendrimers to evaluate the effect of the length of the 
hydrophobic chains on the process of transfection and also because they have an endogenous 
nature and can be metabolized by mammalian cells. Indeed, these medium chain fatty acids have 
been shown to be absorption enhancers and to play a role in the intracellular trafficking of 
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proteins36,37. Low generation PAMAM dendrimers conjugated with lauroyl chloride were also 
shown to have enhanced permeation through Caco-2 cell monolayers37. In the present work, the 
effect of the extent of functionalization was studied by binding a different number of hydrophobic 
chains per dendrimer. Furthermore, MSCs were used in the biological assays instead of 
established cell lines, allowing a more reliable extrapolation of the results for an in vivo situation. 
 
Herein, a new family of gene delivery vectors was developed, which showed a remarkable 
capacity for mediating the internalization of pDNA without significant cytotoxic effects. Nucleic 
acid cellular uptake was positively correlated with the –CH2– content present in the dendrimer 
hydrophobic corona. Gene expression was also greatly enhanced using the new vectors but, in 
this case, the higher efficiency was presented by the vectors containing the smallest hydrophobic 
chains. 
 
 
2. MATERIALS AND METHODS  
 
2.1. Materials and reagents 
 
Generation 5 PAMAM dendrimers (G5) were purchased from Dendritech Inc., USA. 
Plasmid DNA (pDNA) encoding for Enhanced Green Fluorescent Protein and Firefly Luciferase 
(pEGFPLuc, 6.4 kb) with a cytomegalovirus promoter (CMV) was kindly provided by Prof. Tatiana 
Segura (UCLA, USA). pDNA was purified from overnight E. Coli bacteria culture using the 
GenEluteTM HP Endotoxin-Free Plasmid Megaprep Kit and stored in ultrapure water at -20 ºC. All 
other reagents used in the synthesis, if not specified, were obtained from Sigma-Aldrich Co. and 
used without further purification. Cell culture dishes were from Nunc. 
 
 
2.2. Experimental determination of primary amine group content of dendrimers 
 
G5 primary amine group content was determined by spectrophotometry after reaction of 
the free amine groups with TNBS38, as previously described, and using glycine as standard. A 
total of 115 amine groups was attributed to each dendrimer, being this value in agreement with 
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the Mass Spectrometry data supplied by the seller. Based on this result, the TNBS method was 
further used to calculate the concentration of dendrimers (also of functionalized dendrimers) 
when needed. In both cases the standard solutions and the sample solutions were serially diluted 
in 0.1 M sodium tetraborate to a final volume of 1 ml. To each standard and sample, 25 µL of 
TNBS (0.03 M) diluted in water were added. After 15 min at room temperature (RT), absorption 
was measured at 420 nm in a GBC-Cintra 40, UV-Visible spectrophotometer.  
 
 
2.3. Synthesis and characterization of the functionalized dendrimers 
 
In a first step, lauric, myristic, and palmitic fatty acids were activated using carbodiimide 
chemistry as described by Lapidot et. al.39 with slight modifications. Briefly, the fatty acids (0.025 
mol) were dissolved in THF (20 ml) and purged with nitrogen. Then, 0.025 mol of N-
hydroxysuccinimide (NHS) was added and the contents were stirred at 0 ºC. Activation was 
initiated by dropwise addition of dicyclohexylcarbodiimide (DCC, 0.025 mol in 20 ml THF) into the 
above mixture to obtain a reaction ratio of 1:1:1. This mixture was further stirred at RT and under 
nitrogen for 12 h. Dicyclohexylurea, a by-product, was removed by filtration and the filtrate was 
concentrated under reduced pressure to yield white crystals and purified by recrystallization in 
methanol (a 90 % yield was obtained). In a second step, the functionalized dendrimers were 
synthesized by N-acylation reaction of G5 with the activated ester of the fatty acids (Figure 1). 
The degree of functionalization was controlled using the stoichiometry of the reagents. The 
adequate amount of activated fatty acid was dissolved in 1 ml of DMF and added dropwise over 
15 min to 30 mg of G5 dissolved in 1 ml of DMSO. The mixture was allowed to stir 16 h under 
nitrogen and at RT. The reaction mixture was concentrated under reduced pressure and purified 
by extensive dialysis against Phosphate Buffered Saline (PBS) solution and ultra-pure water for 4 
days. All the products presented good water solubility. The conjugates were sterile filtered and 
aliquots were frozen at -20 ºC. The conjugates were characterized by 1H NMR. Spectra were 
recorded at RT, using a Bruker 400MHz Avance II+ NMR spectrometer using D2O as solvent. The 
G5 content of each sample was determined by the TNBS assay. The integrals of the 
characteristic proton peaks of the fatty acids (δ ≈ 0.8, CH3) and of G5 (δ ≈ 2.3, CH2) were used to 
calculate the average number of hydrophobic chains per dendrimer. 
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Figure 1. Strategy of synthesis followed in dendrimer surface functionalization with alkyl chains (activation of the fatty 
acid + conjugation reaction) 
 
 
2.4. Functionalized dendrimers/pDNA complexes assembly 
 
Functionalized dendrimers/pDNA complexes were prepared at several N:P ratios by mixing 
equal volumes (50 µL) of the conjugate solution and the pDNA solution. Unless otherwise stated, 
Hepes-Buffered Glucose (HBG, Hepes 10 mM, Glucose 5% w/w, pH = 7.1) was always used to 
prepare these solutions. Complex solutions were gently vortexed and allowed to incubate for 20 
min at RT prior to experiments. Unmodified G5 was always used as a control. Superfect® 
(Qiagen, Germany) was also used as a reference in gene delivery experiments. SF complexes 
were prepared accordingly the manufacturer’s instructions for transfection of primary cells. 
 
 
2.5. Agarose gel electrophoresis shift assay 
 
Agarose gel (0.7% w/v) containing ethidium bromide (0.05 µL.ml-1) was prepared in Tris-
acetate-EDTA buffer. Complex solutions were prepared at different N:P ratios as described above 
using  1 μg of pDNA diluted in 50 μL of buffer and 2.5 μL of Blue Loading Buffer (Fermentas, 
Germany) were added before the samples were subjected to gel electrophoresis at 75 V. 
Functionalized dendrimer-pDNA binding was shown by a lack of migration of the pDNA in the 
electrophoretic field. 
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2.6. Pico green intercalation assay 
 
200 μL of complex solutions at different N:P ratios were prepared as described above 
using 0.1 μg of pDNA diluted in 100 μL. Hepes-buffered saline (HBS, 10 mM HEPES, 150 mM 
NaCl, pH 7.0) was used to prepare these solutions. Then, 200 μL of PicoGreen (PG, Molecular 
Probes) reagent diluted in Tris-EDTA buffer (TE, 10 mM Tris, 1 mM EDTA, pH 7.5) was added 
and mixtures were further incubated for 5 min.  Three independent experiments were performed. 
PG fluorescence (λex = 485 nm, λem = 535 nm) was measured using a microplate reader (model 
Victor3 1420, PerkinElmer). The % relative fluorescence (%F) was determined using the following 
equation: 
 
% 100 sample blank
DNAonly blank
F F
F
F F
−
= ×
−  
 
 
2.7. Serum nucleases protection assay 
 
The procedure followed was modified from a method described by Gao et al.40. In brief, 
functionalized dendrimers (5 µL) were assembled with 1 µg of pDNA (5 µL) as described above, 
at an N:P ratio of 5. The complexes were then incubated with 5 µL of fetal bovine serum (FBS, 
Gibco), at 37ºC, for 0, 1, and 4 h. At the end of the incubation period, 5 µL of sodium dodecyl 
sulphate (SDS, 4% w/v) was added to release the pDNA from the functionalized dendrimers, and 
the samples were incubated overnight at 60 ºC to facilitate the release of pDNA. Blue Loading 
Buffer (4 µL) was then added to the samples and 10 µL of each was loaded onto the gel (0.7% 
w/v agarose) and subjected to electrophoresis. pDNA and FBS were used as negative controls. 
 
 
2.8. Dynamic light scattering and zeta potential measurements  
 
The size of complexes was measured at 633 nm on a dynamic light scattering instrument 
(Zetasizer Nano ZS, Malvern Instruments). Solutions (100 μL) of polyplexes were prepared at a 
N:P ratio of 5 as described above using 5 μg of pDNA diluted in 50 μL. The solutions were then 
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diluted by adding 700 µL of HBG buffer. Particle sizes were determined for these initial solutions 
at room temperature with a detection angle of 173°. Zeta potential measurements were 
performed using the same instrument with a detection angle of 17°. Zeta potentials were 
calculated using the Smoluchowsky model for aqueous suspensions. The data presented are 
means of three independent sample measurements. 
 
 
2.9. Isolation and culture of rat bone marrow-derived mesenchymal stem cells 
 
Rat bone marrow-derived mesenchymal stem cells (MSCs) were isolated from long bones 
of 8-week-old male Wistar rats according to a standard protocol41. Following euthanasia by 
pentobarbital 20% (v/v), femora were aseptically excised, cleaned of soft tissue, and washed in 
PBS. The metaphyseal ends were cut off and the marrow was flushed out from the midshaft with 
5 ml of α-Minimum Essential Medium (α-MEM) using a 23-Gauge needle and syringe. The cells 
were centrifuged (600 g, 5 min), suspended in fresh medium containing 10% heat-inactivated 
FBS, 50 mg.l-1 ascorbic acid, 100 U.ml-1 penicillin and 100 µg.ml-1 of streptomycin - the basic 
medium - and seeded in 75 cm2 flasks. After removal of non-adherent cells and medium 
exchange at day 3, cells were harvested at day 7, and used in the experiments. 
 
 
2.10. Cellular uptake studies using fluorescence-activated cell sorting (FACS) 
 
Cells were seeded in twelve-well plates at a density of 1.25×104 cell.cm-2 and incubated in 
basic medium at 37ºC, 5% CO2, for 24 h, to yield a cell confluency of around 60-70%. Prior to 
complex formation, pDNA was labelled with PicoGreen dye (Molecular Probes) according to the 
manufacturer’s instructions. Complex solutions (100 µl) were prepared at a N:P ratio of 6 as 
described above. Cells in 0.5 ml of basic medium were then transfected using 100 µl of the 
complex solution (2 μg.cm-2 of pDNA was used). The cells were incubated with each solution for 
1 h and then rinsed twice with PBS. The extracellular fluorescence associated with cell surface-
bound nanoparticles was quenched with 0.4% (w/v) TB for 5 min. The cells were trypsinized, 
pelleted, and resuspended in 400 µl PBS containing 2% FBS for fluorescence-activated cell 
sorting (FACS) analysis (Cytomics FC500, Beckman Coulter). Twenty thousand events were 
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collected in triplicate for each sample. Gating and analysis was performed using CXP software 
analysis program using PG-labelled naked pDNA transfected cells as the primary negative 
control. The positive fluorescence level was established by visual inspection of the histogram of 
the negative control such that less than 1% of positive cells appeared in the positive region. 
Results are expressed as the percentage of fluorescent cells and the fluorescence intensity per 
cell (the mean value). Three independent experiments were performed. 
 
 
2.11. Gene delivery studies- expression of the Luc gene 
 
Two independent experiments were performed and all samples were carried out in 
triplicate. Cells were seeded at 1.25×104 cell.cm-2, in 24-well plates, 24 h prior to transfection. At 
the time of transfection, cells reached a confluency of 60-70%. Before contact with complexes, 
medium was exchanged for 0.5 ml of fresh basic medium. Complex solutions (100 µl) were then 
added to the cells and, after 4 h, the culture medium was again replaced with fresh medium. 
Transfection was carried out using 2 μg.cm-2 pDNA and at a N:P ratio of 6 (optimized conditions). 
Non-transfected cells and cells transfected with naked pDNA were used as negative controls. At 
different time points (48, 72 and 120 h) after transfection began, the media was removed and the 
cells were washed with PBS solution and treated with 100 µl reporter lysis buffer (Promega). Cell 
lysates were analysed for luciferase activity with Promega’s luciferase assay reagent in triplicate 
(following the supplier’s instructions). For each sample, the microplate reader (model Victor3 
1420, PerkinElmer) was set for 3 s delay with signal integration for 10 s. The amount of protein in 
cell lysates was determined using the bicinchoninic acid assay (BCA assay) with bovine serum 
albumin as a standard. The gene delivery efficiency of each sample was characterized by firefly 
luciferase expression and denoted as relative light units per milligram of total protein (RLU.mg-1).  
 
 
2.12. Gene delivery studies - expression of the EGFP gene 
 
Enhanced Green fluorescent protein expression studies were carried out as mentioned 
above for the Luc gene expression. Twenty-four hours after transfection, cells were observed with 
an inverted fluorescence microscope (Nikon Eclipse TE 2000E) equipped with a cold Nikon 
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camera. Digital image recording and image analysis were performed with the NIS Elements 
Advanced Research (version 2.31) software. 
 
 
2.13. Cytotoxicity of the functionalized dendrimers 
 
Cytotoxicity was evaluated by determining the percentage of cell viability (in respect to 
unexposed cells) using the rezasurin reduction assay that establishes a correlation between the 
cellular metabolic activity and the number of viable cells in culture42. Cell viability was studied as 
a function of the functionalized dendrimer type and the concentration. Cells were seeded in 96 
well-FluoroNunc plates at a density of 3×104 cell.cm-2. After 24 h, medium was replaced with 
fresh basic medium and 10 µl of each functionalized dendrimer (diluted in HBG) was added to 
achieve the final desired concentration.  After 4 h, the medium was exchanged for fresh medium 
containing 0.1 mg.ml-1 rezasurin and incubated for another 4 h. Resorufin fluorescence (λex = 530 
nm, λem = 590 nm) was measured in a microplate reader (model Victor3 1420, PerkinElmer). 
Cytotoxicity of the complexes: Cytotoxicity was also evaluated using the rezasurin 
reduction assay. This information was obtained during the experiments performed to study the 
expression of the Luc gene (described above), being cell viability evaluated 24 h post-
transfection. 
 
 
2.14. Fluorescence microscopy studies 
 
Fluorescence microscopy was used to visualize pDNA cellular uptake. Prior to complex 
assembly, pDNA was labelled with rhodamine isothiocyanate (RITC) by a slight modification of a 
reported method43. Briefly, 0.1 mg of pDNA diluted in 297 µl of sodium carbonate-buffered 
solution (0.1 M, pH 9.0) was mixed with 3 µl of RITC solution (100 mM solution prepared in 
dimethyl sulfoxide) at RT, for 5 h. The RITC-labelled pDNA was separated from residual RITC by 
gel filtration using a PD 10 column (GE Healthcare), followed by ethanol precipitation to obtain 
the RITC-labelled pDNA. Experiments were done in the same conditions as the above described 
transfection experiments although using RITC-labelled pDNA at a lower concentration (1 μg.cm-2) 
to avoid blur. Live cells were analyzed under the fluorescence microscope (Nikon Eclipse TE 
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2000E inverted microscope) four hours post transfection after quenching of extracellular 
fluorescence with 0.4% TB for 5 min and washing with PBS. For observation at higher 
magnifications, cells were seeded in 24-well plates containing collagen-treated cover slips. 
Images were taken 2, 4, and 24 h post-transfection. After quenching with 0.4% TB, cells were 
washed twice with PBS and fixed with 3.7% (v/v) formaldehyde prepared in PBS at room 
temperature for 10 min. Cell nuclei were then stained using a 300 nM 4',6-diamidino-2-
phenylindole (DAPI) solution for another 10 min. Cells were washed several times with PBS and 
stored at 4ºC (protected from light). A 100x NA 0.5-1.3 Plan Fluor objective (NIKON) was used for 
these observations.   
 
 
2.15. Statistics 
 
Statistical analyses were performed using GraphPad Prism 5.0 for Windows. Results are 
reported as mean± standard error of mean (s.e.m). Unpaired, Student’s t-test and 2-way ANOVA 
with Bonferroni Post Hoc test were used to assess the statistical differences between the group 
means. 
 
 
3. RESULTS AND DISCUSSION  
 
3.1. Synthesis and characterization of the functionalized dendrimers 
 
Hydrophobic chains were conjugated to the surface of PAMAM dendrimers by N-acylation 
of the dendrimers with the N-hydroxysuccinimide esters of lauric, myristic, and palmitic fatty acids 
(Figure 1). These activated fatty acids were previously prepared using carbodiimide chemistry. 
The objective was to prepare a new family of gene delivery vectors consisting of a G5 core linked 
to 4 and 8 hydrophobic tails of different length (respectively, La1-G5, My1-G5, Pa1-G5 and La2-
G5, My2-G5, Pa2-G5). During the synthesis, the concentration of dendrimers (also of 
functionalized dendrimers) was determined by spectrophotometry based on primary amine 
content, using TNBS method38. The conjugates were characterized by 1H NMR (400MHz) using 
D2O as solvent (Figure 2). Data confirm that the hydrophobic chains were successfully grafted at 
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the periphery of G5 as evidenced by the appearance of the characteristic proton peaks of the 
hydrophobic moieties: methyl protons peak (t, -CH3) at δ ≈ 0.8 and methylene protons peak (m, -
CH2-) at Δδ = 1-1.25. Additionally, new peaks and peak splitting were observed by comparison 
with the G5 spectrum as a consequence of the new chemical environment. Integrals of the 
characteristic proton peaks of the hydrophobic moieties (δ ≈ 0.8, CH 3) and of G5 (δ ≈ 2.3, CH 2) 
were used to calculate the average number of hydrophobic chains effectively attached per 
dendrimer (Table 1). A degree of functionalization varying between 4.2 - 5.3 and of 7.8 – 9.7 was 
obtained for the family of gene delivery vectors prepared. 
 
 
Figure 2. 1H NMR (400MHz) spectra of functionalized dendrimers in D2O. 
 
 
3.2. Characterization of the complexes formed by the functionalized dendrimers and pDNA 
 
The potential of functionalized dendrimers to neutralize, bind and compact plasmid DNA 
(pDNA) was studied due to its importance for efficient gene delivery. Plasmid DNA encoding for 
the enhanced Green Fluorescent Protein and Firefly Luciferase (pEGFPLuc, 6.4 kb) was used. 
Prior to all studies, conjugates were mixed with pDNA at several N:P ratios in HBG, for 
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complexes formation. Agarose gel shift assays (Figure 3) revealed that binding to and charge 
neutralization of pDNA occurred at N:P ratios of one and higher in all cases studied, except when  
La2-G5 was used for which a minimum N:P ratio of two was needed. 
 
Table 1. Identification of the developed gene delivery vectors and characterization of their hydrophobic moieties. 
Fatty acid used in the 
conjugation reaction 
Vector 
abbreviation 
Mean number 
of –CH3–
protons per 
dendrimer[a] 
Mean number 
of –CH2– 
protons per 
dendrimer[b] 
Mean number 
of alkyl chains 
per dendrimer 
Molecular 
weight, MW 
(u.m.a.)[c] 
CH3(CH2)10COOH 
Lauric acid 
La1-G5 
La2-G5 
12.6 
23.4 
72.3 
130.4 
4.2 
7.8 
27914.4 
28569.6 
CH3(CH2)12COOH 
Myristic acid 
My1-G5 
My2-G5 
14.0 
27.9 
93.9 
177.6 
4.7 
9.3 
28137.0 
29103.0 
CH3(CH2)14COOH 
Palmitic acid 
Pa1-G5 
Pa2-G5 
15.8 
28.9 
124.5 
219.0 
5.3 
9.7 
28411.4 
29458.6 
[a]Values used to calculate the mean number of alkyl chains per dendrimer. [b]These values refer to the –CH2– 
content present in dendrimer hydrophobic corona. [c]Calculated based on G5 MW provided by the supplier and the 
number of alkyl chains per dendrimer determined by 1H NMR. 
 
 
Figure 3. Agarose gel electrophoresis shift assay results for N:P ratios ranging from 0 (pDNA only) to 8: (A) G5, (B) 
La1-G5, (C) La2-G5, (D) My-G5, (E) My2-G5, (F) Pa1-G5, and (G) Pa2-G5. Binding is shown by the inhibition of 
pDNA electrophoretic mobility (band 1). Bands 2 and 3 show the relaxed and supercoiled forms of pDNA, 
respectively. 
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By using the PicoGreen (PG) dye (Figure 4), which only presents fluorescence when 
bounded to DNA, we concluded that complete pDNA packaging was achieved at a N:P ratio of 
two both  for G5 and the dendrimers linked to hydrophobic chains. Based on these results, a N:P 
ratio of at least 5 was selected for further experiments. 
 
 
Figure 4. PicoGreen assay. The results are reported as the relative percentage of PG fluorescence, where 100% 
intensity was observed for a N:P of 0 (pDNA only). Results are expressed as the mean ± s.e.m obtained from three 
independent experiments. 
 
At N:P=5, dynamic light scattering (DLS) and ζ-potential measurements were carried out to 
determine the size and colloidal stability of the formed complexes (Figure 5A and 5B). 
Conjugation of hydrophobic chains to G5 resulted in a significant increase (p<0.05) in complex 
mean diameter which ranged between 115 and 180 nm. In general, the size of the complexes 
increased with the length of the hydrophobic chain (this is particularly noticeable for the series of 
complexes formed by the La1-G5, My1-G5, Pa1-G5 vectors). The polydispersity indices (PDI) 
varied among the complexes showing that the heterogeneity of those formed by La1-G5, La2-G5, 
and My2-G5 vectors was lower. As expected, due to a shielding effect of the hydrophobic tails 
over primary amines, functionalization also gave rise to a significant decrease (20-42%, p<0.05) 
in ζ-potential values. In this case, ζ-potential values decreased with the length of the hydrophobic 
chain. These lower ζ-potential values associated with added hydrophobicity conferred by the fatty 
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acid chains, although diminishing the stability of the colloid solution (theoretically, the propensity 
for colloids aggregation increases), can be advantageous as interactions with charged serum 
constituents and, concomitantly, blood clearance can be weaken – a key issue in the in vivo 
situation44. 
 
 
Figure 5. (A) Complex size (mean diameter) and polydispersity indices assessed by DLS, and (B) complexes ζ-
potential. Results were obtained for a N:P ratio of 5. Results are expressed as the mean ± s.e.m obtained from three 
independent experiments. 
 
It is known that unprotected pDNA can be rapidly degraded by nucleases present in serum, 
normal plasma or cytoplasm, reducing any chances of successful transfection. The complexation 
of pDNA with the synthetic vector, resulting in the formation of tightly packed nanoparticles, can 
however confer protection against nucleases action44. The in vitro resistance of the complexes 
formed between pDNA and the functionalized dendrimers to degradation by nucleases present in 
serum was also evaluated. Complexes were incubated with foetal bovine serum (FBS), at 37oC, 
for 0, 1 and 4 h and, after, sodium dodecyl sulphate was added to dissociate the complexes and 
samples were subjected to electrophoresis (Figure 6). Degradation of naked pDNA began 
immediately upon addition of serum, as observed by the decrease in intensity of bands 2 and 3 
(relaxed and supercoiled pDNA, respectively) as well as the migration of degraded pDNA 
throughout the gel. After 1 h, naked pDNA was completely degraded by nucleases present in 
serum. On the contrary, pDNA complexed with G5 or with the functionalized dendrimers did not 
shown any evidence of degradation even after incubating with serum for 4 h, at 37ºC. It should be 
noted that band 4 results from the combination of serum with SDS as shown in the control FBS 
lanes (1-3). Data revealed that the capability to protect pDNA from nucleases degradation shown 
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by G5 was not changed by the incorporation of the hydrophobic chains, irrespective of their 
length and number.  
 
 
Figure 6. pDNA protection from serum nucleases achieved with G5 (lanes 9-11), La1-G5 (lanes 13-15), La2-G5 
(lanes 17-19), My1-G5 (lanes 21-23), My2-G5 (lanes 25-27), Pa1-G5 (lanes 29-31), and Pa2-G5 (lanes (33-35). 
Results were obtained for a N:P ratio of 5. Serum only (lanes 1-3) and naked pDNA added of serum (lanes 5-7) were 
used as controls.  Control samples without addition of serum and SDS correspondent to pDNA (lane 4) and 
complexes formed with G5 (lane 8), La1-G5 (lane 12), La2-G5 (lane 16), My1-G5 (lane 20), My2-G5 (lane 24), Pa1-
G5 (lane 28) and Pa2-G5 (lane 32) were also analyzed. Band 1 is the position of sample loading (complexes without 
serum and SDS). Bands 2 and 3 are relaxed and supercoiled pDNA, respectively. Band 4 results from the complex 
between serum and SDS.  
 
 
3.3. Cellular uptake of the complexes formed by the functionalized dendrimers and pDNA 
 
PicoGreen-labeled pDNA was used to compare complexes uptake by rat bone marrow 
derived MSCs through the fluorescence-activated cell sorting (FACS) technique. Cellular uptake 
was studied in the presence of serum, at a N:P ratio of 5 and using a seeding density of 1.25x104  
cell.cm-2 and 2 µg.cm-2 of pDNA. After 1h of contact between complexes and cells, both the 
number of cells positive for PG-labeled pDNA and the amount of pDNA delivered per cell attained 
with functionalized dendrimers were significantly higher (p<0.01 for La1-G5 and My1-G5, p<0.05 
for La2-G5, My2-G5, Pa1- and Pa2-G5) than those obtained with G5 (Figure 7A). These values  
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Figure 7. (A) Complex uptake by MSCs after 1h of contact. The line shows the number of cells positive for PG-
labeled pDNA whereas the bars reveal the amount of pDNA delivered per cell (displayed as the mean average 
fluorescence intensity). Results are expressed as the mean ± s.e.m obtained from three independent experiments. 
(B) Correlation between the total number of –CH2– groups contained in dendrimer hydrophobic corona and both the 
number of cells positive for PG-labeled pDNA (squares) and the amount of pDNA delivered per cell (circles). (C) 
RITC-labeled pDNA visualization in live cell cultures by fluorescence microscopy, 4 h post-transfection. Original 
magnifiation: 200x. (D) Distribution of RITC-labeled pDNA inside cells, 2, 4 and 24 h after transfection, when using 
G5 and La2-G5. Cell nuclei were stained with DAPI (blue). Original magnification: 1000x. 
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generally increased with the number of hydrophobic chains grafted per dendrimer (La1-G5<La2-
G5; My1-G5<My2-G5; Pa1-G5<Pa2-G5 and Pa1-G5≈Pa2-G5 for, respectively, the number of 
cells positive for PG-labeled pDNA and the amount of pDNA delivered per cell). In addition, a 
linear correlation was also found between them and the total number of -CH2- groups present in 
the hydrophobic chains attatched to the dendrimer (Figure 7B). It is evident that functionalization 
with lipids has a beneficial effect in the internalization process, probably by improving the 
transport of the complexes pDNA/functionalized dendrimers across the plasma membrane. 
Abbasi et al. have also found an increase in cellular uptake with increasing lipophilic character of 
lipid-substituted poly(L-Lysine) nucleic acid carriers45. The above reported results were 
corroborated by fluorescence microscopy images. Figure 7C shows the merged bright field and 
fluorescent microscopy images of MSCs 4 hours after transfection with RITC-labeled pDNA. 
Although these experiments provide only qualitative data, it can be seen that naked pDNA was 
unable to enter cells, G5 complexes were able to enter a few cells in a very small amount and 
functionalized dendrimer complexes entered many cells in a much higher quantity. Images taken 
at a higher magnification and after staining the cell nucleus with DAPI (Figure 7D), show a much 
higher accumulation of RITC-labeled pDNA inside cells for transfection carried out with La2-G5 
(the example shown) when compared to G5. 24 hours post-transfection, pDNA is mainly located 
at the cell nucleus periphery although some small pink spots (due to RITC-labeled pDNA and 
DAPI co-localization) can be seen inside the nucleus. 
 
Though dendrimers are reported to be internalized by cells via nonspecific adsorptive 
endocytosis17-21 mainly due to nonspecific charge interactions, the present results clearly show 
that the hydrophobic moieties play a specific role in the process of cellular uptake. Indeed, the 
amount of pDNA internalized is higher when functionalized dendrimers are used, even if the 
charge (ζ-potential) presented by their complexes with pDNA is lower than that obtained using the 
native dendrimer G5.  
 
 
3.4. Gene expression studies 
 
The preceding section demonstrated the enhanced capability of functionalized dendrimers 
to internalize pDNA but, for protein expression, endossomal disruption, complex dissociation and 
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nuclear translocation of pDNA must occur17-21. To assess the ability of functionalized dendrimers 
to efficiently deliver exogenous genes, MSCs were incubated in optimized conditions in the 
presence of 10 %FBS, and for 4 h. Cells were then assayed for expression of the Luciferase 
(Luc) reporter gene after 48, 72 and 120 h post-transfection (Figure 8A). Results were normalized 
to protein content and are shown as RLU. 
 
Figure 8. (A) Luc gene expression achieved with the functionalized dendrimers, 48, 72 and 120 h post-transfection. 
SF was used for comparison. (B) Complex cytotoxicity evaluation 24 h post-transfection. Results are expressed as 
the mean ± s.e.m. and were obtained from two independent experiments. 
 
A transient expression of the Luc gene was obtained in all cases as RLU values decrease with 
time. For all time periods, functionalized dendrimers lead to higher gene delivery efficiencies than 
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G5 (p<0.05), with exception for the Pa2-G5 carrier. After 48h, La1-G5 and La2-G5 functionalized 
dendrimers presented transfection levels that were, respectively, 4.5 and 2.1-fold higher than 
those obtained with native G5 and SF. My1-G5 (1.8-fold higher) and Pa1-G5 (2.1-fold higher) 
vectors showed a moderate increase in transfection levels when compared to G5. Gene delivery 
efficiency mediated by the functionalized dendrimers followed the trend La1-G5≈La2-G5>Pa1-
G5≈My1-G5>My2-G5>Pa2-G5, generally showing a decrease with the extent of –CH2– 
substitution. Results show that for a high –CH2– content, transfection efficiency can decrease to 
values smaller that those obtained with the native dendrimer, as happens with Pa2-G5. 
 
Gene delivery achieved by functionalized dendrimers was also qualitatively studied, 24 h 
post-transfection, by visualization of Enhanced Green Fluorescent Protein expression using 
fluorescence microscopy (Figure 9). These results confirmed the quantitative analysis using the 
Luc reporter gene. Surprisingly, our findings with this new family of gene delivery vectors were 
different from those obtained by Takahashi et al.27-29 that prepared PAMAM dendron-bearing 
lipids (previously mentioned). Their results showed that, in the presence of serum, the systems 
containing longer lipids presented higher transfection activity. Also in opposition to our results, the 
work dealing with lipid-substituted poly(L-Lysine)45 concluded that the extent of –CH2- substitution 
positively contributed for effective DNA delivery.  
 
 
Figure 9. Fluorescence microscopy images showing Enhanced Green Fluorescent Protein expression 24 h post-
transfection. Original magnification: 100x 
pDNA 
SF Pa1 Pa2 
G5
LA2 
LA1 
My1 My2 
 
CHAPTER IV. PAMAM Functionalization using Hydrophobic Chains for Improved Gene Delivery 
 
122 
 
On the other hand, the gene delivery efficiency presented by the amphiphilic dendrimers of 
Joester et al.34,35 greatly varied not only with the nominal charge but also with the number of C12 
chains carried by dendrimers. In this case, the dendrimer showing the higher transfection 
efficiency was neither the one with less C12 chains nor the one with more C12 chains. It seems 
then that there is not a universal trend in transfection efficiency when hydrophobic moieties are 
associated to cationic polymers. Specially comparing our results with the results of Takahashi et 
al., based on the proximity of both systems (dendron/hydrophobic tails vs dendrimer/hydrophobic 
tails), we believe that the architecture of the nucleic acid carrier plays an important role in the 
process. Of course that variables such as charge, size, and flexibility of the carrier must not be 
forgotten, as well as variables related with experimental conditions (serum presence, type of cells 
used, etc). 
 
Cell viability was evaluated simultaneously to transfection experiments using the rezasurin 
reduction assay (Figure 8B). The less lipophilic functionalized dendrimers (La1-G5, La2-G5 and 
My1-G5) were as cytotoxic as G5 dendrimers whereas the more lipophilic functionalized 
dendrimers (My2-G5, Pa1-G5 and Pa2-G5) presented a cytotoxicity similar to SF (more toxic than 
G5, at least when using MSCs). Cell viability however remained above 70% in all situations and 
cytotoxicity results, per se, do not explain the accentuated decrease in transfection efficiency 
observed for the more lipophilic dendrimers. Studies on the cytotoxicity of vectors alone (not 
complexed with pDNA) were also performed (Figure 10). As expected, cytotoxicity was 
dependent on concentration but, till 20 μg.ml-1 (the concentrations used in the present study were 
included in this range), all the systems displayed a high level of cell viability (>70%). For higher 
concentrations, the presence of the hydrophobic moieties had a strong effect on dendrimer 
cytotoxicity revealing the destabilizing nature of lipids over biological membranes46. 
 
Several barriers to an efficient gene delivery are described in the literature17-21. These include 
vector (or complex) cytotoxicity, complex entrance into the cell, entrapment of the complex and 
degradation of pDNA inside endo-lysosomes, release of pDNA from the complex, pDNA diffusion 
inside cytoplasm, pDNA degradation in cytoplasm, and pDNA nuclear translocation. At this point, 
it is clear that for the developed systems the extent of gene expression was not dependent on 
pDNA cellular uptake (for which the -CH2- content acted in an opposite direction) neither on 
cytotoxicity.  
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Figure 10. Cytotoxicity evaluation of the functionalized dendrimers. Each data point represents the mean ± s.e.m. of 
two independent measurements. 
 
Furthermore, the studies related with the stability of complexes in the presence of serum have not 
shown significant differences among the vectors (all are shown to confer resistance against 
nucleases degradation). Also, once separated from the vector, pDNA degradation in cytoplasm 
should be similar in all cases. Likely, without discarding other possibilities, the higher gene 
expression values obtained with La1-G5 and La2-G5 vectors can be related with an easier 
release of pDNA from their complexes. In their study, Abbasi et al.45 showed that poly(L-Lysine) 
polymers possessing a high level of hydrophobicity were less susceptible to dissociation. Indeed, 
although a fast complex dissociation in cytoplasm might facilitate pDNA degradation by 
nucleases, pDNA must become accessible to the transcriptional machinery in the nucleus in 
order to be translated in the corresponding protein. The higher gene expression values obtained 
with La1-G5 and La2-G5 vectors can also be due, in case the dissociation of the complexes only 
occur in the vicinity of the nucleus, to a higher diffusion mobility of the complexes in the 
cytoplasm (complexes formed between La1-G5 and La2-G5 and pDNA were shown to be smaller 
than complexes formed with the other vectors). Endo-lysosome disruption (by interference with 
the lipids in its membrane) is not expected to be facilitated for La1-G5 and La2-G5 vectors in 
comparison with the other systems due to their lowest -CH2- content. 
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Anyway, the difficulty in nuclear translocation of pDNA is present in all situations. 
Fluorescence microscopy images clearly show a high accumulation of pDNA (or its complexes) at 
nucleus periphery after transfection. For nuclear translocation, due to the high size of the pDNA 
molecule, the disassembly of the nuclear envelope must occur and this will only happen during 
mitosis. Strategies must, then, be developed to overcome this barrier in slowly dividing cells, as is 
the case of MSCs. For now, based on the very good capacity of this new family of gene delivery 
vectors to mediate internalization of nucleic acids, we hypothesize that these systems may be 
explored for RNA delivery (including antisense RNA, small interfering RNA and micro RNA) since 
the action site of these molecules is in cytoplasm. Presently, ongoing work at our laboratory is 
devoted to the application of these new vectors for gene silencing. Further experiments are in 
progress to understand the mechanism of gene delivery using this family of vectors. 
 
 
4. CONCLUSIONS 
 
Generation 5 PAMAM dendrimer was successful functionalized at its surface with 
hydrophobic alkyl chains that varied in length and number. New gene delivery vectors were then 
synthesized which showed ability to neutralize, bind and compact pDNA, as well as to confer it 
protection against serum nucleases. Complexes formed between the vectors and pDNA 
presented sizes and ζ-potential values that, respectively, increased and decreased with the 
length of the hydrophobic tails. In vitro MSCs culture experiments revealed a remarkable capacity 
of these vectors for internalizing pDNA with very low levels of cytotoxicity, being this effect 
positively correlated with the -CH2- content present in the hydrophobic moiety. Gene expression 
was also enhanced using the new vectors but, in this case, the higher efficiency was shown by 
the vectors containing the smallest hydrophobic chains – La1-G5 and La2-G5 functionalized 
dendrimers. 
 
This new family of gene delivery vectors can have important applications in gene delivery 
and, hence, in tissue engineering and regeneration applications where MSCs are often used. Its 
capacity for internalizing nucleic acids can also be explored for RNA delivery based therapies.  
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CHAPTER V. 
Receptor-Mediated Gene Delivery using PAMAM Dendrimers Conjugated with Peptides 
Recognized by Mesenchymal Stem Cells 
 
 
ABSTRACT  
Mesenchymal stem cells (MSCs) can differentiate into multiple cell types, including cells from the 
osteogenic, chondrogenic, myogenic and adipogenic lineages. This property makes them suitable 
candidates for the delivery of therapeutic genes, being necessary the development of efficient 
and safe vectors to attain that purpose. Moreover, specific transfection of MSCs may be required 
to avoid unwanted side effects in other tissues. We have synthesized and characterized a novel 
series of gene delivery vectors based on poly(amidoamine) (PAMAM) dendrimers functionalized 
with peptides displaying high affinitiy to MSCs. Novel gene delivery vectors were designed that 
exhibit low cytotoxicity, receptor-mediated gene delivery into MSCs and transfection efficiencies 
superior to those presented by native dendrimers and by Superfect® (a commercially available 
gene delivery system). 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following publication (communication): 
Santos JL, Pandita D, Rodrigues J, Pêgo AP, Granja PL, Tomás H. Receptor-Mediated Gene Delivery using 
PAMAM Dendrimers Conjugated with Peptides Recognized by Mesenchymal Stem Cells (submitted). 
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1. INTRODUCTION 
 
Bone marrow derived mesenchymal stem cells (MSCs) are multipotent cells that can 
differentiate into a variety of cell types, thus being of key importance in the field of tissue 
regeneration and engineering1,2. When devising strategies for therapeutic applications, the 
introduction of exogenous genes in these cells is often desirable, as their expression can 
influence cell mitosis and differentiation. For example, MSCs isolated from a patient (autologous 
cells) can be propagated and transfected in vitro within a scaffold and using genes encoding for 
proteins that promote osteogenesis (such as BMP- 2). After, the construct can be implanted in a 
patient’s skeletal defect to help bone regeneration. Viral systems, because of their sophisticated 
machinery, are by far the most effective nucleic acids delivery carriers but, besides being 
refractory to repeated infections, may raise safety problems such as acute toxicity, 
immunogenicity, and oncogenicity3-5. Non-viral systems, on the other hand, have been shown to 
present a limited success in primary cell transfection, as is the case of MSCs, being necessary to 
develop efficient and safe vectors to attain that purpose6, 7. Additionally, specific transfection of 
MSCs may be required to avoid unwanted side effects in other tissues, making the design of 
gene delivery vectors for cell targeting an important challenge.  
 
Herein, we report the synthesis, characterization and evaluation of novel gene delivery 
vectors based on poly(amidoamine) (PAMAM) dendrimers conjugated to peptides recognized by 
receptors at MSCs membrane. Indeed, very recently, we have demonstrated that PAMAM 
dendrimers (generations 5 to 7), although showing low transfection efficiency, were able to deliver 
the hBMP-2 gene into MSCs, thus promoting in vitro osteogenesis8. We then hypothesized that 
by functionalizing dendrimers with peptides recognized by receptors at MSCs membrane, 
transfection efficiency could be improved and MSCs targeting could be achieved. A low affinity 
MSCs binding (LAB) peptide and a high affinity MSCs binding (HAB) peptide were used in the 
studies, based on a previously published patent9. With this biomimetic approach, novel gene 
delivery vectors were designed that exhibit low cytotoxicity, receptor-mediated gene delivery into 
MSCs and transfection efficiencies superior to those presented by native dendrimers and by 
Superfect® (SF), a commercially available gene delivery system made of partially degraded 
PAMAM dendrimers. 
 
 
CHAPTER V. Receptor-Mediated Gene Delivery by PAMAM-Peptide Conjugates 
 
133 
 
2. MATERIALS AND METHODS 
 
2.1. Materials and reagents 
 
Generation 5 poly(amidoamine) PAMAM dendrimers (G5) ethylenediamine-cored were 
obtained from Dendritech Inc. (USA). Cysteine-modified low affinity binding and high affinity 
binding peptides (LAB- and HAB-peptides) were synthesised with a purity of 80-90% and 
characterized by HPLC and MS at the University of Virginia Biomolecular Research Facility 
(Charlottesville, Virginia, USA). Plasmid DNA (pDNA) encoding enhanced Green Fluorescent 
Protein and Firefly Luciferase (pEGFPLuc, 6.4 kb) with a cytomegalovirus promoter (CMV) was 
generously provided by Prof. Tatiana Segura (Dep. of Chemical and Biomolecular Engineering, 
UCLA, USA). The plasmid was purified from E.coli cultured overnight using the GenElute™ HP 
Endotoxin-Free Plasmid Megaprep Kit and stored in ultrapure water at -20ºC. All other reagents 
used, if not specified, were obtained from Sigma-Aldrich Co. and used without further purification. 
Cell culture dishes were from Nunc. 
 
 
2.2. Experimental determination of primary amine group content of dendrimers 
 
The primary amine group content of G5 PAMAM dendrimers was determined by 
spectrophotometry after reaction of the free amine groups with TNBS as described in the 
literature10, and using glycine as standard. A total of 115 amine groups was attributed to each 
dendrimer, this value being in agreement with the Mass Spectrometry data furnished by 
Dendritech Inc.. Based on this result, the TNBS method was further used to calculate the 
concentration of dendrimers (also of functionalized dendrimers) when needed. In both cases the 
standard solutions and the sample solutions were serially diluted in 0.1 M sodium tetraborate to a 
final volume of 1 ml. To each standard and sample 25 µl of TNBS (0.03 M) diluted in water was 
added. After 15 min at RT, absorption was measured at 420 nm in a GBC-Cintra 40, UV-Visible 
spectrophotometer.  
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2.3. Synthesis and characterization of peptide-functionalized G5 PAMAM dendrimers 
 
In a first step, G5 PAMAM dendrimers (Figure 1, compound 1, C1) were substituted with 
various amounts of the bifunctional 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester 
(SPDP), as described earlier by Szoka et al.11. G5 PAMAM dendrimers (0.50 µmol) in 2 ml buffer 
(0.25 M NaCl, 0.1 M phosphate, pH 8) were mixed with SPDP (1-4 µmol) dissolved in 250 µl 
ethanol. The reaction was carried out at RT and under a nitrogen atmosphere. Several 
compounds were obtained (compounds 2, C2) by varying the molar ratio dendrimer/pyridyldithiol 
(PDP) (1/2, 1/4 and 1/8). The mixtures were allowed to react for 3 h, at RT, under nitrogen and 
with continuous stirring. Afterwards, low molecular weight products were removed by gel 
permeation chromatography on a PD-10 column (GE Healthcare) equilibrated in 0.15 M NaCl, 0.1 
M phosphate buffer, pH 7.4. The fractions containing dendrimers linked to PDP were pooled, 
concentrated, snap frozen in liquid nitrogen and stored at -80 ºC. The content in C2 was 
estimated by TNBS assay as described previously. The degree of modification with the SPDP 
linker was evaluated spectrophotometrically at 343 nm by the release of pyridine-2-thion 
(compound 4, C4) after reduction of an aliquot with excess dithiothreitol (DTT, 0.1 M). As 
calibration standards, known concentrations of SPDP solutions were treated with 0.1 M DTT 
under the same conditions, and the changes in absorbance were used as a measure of pyridine-
2-thion (C4) in solution. In a second step, cysteine-modified LAB and HAB peptides were 
dissolved in acetic acid (10% v/v) and mixed, under nitrogen, with C2 diluted in 500 mM 
phosphate buffer, pH 8. An excess of peptide (1.8- to 2.2-fold) to PDP present in C2 was used to 
increase reaction yields. After 3 h at RT, the amount of released pyridine-2-thion (C4) was 
measured at 343 nm to determine the extent of reaction. Peptide-functionalized dendrimers (C5) 
were purified by gel filtration using PD-10 columns equilibrated in 0.5 M NaCl, 20 mM sodium 
acetate, pH 5. Conjugates were applied to the column and the void fractions containing the 
conjugates were dialyzed against phosphate buffered saline (PBS) solution, pH 7.2, using dialysis 
tubes with a molecular weight cut-off of 10 kDa (Spectrum Laboratories) for 3 days. After dialysis, 
conjugates were sterile filtered and aliquots were snap frozen in liquid nitrogen and stored at -
80ºC. Conjugates were characterized by 1H NMR using D2O as solvent in a Bruker 400 MHz 
Avance II+ NMR spectrometer. 
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Figure 1. The two-step reaction for the synthesis of peptide-functionalized G5 PAMAM dendrimers (pathway A+B), 
and for indirect estimation of the number of peptide units by spectrophotometry (pathway A+C). Note: The amine 
content of G5 PAMAM dendrimers (115 amines/dendrimer) was previously determined experimentally  
 
 
2.4. Polyplex preparation 
 
Peptide-functionalized dendrimers/pDNA complexes were prepared at several N:P ratios 
by mixing equal volumes of the conjugate solution and the pDNA solution. Conjugate and pDNA 
concentrations varied according to the experiments. Hepes-buffered Glucose (HBG, Hepes 10 
mM, Glucose 5% w/w, pH = 7.1) was always used to prepare these solutions unless otherwise 
stated. Polyplex solutions were vortexed gently and allowed to incubate for 20 min at room 
temperature prior to experiments. The generation 5 of PAMAM dendrimers was always used as a 
control. Superfect (Qiagen, Germany) was also used as a reference in gene delivery 
experiments. Superfect polyplexes were prepared according to the manufacturer’s instructions for 
transfection of primary cells.  
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2.5. Agarose gel electrophoresis retardation assay 
 
Gel electrophoresis in agarose gels was carried out at 75 V. Agarose gel (0.7 % w/v) 
containing ethidium bromide (0.05 µl.ml-1) was prepared in Tris-acetate-EDTA buffer. Polyplex 
solutions were prepared at different N:P ratios, as described above, using 1 µg of pDNA diluted 
in 50 µl of buffer and 2.5 µl of Blue Loading Buffer (Fermentas, Germany) were added before the 
samples were subjected to gel electrophoresis. Functionalized dendrimers-pDNA interaction is 
shown by a lack of migration of the pDNA in the electrophoretic field.  
 
 
2.6. Pico green intercalation assay  
 
200 µl of polyplex solutions at different N:P ratios were prepared as described above using 
0.1 µg of pDNA and an adequate amount of peptide-functionalized dendrimer, both diluted in 100 
µl of Hepes-buffered saline (HBS, 10 mM HEPES, 150 mM NaCl, pH 7.0). Then, 200 µl of 
PicoGreen (PG, Molecular Probes) reagent, diluted in Tris-EDTA buffer (TE, 10 mM Tris, 1 mM 
EDTA, pH 7.5), was added and mixtures were further incubated for 5 min. Three independent 
experiments were performed. PG fluorescence (λex = 485 nm, λem = 535 nm) was measured using 
a microplate reader (model Victor3 1420, PerkinElmer). The % relative fluorescence (%F) was 
determined using the following equation: 
 
% 100 sample blank
DNAonly blank
F F
F
F F
−
= ×
−  
 
 
2.7. Dynamic light scattering and zeta potential measurements  
 
The size of the polyplexes was measured at 633 nm on a dynamic light scattering 
instrument (Zetasizer Nano ZS, Malvern Instruments). Solutions (100 µl) of polyplexes were 
prepared at a N:P ratio of 5, as described above, using 5 µg of pDNA diluted in 50 µl HGB. The 
solutions were then diluted by adding 700 µl of HGB. Particle sizes were determined for these 
initial solutions at room temperature with a detection angle of 173°. Zeta potential measurements 
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were performed using the same instrument with a detection angle of 17°. Zeta potentials were 
calculated using the Smoluchowsky model for aqueous suspensions. The data presented are 
means of three independent sample measurements. 
 
 
2.8. Isolation and culture of rat bone marrow-derived mesenchymal stem cells 
 
Rat bone marrow-derived MSCs were isolated from long bones of 8-week-old male Wistar 
rats. Following euthanasia by pentobarbital 20% (v/v), femora were aseptically excised, cleaned 
of soft tissue, and washed in PBS. The metaphyseal ends were cut off and the marrow was 
flushed out from the midshaft with 5 ml of α-Minimum Essential Medium (α-MEM) using a 23-
Gauge needle and syringe. The cells were centrifuged (600 g, 5 min), suspended in fresh 
medium containing 10% heat-inactivated foetal bovine serum (FBS, Gibco), 50 µg.ml-1 ascorbic 
acid, 100 U.ml-1 penicillin and 100 µg.ml-1 of streptomycin - the basic medium - and seeded in 75 
cm2 flasks. After removal of non-adherent cells and medium exchange at day 3, cells were 
harvested at day 7 by trypsinization, and used in subsequent experiments. 
 
 
2.9. Cellular uptake studies by fluorescence-activated cell sorting (FACS) 
 
Cells were seeded in 12-well plates at a density of 1.25×104 cell.cm-2 and incubated in 
basic medium at 37ºC, 5% CO2, for 24 h, to yield a cell confluency of around 60-70%. Prior to 
polyplex formation, pDNA was labelled with PicoGreen dye (Molecular Probes) according to the 
manufacturer’s directions. Polyplex solutions (100 µl) were prepared at a N:P ratio of 5 as 
previously described. Cells in 0.5 ml of basic medium were then transfected using 100 µl of the 
polyplex solution (2 µg.cm-2 of pDNA was used). The cells were incubated with each solution for 
2 h and then rinsed twice with PBS. The extracellular fluorescence associated with cell surface-
bound nanoparticles was quenched with 0.4% (w/v) TB for 5 min. The cells were trypsinized, 
pelleted, and resuspended in 400 µl of PBS containing 2% FBS for FACS analysis (Cytomics 
FC500, Beckman Coulter). Twenty thousand events were collected in triplicate for each sample. 
Gating and analysis was performed using CXP software analysis program, using PG-labelled 
naked pDNA transfected cells as the primary negative control. The positive fluorescence level 
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was established by visual inspection of the histogram of the negative control, such that less than 
1 % of positive cells appeared in the positive region. Results are expressed as the percentage of 
fluorescent cells and the fluorescence intensity per cell (the mean value). Three independent 
experiments were performed. 
 
 
2.10. Intracellular trafficking of pDNA  
 
Fluorescence microscopy was used to study the intracellular trafficking of pDNA. Prior to 
polyplex formation, pDNA was labelled with RITC by a slight modification of a reported method12 
Briefly, 0.1 mg of pDNA diluted in 297 µl of sodium carbonate-buffered solution (0.1 M, pH 9.0) 
was mixed with 3 µl of RITC solution (100 mM solution prepared in dimethyl sulfoxide) at room 
temperature, for 3 h. The RITC-labelled pDNA was separated from residual RITC by gel filtration 
using a PD-10 column (GE Healthcare), followed by ethanol precipitation to obtain the RITC-
labelled pDNA. Twenty-four hours prior to transfection, cells were seeded at a density of 1.25×104 
cell.cm-2 in 24-well plates containing collagen-treated cover slips. Before contact with polyplexes, 
medium was exchanged for fresh basic medium. Transfection was carried out with complexes 
prepared at an N:P ratio of 5 using 1 μg.cm-2 RITC-labeled pDNA. The distribution of pDNA inside 
cells was analyzed 2 and 4 h after transfection. Thirty minutes prior, the acidic late endosome and 
lysosome compartments were stained with the addition of LysoSensor DND-189 dye (Molecular 
Probes) to the medium at a final concentration of 1 µM. After quenching with 0.4% (w/v) TB, cells 
were washed twice with PBS and fixed with 3.7% (v/v) formaldehyde prepared in PBS at RT for 
10 min. Cell nuclei were then stained using a 300 nM 4',6-diamidino-2-phenylindole (DAPI) 
solution for another 10 min. Cells were washed several times with PBS and stored at 4ºC 
(protected from light).  Fluorescence images were acquired using a Nikon Eclipse TE 2000E 
inverted microscope equipped with a 100x NA 0.5-1.3 Plan Fluor objective. 
 
 
2.11. Gene delivery studies 
 
Gene delivery was studied based on reporter gene expression (Luciferase, Luc, and 
Enhanced Green Fluorescent protein, EGFP). Expression of the Luc gene: Two independent 
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experiments were performed and all samples were performed in triplicate. Cells were seeded at 
1.25×104 cell.cm-2, in 24-well plates, 24 h prior to transfection. At the time of transfection, cells 
reached 60-70%  confluency. Before contact with polyplexes, medium was exchanged for 0.5 ml 
of fresh basic medium. Polyplex solutions (100 µl) were then added to the cells and, after 4 h, the 
culture medium was again replaced with fresh medium. Transfection was carried out at a N:P 
ratio of 5 and using 1 and 2 μg.cm-2 pDNA. Non-transfected cells and cells transfected with naked 
pDNA were used as negative controls. At different time points (48, 72 and 96 h) after transfection, 
the media was removed and the cells were washed with PBS solution and treated with 100 µl 
reporter lysis buffer (Promega). Cell lysates were analysed for luciferase activity with Promega’s 
luciferase assay reagent in triplicate (following the supplier’s instructions). For each sample, the 
microplate reader (model Victor3 1420, PerkinElmer) was set for 3 s delay with signal integration 
for 10 s. The amount of protein in cell lysates was determined using the bicinchoninic acid assay 
(BCA assay) with bovine serum albumin as a standard. The gene delivery efficiency of each 
sample was characterized by firefly luciferase expression and denoted as relative light units 
(RLU). Specific receptor-mediated gene delivery was confirmed by saturating cell receptors with 
the HAB peptide prior to transfection. Cells were incubated with a 100 µM peptide solution for 1 
h. Subsequently, cells were washed twice with PBS and fresh basic medium was added. 
Polyplexes based on HAB peptide functionalized dendrimers were then added (a pDNA 
concentration of 1 µg.cm-2 was used in these assays) and allowed to incubate for 4 h. Luciferase 
activity was assessed 48 h post-transfection. 
Expression of the EGFP gene: Enhanced Green Fluorescent protein expression studies were 
carried out as mentioned above for the Luc gene expression. Twenty-four hours after 
transfection, cells were observed with an inverted fluorescence microscope (Nikon Eclipse TE 
2000E) equipped with a cold Nikon camera. Digital image recording and image analysis were 
performed with the NIS Elements Advanced Research (version 2.31) software. 
 
 
2.12. Cytotoxicity studies 
 
The cytotoxicity of the gene delivery vectors (alone) and of the polyplexes they form with 
pDNA was studied. Cytotoxicity was evaluated by determining the percentage of cell viability (in 
respect to unexposed cells) using the rezasurin reduction assay that establishes a correlation 
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between the cellular metabolic activity and the number of viable cells in culture13. Gene delivery 
vector cytotoxicity: Cell viability was studied as a function of the gene delivery vector type and 
concentration. Cells were seeded in 96 well-FluoroNunc plates at a density of 3x104 cell.cm-2. 
After 24 h, medium was replaced with fresh basic medium and 10 µl of each polymer (diluted in 
HBG) was added to achieve the final desired concentration. After 4 h, the medium was 
exchanged for fresh medium containing 0.1 mg.ml-1 rezasurin and incubated for another 4 h. 
Resorufin fluorescence (λex = 530 nm, λem = 590 nm) was measured in a microplate reader 
(model Victor3 1420, PerkinElmer). 
Polyplex cytotoxicity: The information about polyplex cytotoxicity was obtained during the 
experiments performed to study the expression of the Luc gene (described above), being cell 
viability evaluated 24 h post-transfection  
 
 
2.13. Statistics 
 
Statistical analyses were performed using GraphPad Prism 5.0 for Windows. Results are 
reported as mean± standard error of mean (s.e.m). Unpaired, Student’s t-test and 2-way ANOVA 
with Bonferroni Post Hoc test were used to assess the statistical differences between the group 
means.  
 
 
3. RESULTS AND DISCUSSION  
 
Generation 5 PAMAM dendrimers (G5) with amine termini (C1) were conjugated to LAB and HAB 
peptides via a two-step method using the 3-(2-pyridyldithio) propionic acid N-hydroxy-succinimide 
ester (SPDP), a heterobifunctional crosslinker which contains both amine- and sulfhydryl-reactive 
groups (Figure 1). For linkage, a cysteine residue was present at the end of both amino-acid 
sequences - NSMIAHNKTRMHGGGSC (LAB peptide) and SGHQLLLNKMPNGGGSC (HAB 
peptide). During the synthesis, the concentration of dendrimers (also of functionalized 
dendrimers) was determined by spectrophotometry, based on primary amine content. The degree 
of functionalization was under stoichiometric control and was indirectly estimated by 
spectrophotometric quantification of pyridine-2-thion (C4) that is released after reduction of the 
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dendrimer-PDP intermediate (C2) with excess of dithiothreitol (DTT) and after reaction of C2 with 
the peptides (Table 1).  
 
Table 1. Average number of PDP and of peptides per dendrimer, respectively, after reactions A and B. *Theoretical 
value based on the molecular weight of dendrimers provided by the supplier. 
Peptide 
Average number of PDP 
per dendrimer 
(after reaction A) 
Average number of 
peptides per dendrimer 
(after reaction B) 
Mol. weight* 
(u.m.a.) 
NSMIAHNKTRMHGGGSC 
LAB peptide 
2.1 2.1 31008 
4.0 3.9 34866 
SGHQLLLNKMPNGGGSC 
HAB peptide 
2.2 2.1 30830 
4.1 4.1 34510 
8.2 8.1 41870 
 
The conjugates were further characterized by 1H NMR spectroscopy (Figure 2) using D2O as 
solvent in a Bruker 400 MHz Avance II+ NMR spectrometer at RT. Figure 2 exemplifies 1H NMR 
characterization for the conjugate G5-(HAB)8. As can be seen, the 1H NMR showed the 
appearance of new proton signals such as the imidazole protons around δ = 6.85 (s, 8H) and δ = 
7.6 (s, 8H) (Histidine aminoacid), methylene protons around δ = 3.9 (CH2, s, 64H) (Glycine 
aminoacid), pyrrolidine protons at δ = 2 (CH2, s, 16H) (Proline aminoacid), and methyl protons 
around δ = 0.7 – 0.9 (CH3, s, 144H) and methine protons (CH, s, 18H) at δ = 1.5 (Leucine 
aminoacid), thus confirming that the peptides were successfully conjugated to G5 PAMAM 
dendrimers in a ratio of 8:1. 1H NMR spectra were all in accordance with the results shown in 
table 1. 
 
Conjugates with two (G5-(HAB)2 and G5-(LAB)2) and four (G5-(HAB)4 and G5-(LAB)4) 
peptide arms were first prepared. As previous gene delivery experiments revealed promising 
results with conjugates bearing the HAB peptide, a conjugate with eight HAB peptide arms (G5-
(HAB)8) was also synthesized to better evaluate the influence of the number of attached peptides 
on the behavior of conjugates as gene delivery vehicles. 
 
 
 
CHAPTER V. Receptor-Mediated Gene Delivery by PAMAM-Peptide Conjugates 
 
142 
 
 
 
Figure 2. 1H NMR of (A) G5-(HAB)8 and of (B) G5 native dendrimer. The inset shows the imidazole proton peaks 
from the amino acid histidine. 
 
 
Peptide-functionalized dendrimers were first investigated for their ability to bind, neutralize 
and compact plasmid DNA (pDNA). Plasmid DNA encoding for enhanced Green Fluorescent 
Protein and Firefly Luciferase (pEGFPLuc, 6.4 kb) was used. Prior to all studies, conjugates were 
mixed with pDNA at several N:P ratios in HBG for polyplex formation. Agarose gel retardation 
assays (Figure 3A) revealed that binding to and charge neutralization of pDNA occurred at N:P 
ratios of 1 and higher when native dendrimers were used, whereas for conjugated dendrimers the 
hampering of pDNA migration occurred at N:P ratios of 2 and higher. By using the PicoGreen 
(PG) dye (Figure 3B), which, when not bound to DNA has virtually no fluorescence, we concluded 
that complete pDNA packaging was achieved at a N:P ratio of 2 for the native dendrimer and at a 
N:P ratio of at least 4 for the conjugated dendrimers. Based on these results, a N:P ratio of 5 was 
selected for further experiments. At this ratio, dynamic light scattering (DLS) and ζ-potential 
measurements were performed to examine the size and colloidal stability of the formed 
polyplexes (Figures 4A and 4B). 
 
HISTIDINE
GLYCINE
PROLINE LEUCINE
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Figure 3. (A) Agarose gel retardation assay results for N:P ratios ranging from 0 (pDNA only) to 8: (a) G5; (b) G5-
(HAB)2; (c) G5-(HAB)4; (d) G5-(HAB)8; (e) G5-(LAB)2; (f) G5-(LAB)4. Binding is shown by the inhibition of pDNA 
electrophoretic mobility (band 1). Bands 2 and 3 show the relaxed and supercoiled forms of pDNA, respectively.  (B) 
PicoGreen assay. The results are reported as the relative percentage of PG fluorescence, where 100% intensity was 
observed for a N:P of 0 (pDNA only). Results are expressed as the mean ± s.e.m obtained from three independent 
experiments. 
 
Conjugation of peptides to native dendrimers caused a significant increase (p<0.05) in 
polyplex size which, nevertheless, ranged between 110 and 160 nm in diameter. The 
polydispersity indices (PDI) were only slightly increased by the incorporation of peptides, 
revealing that the level of homogeneity in the samples remained nearly constant. The 
incorporation of peptides also resulted in a significant decrease (about 40%, p<0.001) in ζ-
potential values. Even if this fact can be interpreted as an increase in colloid hydrophobicity and 
concomitant instability that may lead to aggregate formation, it is also challenging since the 
positive, low-charged polyplexes obtained might establish reduced interactions with counter ions 
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and plasma proteins, which are known to promote blood clearance and interfere with transfection 
in vivo14,15. Taken together, results suggest that the peptide arms around dendrimers have a 
shielding effect over primary amines, reducing polyplexes ζ-potential, conducting to the need of 
using higher N:P ratios for full pDNA compaction and increasing polyplex size. A similar effect 
was reported using poly(ethylene glycol) chains linked to PAMAM dendrimers16.  
 
 
Figure 4. (A) Polyplex size (mean diameter) and polydispersity indices assessed by DLS, and (B) polyplexes ζ-
potential. Results were obtained for a N:P ratio of 5. Results are expressed as the mean ± s.e.m obtained from three 
independent experiments. 
 
 
PicoGreen-labeled pDNA was used to compare polyplex uptake by rat bone marrow 
derived MSCs via fluorescence-activated cell sorting (FACS) (Figure 5). The experiments were 
done under the same conditions used in the following transfection assays. Cellular uptake was 
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studied in the presence of 10% (v/v) serum, at a N:P ratio of 5 and using a seeding density of 
1.25x104 cell.cm-2 and 2 µg.cm-2 pDNA. After 2 h of contact between polyplexes and cells, both 
the number of cells positive for PG-labeled pDNA and the amount of pDNA delivered per cell 
achieved with HAB peptide-functionalized dendrimers (G5-(HAB)2 and G5-(HAB)4 were 
significantly higher (p<0.05) than those obtained with native dendrimers and similar to those 
reached using SF. However, pDNA internalization using G5-(HAB)8 was lower possibly due to the 
fact that this vector interacts with a higher number of receptors at the cell membrane causing a 
saturation-like phenomenon and hampering the cellular uptake process17 Cellular uptake values 
for LAB peptide-functionalized dendrimers were only slightly higher than those obtained with 
native dendrimers. 
 
 
Figure 5. Polyplex uptake by MSCs after 2 h of contact. The line shows the number of cells positive for PG-labeled 
pDNA, whereas the bars reveal the amount of pDNA delivered per cell (displayed as the mean average fluorescence 
intensity). Results are expressed as the mean ± s.e.m obtained from three independent experiments. 
 
Figure 6 shows the distribution of RITC-labeled pDNA (red) inside cells after transfection 
using native dendrimers and peptide-functionalized dendrimers (G5-(HAB)4 and G5-(LAB)4). The 
acidic late endosome and lysosome compartments were stained with LysoSensor Green DND-
189 (green), and the nucleus with DAPI (blue). The images were obtained using a lower 
concentration of pDNA (1µg.cm-2) to diminish blur. Two hours post-transfection, a higher 
accumulation of pDNA could be observed inside cells when using HAB peptide functionalized-
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dendrimers. These data are in agreement with FACS results, which showed that HAB peptide-
functionalized dendrimers were able to deliver a high amount of pDNA per cell.  
 
Figure 6. Cellular distribution of (RITC)-labeled pDNA (2 and 4 h post-transfection) using native dendrimers and G5-
(HAB)4 and G5-(LAB)4 as vectors. The acidic late endosome and lysosome compartments were stained with 
LysoSensor Green DND-189 (green), and the nucleus with DAPI (blue). Original magnification: 1000x. 
 
As time progressed, it was possible to observe the appearance of orange spots representing the 
co-localization of pDNA and endosome/lysosome compartments. pDNA co-localization with the 
nucleus (pink dots, white arrows) could already be observed after 2 h when HAB peptide-
functionalized dendrimers were used. 
 
To quantitatively investigate if the conjugation of peptide to dendrimers was beneficial in 
terms of gene delivery, rat bone marrow derived MSCs were assayed for expression of the Luc 
reporter gene after 48, 72 and 96 h post-transfection (Figure 7A and 7B). Results were 
normalized to protein content and are shown as relative light units (RLU). A transient expression 
of the Luc gene was obtained in all cases with HAB peptide-functionalized dendrimers containing 
4 and 8 peptides per dendrimer leading to an earlier gene expression possibly related with a 
faster polyplex cellular uptake and pDNA trafficking to the nucleus.  After 48 h, HAB peptide-
functionalized dendrimers containing four and eight peptides per dendrimer presented 
transfection levels that were, respectively, 10 and 5.5-fold higher than those obtained with native 
dendrimers and 2.5 and 1.5 higher than those achieved with Superfect. 
2 h
4 h
G5 G5-(LAB)4G5-(HAB)4
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Figure 7. (A) Luc gene expression achieved with HAB peptide-functionalized dendrimers, (B) Luc gene expression 
achieved with LAB peptide-functionalized dendrimers, and (C) comparison of Luc gene expression 48 h post-
transfection achieved with HAB peptide-functionalized dendrimers for different pDNA concentrations (1 µg.cm-2 and 
2 µg.cm-2). (D) Cytotoxicity evaluation 24 h post-transfection. Results are expressed as the mean ± s.e.m. and were 
obtained from two independent experiments. 
 
Although more moderate, a positive difference could still be noticed after 72 h post-transfection 
between these vectors and all the others. Transfection efficiency was dependent on pDNA 
concentration as shown by decreasing it to 1 µg.cm-2 (Figure 7C). In this case, the enhancement 
of transfection efficiency is not so high but a positive influence of HAB peptides on gene delivery 
is still observed. On the other hand, the transfection efficiency observed with conjugates bearing 
LAB peptides was only slightly higher than that obtained with native dendrimers, reflecting the low 
affinity characteristics of this peptide for MSCs. Gene delivery achieved by peptide-functionalized 
dendrimers was also qualitatively studied, 24h post-transfection, by visualization of Enhanced 
Green Fluorescent Protein expression using fluorescence microscopy. Results are shown in 
Figure 8. 
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Figure 8. Fluorescence microscopy images showing Enhanced Green Fluorescent Protein expression 24 h post-
transfection using: (A) naked DNA, (B) G5 PAMAM dendrimers, (C) Superfect, (D) G5-(HAB)2, (E) G5-(HAB)4, (F) 
G5-(HAB)8, (G) G5-(LAB)2, and (H) G5-(LAB)4. Original magnification: 200 x. 
 
 
Cell viability was assessed simultaneously to transfection experiments using the rezasurin 
reduction assay. As shown in Figure 7D, the remarkable enhancement of the Luc gene expression 
presented in particular by G5-(HAB)4 and G5-(HAB)8 vectors was accomplished with minimal 
cytotoxic effects to cultured cells (viability was around 80-90%). In contrast, the transfection 
efficiency obtained with Superfect was accompanied by a notable decrease (~40%) in cell 
viability. In general, polyplexes formed by native dendrimers presented a higher toxicity than 
those formed by the modified polymers. Studies on the cytotoxicity of vectors alone were also 
performed (Figure 9), revealing that functionalized dendrimers display a significantly lower toxicity 
than native dendrimers and SF, particularly for the highest concentrations. These facts may be 
explained by the partial shielding of primary amines (primarily responsible for cytotoxicity effects) 
achieved in the conjugated peptides. 
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Figure 9. Cytotoxicity evaluation of peptide-functionalized dendrimers. Each data point represents the mean ± s.e.m. 
of two independent measurements 
 
The receptor-mediated nature of gene delivery conducted by conjugates attached to HAB 
peptides was confirmed by saturating cell receptors with the peptide prior to transfection (a 0.1 
mM peptide solution was incubated with cells for 1 h). In this case, the level of transfection 
achieved with HAB peptide-functionalized dendrimers was similar to that attained with native 
dendrimers (Figure 10A). No cytotoxic effect associated with the previous saturation of cell 
receptors with the peptide was observed (Figure 10B).  
 
 
Figure 10. (A) Luc gene expression achieved with HAB peptide-functionalized dendrimers with and without 
saturation of cell receptors by HAB peptide prior to transfection. (B) Cytotoxicity evaluation 24 h post-transfection. 
Results are expressed as the mean ± s.e.m. and were obtained from two independent experiments.   
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In conclusion, conjugation of PAMAM dendrimers with peptides with high binding affinity for 
MSCs provides a mechanism for cell specific recognition, giving rise to a new family of gene 
delivery vectors presenting low cytotoxicity and transfection efficiencies superior to those of 
native dendrimers or partially degraded dendrimers. These systems represent a step forward in 
the gene delivery field and may have important applications in tissue engineering and 
regeneration 
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CHAPTER VI. 
 
 
1. CONCLUSIONS 
 
The main aim of this thesis was to explore the in vitro capacity of several PAMAM 
dendrimer based nanomaterials to deliver genes to MSCs. From the overall work, some 
conclusions can be drawn/comments can be made: 
(a) Throughout this dissertation, PAMAM dendrimers (with amine termini) were shown to 
be very interesting materials for gene delivery into MSCs. In one hand, their globular architecture 
and cationic nature allows them to interact with the negatively charged DNA molecules resulting 
in their condensation. In the other hand, their high degree of branching and multivalency 
characteristics allows their functionalization with biological targeting molecules.  
(b) Native dendrimers are able to transfect MSCs. The generation number, the N:P ratio 
and the cell passage number were found to have a significant impact on transfection efficiency. 
By using a plasmid encoding the hBMP-2 gene, MSCs can be induced to produce BMP-2 and to 
differentiate towards the osteoblastic lineage. Results from chapter II clearly show that even if a 
low transfection level is obtained, it is sufficient for the in vitro osteogenic differentiation of MSCs 
(as shown by the analyzed osteogenic markers). Transfection in HEK 293T is much higher, 
confirming that the process of gene delivery is also cell type dependent.  
(c) Functionalization of PAMAM dendrimers with RGD containing peptides, alkyl groups 
and MSCs high affinity binding peptides resulted in an improvement in the level of gene delivery 
in comparison with the native dendrimers and, with exception for the first case, with the 
commercial product SuperFect®. All these approaches aimed at establishing specific interactions 
with the cell membrane, either through receptors at its surface or by interfering with its constituent 
lipids. Vector’s capacity to condense pDNA was not affected by functionalization. In general, the 
cytotoxicity of the functionalized dendrimers was low, being inferior to that showed by SuperFect® 
and having similar values to those showed by native dendrimers. Conjugation of dendrimers with 
RGD containing peptides (chapter III) allowed the formation of RGD nanoclusters and revealed 
the importance of these structures on the modulation of the gene transfer process. Alkyl chain-
functionalized dendrimers (chapter IV) presented a remarkable capacity for internalizing pDNA, 
being this effect positively correlated with the –CH2– content present in the hydrophobic corona – 
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these new vectors can then be very promising for RNA delivery based therapies. Gene 
expression was also enhanced using the new vectors but, in this case, the higher efficiency was 
shown by the vectors containing the smallest hydrophobic chains. A receptor-mediated gene 
delivery was obtained with PAMAM dendrimers conjugated with peptides displaying high binding 
affinity towards MSCs (chapter V). These new multifunctional materials can be potentially used 
for a large variety of therapeutic applications including the delivery of drugs and genes that could 
help in the treatment of musculoskeletal disorders (genetic or acquired), osteoporosis and 
metastatic cancer.  
(d) MSCs are indeed very difficult to transfect.  Despite the improvements in gene delivery 
attained with the functionalization of dendrimers described in this thesis, the levels of gene 
expression are modest if we compare them with the results obtained for other types of cells 
(chapter II). Fluorescence microscopy images of cells after transfection with RITC-labeled pDNA 
always show a high accumulation of nucleic acid in cytoplasm in respect to the quantity found 
inside the nucleus. These results suggest that the major barriers to an efficient non-viral gene 
delivery is the release of pDNA from PAMAM dendrimer based vectors and/or degradation of 
pDNA inside cytoplasm and/or pDNA nuclear translocation. 
 
 
2. PERSPECTIVES 
 
The results presented in this thesis raise new queries and demand supplementary studies 
in order to extend our knowledge about gene therapy strategies making use of mesenchymal 
stem cells as cellular vehicles and PAMAM dendrimer based gene carriers.  
 
From our results, as previous mentioned, it seems that the main barrier to an efficient non-
viral gene delivery is the release of pDNA from PAMAM dendrimer based vectors and/or 
degradation of pDNA inside cytoplasm and/or pDNA nuclear translocation. More studies are then 
needed to address this issue, such as a detailed investigation of the trafficking of pDNA inside 
cells. For this, cellular localization of pDNA alone and of vector/pDNA complexes (co-localization 
studies of vectors and pDNA) using cell compartment biomarkers could give valuable information. 
Further experiments aimed at the evaluation of pDNA stability during its trafficking to cell nucleus 
should also be important (resistance to changes in pH, resistance to nucleases, etc.). Finally, the 
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physicochemical characterization of vector/pDNA complexes also deserves a profound 
investigation. Transmission electron microscopy and atomic force microscopy, for example, can 
provide information concerning the interaction between pDNA and gene delivery vectors that will 
help on the design of more efficient gene carriers. Concerning the low release of pDNA from 
dendrimers, the use of dendrimers with more flexible cores and biodegradable components might 
be recommendable. In order to improve the nuclear translocation of pDNA, a peptide sequence 
presenting nuclear translocation properties can also be fitted to dendrimers or even to the 
backbone of pDNA molecules. 
 
So far the biological performance of the PAMAM dendrimer based vectors developed in 
this thesis was only studied using in vitro cell culture assays. As a next step, the potential of these 
vectors for gene delivery needs an in vivo evaluation. For an in vivo application several animal 
models and strategies can be adopted. By analyzing the literature (chapter I), a cell-mediated 
gene therapy approach should be the best option. Here, cells are harvested from the adult 
animal, genetically engineered in vitro to express the therapeutic gene, selected for enrichment in 
the cells expressing the gene of interest, seeded in a scaffold and, then, implanted at the wound 
site. Using this methodology, the implanted genetically engineered MSCs may enhance tissue 
regeneration through two mechanisms: by directly participating in tissue regeneration and by 
producing growth factors that will enhance the function of native cells in or around the tissue 
defect through paracrine signaling. Other strategies can be followed considering the advantages 
and drawbacks of each methodology and depending on the work’s ultimate goal.  
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
REDE/1517/RMN/2005 
União Europeia Governo da República Portuguesa Região Autónoma da Madeira
